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A brief summary of the work to be incorporated in the thesis entitled 
“STUDIES ON SOME COMPOUNDS OF THERAPEUTIC INTEREST”  
has been summarized as under. 
 
 
CHAPTER: - 01 STUDIES ON OXADIAZOLES. 
CHAPTER: - 02 STUDIES ON MANNICHBASES.  
CHAPTER: - 03 STUDIES ON PYRAZOLINES. 
CHAPTER: - 04 STUDIES ON PRIMIDINE-2-THIONES. 
CHAPTER: - 05 STUDIES ON CYANOPYRIDINES. 
CHAPTER: - 06 STUDIES ON DIHYDROPYRIMIDINES. 
CHAPTER: - 07 STUDIES ON THIAZOLOPYRIMIDINES. 
CHAPTER: - 08 BIOLOGICAL ACTIVITY STUDIES. 
  
 
CHAPTER: - 01:- STUDIES ON OXADIAZOLES: 
 
 
The chapter deals with the preparation and structure elucidation of some novel 
Schiff’s bases and oxadiazoles.  
 A large number of compounds derived from azomethine group have been reported as 
active biological entities, where 1,3,4,-oxadiazoles play a vital role owing to their wide range 
of therapeutic activities such as analgesic, anti-inflammatory, antitubercular, antimicrobial 
etc. Thus considerable interest has been aroused to design the compounds with oxadiazole 
heteroycle in search of drug with better improved potential and to studying their therapeutic 
potency with several microbes. 
 The constitution of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
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SECTION: 1.1:- SYNTHESIS & STRUCTURE ELUCIDATION OF 4-ISOPROPOXY-     
N'-[(1E) – (ARYL) METHYLENE] BENZOHYDRAZIDE.  
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by the condensation of 4-isopropoxy benzoic 
acid hydrazide with different aromatic carboxaldehyde in the presence of catalytic amount of 
glacial acetic acid. 
 
SECTION: 1.2:-SYNTHESIS & STRUCURE ELUCIDATION OF 2-(4-ISOPROPOXY 
PHENYL) - 5 - (ARYL) - 1, 3, 4- OXADIAZOLES. 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by two routes: Route-1:- oxidative 
cyclisation of Schiff’s base with potassium permanganate, Route-2:-oxidative cyclisation of 
Schiff’s base with chloramine-T in presence of proper solvent and the percentage yield were 
compared. 
 
 
O
NH
O
CH3
CH3
N
R
Compound - (I) 
O
N
O
CH3
CH3
N
R
Compound - (II) 
 
  R= Aryl 
R= Aryl 
5 
 
 
 
CHAPTER: - 02:- STUDIES ON MANNICHBASES. 
 
The chapter deals with the preparation and structure elucidation of some novel 
mannichbases. 
 Compound containing bridge N-atom exhibit pronounced pharmacological activities. 
Mannich base derivatives with bridge N-atom have been found to be potent drug in medicinal 
science and possess a wide range of therapeutic activities like antihypertensive, 
antidepressant, anticholesterinic, antifungal and antibacterial etc. By considering this valid 
observation, we have synthesized some newer mannich bases, which are described as under. 
 The constitution of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 2.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-(4-
ISOPROPOXY PHENYL) 3-N-(ARYL) AMINO METHYL -1, 3, 4 
OXADIAZOLE -5 (4H) –THIONE. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 The above compounds were synthesized by the condensation of 2-(4-isopropoxy 
phenyl) -1, 3, 4,-oxadiazole -5(4H)-thione with different aromatic amines in presence of 
formaldehyde using methanol as a solvent. 
 
 
 
O
CH3
CH3
O
NN
S
NH
R
Compound- (III)     R=Aryl 
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CHAPTER: - 03:- STUDIES ON PYRAZOLINES. 
 
The chapter deals with the preparation and structure elucidation of some novel 
chalcones and their heterocyclic derivatives. 
 Chalcone derivatives signify various biological activities such as analgesic, anti-
inflammatory, antitubercular, antimicrobial etc. Over and above chalcones are good synthons 
for various organic molecules. This valid observation led us to synthesize some novel 
chalcones as a synthone for various heterocyclic compounds.  
 The constitutions of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 3.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-
DICHLORO N-(3-SUBSTITUTED STYRYL CARBONYL) 
BENZAMIDE. 
 
 
 
 
 
 
 
 
  
 
  
  
 The above compounds were synthesized by the condensation of N-(3-acetylphenyl)-2, 
3-dichlorobenzamide with different aromatic carboxaldehyde in presence of basic catalyst by 
using proper solvent. 
 
 
O
NH
ClCl O
R
Compound- (IV) 
 
R= Aryl 
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SECTION: 3.2:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-
DICHLORO-  N- {3- [3-ARYL-1[H] PYRAZOLINE-5-YL} PHENYL] 
BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
  
 
The above compounds were synthesized by the cyclocondensation of compound 
(IV) with alcoholic hydrazine hydrate. 
 
SECTION: 3.3:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-
DICHLORO-   N - {3-[3-(ARYL)-1-PHENYL - 1[H] PYRAZOLINE – 
5 - YL} PHENYL] BENZAMIDE. 
 
                      
 
 
 
 
 
              
 
 
 
 
The above compounds were synthesized by the cyclocondensation of compound (IV) 
with phenyl hydrazine in glacial acetic acid. 
O
NH
Cl
Cl
N
N
R
Compound - (VI) 
 
Cl
Cl
O
NH
N
NH
R
Compound - (V) 
 
R= Aryl 
 
R= Aryl  
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SECTION: 3.4:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-
DICHLORO-   N - {3-[3-(ARYL)-1-ACETYL - 1[H] PYRAZOLINE – 
5 - YL} PHENYL] BENZAMIDE.] 
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by the cyclocondensation of compound - 
(IV) with hydrazine hydrate in glacial acetic acid. 
 
SECTION: 3.5:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-DI 
CHLORO -N– [3-{3-(ARYL) -1- THIOCARBAMIDO-1[H]-         
PYRAZO LINE – 5 - YL} PHENYL] BENZAMIDE. 
  
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by the cyclocondensation of compound (IV) 
with thiosemicarbezide in presence of sodium methoxide using anhydrous methanol. 
 
O
NH
Cl
Cl
N
N
R
O
CH3
Compound - (VII) 
 
O
NH
Cl
Cl
N
N
R
S
NH2
Compound - (VIII) 
 
       R= Aryl 
       R= Aryl 
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CHAPTER: - 04:- STUDIES ON PYRIMIDINE-2-THIONES. 
 
 The chapter deals with the preparation and structure elucidation of some novel 
pyrimidine-2-thiones. 
 Pyrimidine-2-thione nucleus possesses notable pharmaceutical importance and 
genetic activities, some of their derivatives occur as usual product like nucleic acids and 
vitamin B. The present popularity of these pyrimidine derivatives are mainly due to their 
close structural relationship to the clinically important calcium channel blockers. This valid 
clarification led us to synthesize some new pyrimidine-2-thiones in search of agents having 
better therapeutic potency. 
 The constitution of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 4.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-
DICHLORO- N – [3-{4-(ARYL)-2-MERCAPTO -1, 4,-DIHYDRO 
PYRIMIDINE 6-YL}] BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by the cyclocondensation of compound (IV) 
with thiourea in presence of sodium methoxide using anhydrous methanol. 
 
 
O
NH
Cl
Cl
NH
N
H
R
S
Compound - (IX) 
 
 R= Aryl 
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CHAPTER: - 05:- STUDIES ON CYANOPYRIDINES 
 
The chapter deals with the preparation and structure elucidation of some novel 
cyanopyridines. 
In continuation of our synthetic manipulation about pharmacologically active 
compounds, some cyanopyridines possess antibacterial, antifungal, antidiabetic, 
anticholesterinic and antihypertensive activity. To approach this goal, preparation of some 
novel cyanopyridines have been undertaken which are described as under. 
 The constitution of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 5.1:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-
DICHLORO-N-[3-(2-AMINO-4-ARYL-3-CYANO PYRIDINE-6-YL)] 
BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by the cyclocondensation of the compound- 
(IV) with malononitrile and ammonium acetate by using proper solvent. 
 
 
 
Cl
Cl
O
NH
N NH2
CN
R
Compound - (X) 
 
R= Aryl 
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CHAPTER: - 06:- STUDIES ON DIHYDROPYRIMIDINES 
 
The chapter deals with the preparation and structure elucidation of some novel 
dihydropyrimidine derivatives. 
 Dihydropyrimidine derivatives represent one of the most active classes of compounds 
possessing a wide spectrum of pharmacological activities such as anti-inflammatory, 
antiviral, antimicrobial, antitumor, calcium channel blockers, antihypertensive agent and 
anticancer. This observation prompted us to synthesize newer dihydropyrimidines in search 
of better therapeutic agent. 
 The constitutions of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 6.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -                   
[5 - (3, 4 – DIMETHYL)-PHENYL AMINO CARBONYL] – 6 – 
PHENYL - 1, 4 -DIHYDROPYRIMIDINE-2(1H)-ONES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by multi components biginelli reaction which 
involves the condensation of N-(3, 4-dimethylphenyl)-3-oxo-3-phenylpropanamide with urea 
and aryl carboxaldehydes. 
 
NH
N
H
RO
NH
O
CH3
CH3
Compound – (XI)   R= Aryl 
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SECTION: 6.2:- SYNTHESIS AND STRUCTURE ELUCIDATION OF N-PHENYL- 4 
-ARYL-[5-(3, 4 - DIMETHYL)-PHENYL AMINO CARBONYL] – 6 – 
PHENYL - 1, 4 -DIHYDROPYRIMIDINE-2(1H)-ONES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were synthesized by multi components biginelli reaction which 
involves the condensation of N-phenyl urea, and N-(3,4-dimethylphenyl)-3-oxo-3-
phenylpropanamide and substituted aromatic carboxaldehydes. 
 
SECTION: 6.3:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -              
[5 -(3,4–DIMETHYL)-PHENYL AMINOCARBONYL]–6 – PHENYL 
- 1, 4 -DIHYDROPYRIMIDINE-2(1H)-AMINO. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH
N
H
RO
NH
CH3
CH3
NH
Compound - (XIII) 
 
R= Aryl 
Compound - (XII) 
 
   R= Aryl 
N
N
H
R
O
O
NH
CH3
CH3
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The above compounds were synthesized by the condensation of N-(3, 4-
dimethylphenyl)-3-oxo-3-phenylpropanamide with guanidine hydrochloride and aromatic 
carboxaldehyde in presence of basic catalyst and DMF as a solvent. 
 
CHAPTER: -07:- STUDIES ON THIAZOLOPYRIMIDINES. 
 
The chapter deals with the preparation and structure elucidation of thiopyrimidines 
and its fused derivative thiazolopyrimidines.  
Fused pyrimidines have become of considerable pharmacological interest. Many of 
these compounds have proved to be active anticancer, antipyretic and anti-inflammatory 
agents and also exhibited modest activity against gram positive bacterial strains. In 
continuation of our interest in the chemistry of fused pyrimidines, we would like to report 
some new synthesized compounds. 
 The constitution of newly synthesized and purified compounds have been delineated 
by elemental analysis, IR, PMR & mass spectral studies. Purity of all compounds have been 
checked by thin layer chromatography using precoated silica gel plates and appropriate 
solvent system. 
 
SECTION: 7.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -              
[5 - (3, 4 – DIMETHYL)-PHENYL AMINO CARBONYL] – 6 – 
PHENYL - 1, 4 -DIHYDROPYRIMIDINE-2(1H)-THIONES. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Compound - (XIV) 
 
R= Aryl 
NH
N
H
R
NH
O
CH3
CH3
S
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The above compounds were synthesized by multicomponent biginelli reaction which 
involves the condensation of N-(3, 4-dimethylphenyl)-3-oxo-3-phenylpropanamide with 
thiourea and aryl carboxaldehydes. 
 
SECTION: 7.2:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-ARYLIDENE 
- 4 (4′-METHOXYPHENYL) - 5 - (3,4-DIMETHYL PHENYLAMINO) 
CARBONYL - 6-PHENYL - 4,7 DIHYDRO THIAZOLO [3,2-α] - 
PYRIMIDINE 3-ONES. 
 
                                 
 
                                  
 
 
 
 
 
 
 
 
 
 
 
 
The above compounds were prepared by the condensation of compound-(XIV) with 
chloroacetic acid, sodium acetate and different aromatic carboxaldehydes in presence of 
glacial acetic acid and acetic anhydride. 
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CHAPTER: - 08:- BIOLOGICAL ACTIVITY STUDIES. 
 
The chapter deals with the biological activity studies of purified compounds described 
in chapter 1 to 7. 
The purified organic compounds have been screened for their in vitro Antibacterial 
activities against Gram positive bacterial strain like S.aureus and S.pyogenus and Gram 
negative bacterial strain like E.coli and P.aeruginosa and Antifungal activities against 
fungal strains like C.albicans, A.niger , and A.clavatus. at different concentrations and MIC 
(Minimum Inhibitory Concentration) were also determined using broth dilution method.  
The antimicrobial activities of synthesized compounds have been compared with 
standard drugs like Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin and 
Norfloxacin for antibacterial and Nystatin and Greseofulvin for antifungal activities. Selected 
compounds have also been sent for Antitubercular activity studies. 
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STUDIES ON SOME COMPOUNDS OF THERAPEUTIC INTEREST 
 
 
The primary objective of medicinal chemistry is the design and discovery of new 
compounds that are suitable for use as drugs. This process requires a team effort. It not only 
involves chemists but also workers from a wide range of disciplines such as biology, 
biochemistry, pharmacology, computing and medicine amongst others. The brief introduction 
regarding studies on therapeutic interested compounds (drugs) is as under. 
 
(A) Drug: 
The word drug is derived from the French word “drogue” which means ‘a dry herb’. It 
is the single active chemical entity present in a medicine that is used for diagnosis, 
prevention, treatment / cure of a disease. This disease oriented definition of drug does not 
include contraceptives or use of drugs for improvement of health. According to “WHO” a 
drug may be defined as “Any substance or product which is used or intended to be used for 
modifying or exploring physiological system as pathological status for the benefit of the 
recipient”. 
 
(B) Pharmacology: 
Pharmacology is the science of drugs. In a broad sense, it deals with interaction of 
exogenously administered chemical molecules (drugs) with living system. It encompasses all 
aspects of knowledge about drugs, but most importantly those that are relevant to effective 
and safe use for medicinal purposes. For thousands of years most drugs were crude natural 
products of unknown composition and limited efficiency. Only the over effects of these 
substances on the body were rather imprecisely known, but how the same were produced was 
entirely unknown. Over the past 100 years or so, drugs have been purified, chemically 
characterized and a vast variety of highly potent andselective new drugs has been developed. 
The two main divisions of pharmacology are pharmacodynamics and pharmacokinetics. 
 
(a) Pharmacodynamics : It is derived from the Greek word “dynamic”means power. What 
the drugs does to the body? This includes physiological and biochemical effects of drugs 
and their mechanism of actionat macromolecular / sub cellular organ systems. 
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(b) Pharmacokinetics : It is derived from the Greek word ‘Kinesis’ means movement. What 
the body does to the drug ? This refers to movements of the drug in and alternation of the 
drug by the body; includes absorption, distribution, binding / localization / storage, 
biotransformation and excretion of the drug.Some other important aspects of pharmacology 
are given as under: 
 
* Pharmacotherapeutics : It is the application of pharmacodynamic information together 
with knowledge of the disease for its prevention, mitigation or cure. 
 
* Clinical Pharmacology : It is the scientific study of drug in man. It includes 
pharmacodynamic and pharmacokinetic investtigation in healthy volunteers and in patients; 
evaluation of efficiency and safety of drugs and comparative trials with other forms of 
treatments; surveillance of patterns of drug uses, adverse effects, etc. 
 
* Chemotherapy : It is the treatment of systemic infection / malignancy with specific drugs 
that have selective toxicity for the infecting organism / malignant cell with less effect on the 
host cells. 
 
� Drugs in general, can thus be divided into : 
 
* Pharmacodynamic agents : These are chemical substances designed to have 
pharmacodynamic effect in the recipient. 
 
* Chemotherapeutic agents : These are chemical substances designed for the treatment of 
infectious diseases or by the proliferation of malignant cells. 
 
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs as “those that satisfy 
the healthcare needs of majority of the population; they should therefore be available at all 
times in adequate amounts and in appropriate dosage form”. 
 
It has been realized that only a handful of drugs out of the multitude available can 
meet the health needs of majority of the people in any country, and that may be well tested 
and cheaper drugs are equally (or more) efficient and safe as their newer more expensive 
congeners. For optimum utilization of resources, governments (specially in developing 
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countries) should concentrate on these drugs by identifying them as Essential Drugs. The 
“WHO” has laid down criteria guide selection of an essential drug : 
(I) Adequate data on its efficiency and safety should be available from clinical studies. 
(II) It should be available in a form in which quality, including bioavailability and stability on 
storage can be assured. 
(III) Its choice should depend upon pattern of prevalent diseases; availability o f facilities and 
trained personnel; financial resources; genetic, demographic and environmental factors. 
(IV) In case of two or more similar drugs, choice should be made on the basis of their relative 
efficiency, safety, quality, price, availability and cost benefit ratio should be a major 
consideration. 
(V) Choice may also be influenced by comparative pharmacokinetic properties and local 
facilities for manufacture and storage.(VI) Most essential drug should be single compound. 
Fixed ratio combination products should be included only when dosage of each ingredient 
meets the requirements of a defined population group, and when the combination has a 
proven advantage. 
(VII) Selection of essential drug should be a continuous process which should take into 
account the changing priorities for public health action, epidemiological condition as well as 
availability of better drugs/ formulations and progress in pharmacological knowledge. 
 
(C) Drug Development: 
 
Many natural products by trial and error, came into practise for combating human 
ailments existent during early human observation. With the advent of modern scientific 
approach, various plant medicines came underchemical scrutiny, ultimately leading to the 
isolation of active principles sincerely. 
Such compounds either in extract form or in pure form became a part of 
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use for over 5000 
years for the treatment of various types of fever and respiratory ailments, its active principle, 
Ephidrine was isolated in 1887. In 1925 chemical investigations followed by pharmacological 
evaluation led this compound into the modern medicine. Similarly during this period, urea 
stibamine was introduced as the first drug in 1920 for the treatment of Kala-azar. In 1930, De 
Rauwolfia preparation were first employed for sedative and hypotensive properties. A drug is 
a substance having abnormal effect on certain body functions eg. Strychnine stimulates the 
action of heart and aspirin retards its action. Since both of them effects abnormally, the two 
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substances are known as drugs. Chemical sciences contributed extensively new discoveries 
leading to useful drugs since after 1930. The modern concept of drug discovery started in 
1933 by Gerhand Domagk with his finding of “Prontosil Red”, a compound responsible for 
the antibacterial activity. The advent of sulphonamides drew the attention for the different 
activities of various chemicals for bacterial and human cells, this important factor prompted 
Florey and Chain in 1939 to investigate penicillin which was discovered ten years earlier by 
Alexander Fleming. The spectacular chemotherapeutical properties of penicillin and its 
dramatic war-time development for the treatment of wounds made penicillin, a most 
commonly used inexpensive drug. A large number of important drugs have been introduced 
during the period of 1940 to 1980. This period is known as “Golden period” of new drug 
discovery. Thus starting from 1933 - the first antibacterial drug prontosil leading to various 
sulpha drugs ; 1940 – penicillin ; 1945 – chloroquine – antimalarial ; 1950 – Methyldopa 
– anti-hypertensive; 1967 – chlorothiazine -diuretic; 1958 - adrenergic beta blockers 
coronary vasodilatory; 1960 – semi synthetic penicillin -antibacterial; 1965 -trimethoprim-
antimicrobial;1967- disodium chromoglycoate - antiallergic; 1972 - cimetidine H2– 
antagonist; 1975 -verapamil- calciumantagonist and 1981 - captopril - antihypertensive. 
There are some specific examples representing new therapeuticagent eg. Metormine 
glipizide-anti diabetic. 
 
(D) Latest Drug Developments: 
 
The current interest in the creation of large, searchable libraries of organic compounds 
has captured the imagination of organic chemists and the drug discovery community. In 
numerous laboratories the efforts are focused on the introduction of chemical diversity, which 
have been recently reviewed and pharmacologically interesting compounds have been 
identified from libraries of widely different compositions. 
The process of drug design is extensively driven by the instinct and experience of 
pharmaceutical research scientists. It is often instructive to attempt to “capture” these 
experiences by analyzing the historical record that are successful drug design projects of the 
past. From this analysis, the inferences are drawn which play an important role in shaping our 
current and future projects. Towards this region, we would like to analyse the structures of a 
large number of drugs - the ultimate product of a successful drug design effort. Our goal for 
this is to begin to deconvolute this information in order to apply it to design of new drugs. 
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Different kinds of drugs are developed for different types of diseases viz. which can 
be defined with their names of the modern drugs are as under. 
 
(a) Anticancer drugs 
The drugs, which stops the abnormal growth of cell tissues in human body, are termed 
as anticancer drug. Vinblastin and Busulphan are the novel anticancer drugs. 
(b) Hepatoprotective drugs 
Drugs, which gives vitality to liver and protects liver by giving immunity power 
against antibodies, are termed as Hepatoprotective drug. 
 
(c) Antimalarial drugs 
Drugs, which kills the plasmodium causing malaria are called antimalarial drug. 
Combination of Sulphamethoxazole with Pyrimethamine is a novel antimalarial drug. 
 
(d) Drug for meningitis 
Drugs, which cures the inflammation of meningitis, are termed as meningitis drugs 
Cifalexin is a novel meningitis drug. 
 
(e) Drug for typhoid 
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are known as 
typhoid drugs. A novel drug for typhoid is Ciprofloxacin. 
 
(f) Antidiabetic drugs 
Drugs, which converts the excess glucose of blood into glycogen are termed as 
antidiabetic drugs. Novel antidiabetic drugs are Metformin, Glipizide and Gliclazide. 
 
(g) Antitubercular drugs 
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures lesions 
of pleural cavity. A novel antitubercular drug is Ethambutol. 
 
(h) Antiasthamatic drugs 
Drugs, which prevents the attack of asthama and gives relax respiration are called 
antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline, Theophylline and 
Asmon. 
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(i) Antihypertensive drugs 
Drugs, which normalizes the blood pressure by dilating blood vessels are called 
antihypertensive drugs. Novel antihypertensive drugs are Atenolol, Amlodipine and 
Nifedipine. 
 
(j) Anti-AIDS drugs 
Drugs, which kill the viruses of AIDS i.e., HIV-1 and HIV-2, are called anti-AIDS 
drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine.  
The ultimate product of a successful drug design effort. Our goal for this is to begin to 
deconvolute this information in order to apply it to design of new drugs. 
 
AIMS AND OBJECTIVES 
 
In the pharmaceutical field, these have always been and will continue to be a need for 
new and novel chemical inhibitors of biological function. Our efforts are focused on the 
introduction of chemical diversity in the molecular fram work in order to synthesizing 
pharmacologically interesting compounds of widely different composition. 
During the course of our research work, looking to the application of heterocyclic 
compounds, several entities have been designed, generated and characterized using spectral 
studies. The details are given as under. 
1. To synthesize therapeutically active compounds like Schiff’s bases, oxadiazole , 
mannichbases, pyrazolines, cyanopyridines, thiopyrimidines, dihydropyrimidines and 
thiazolopyrimidines. 
2. To characterize these products for structure elucidation using several spectroscopic 
techniques like IR, PMR and Mass spectral studies. 
3. To assess the reaction and purity of the compounds were done by TLC. 
4.  To evaluate these products for better drug potential against different strains of 
bacteria and fungi. 
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In view of these facts, the research work presented in thesis is as follows. 
 
CHAPTER: - 01 STUDIES ON OXADIAZOLES. 
CHAPTER: - 02 STUDIES ON MANNICHBASES.  
CHAPTER: - 03 STUDIES ON PYRAZOLINES. 
CHAPTER: - 04 STUDIES ON PRIMIDINE-2-THIONES. 
CHAPTER: - 05 STUDIES ON CYANOPYRIDINES. 
CHAPTER: - 06 STUDIES ON DIHYDROPYRIMIDINES. 
CHAPTER: - 07 STUDIES ON THIAZOLOPYRIMIDINES. 
CHAPTER: - 08 BIOLOGICAL ACTIVITY STUDIES. 
  
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
CHAPTER - 1 
STUDIES ON 
OXADIAZOLES 
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INTRODUCTION 
Azomethine derivatives have been found to be potent drug in pharmaceutical 
industries and possess a wide spectrum of biological activity. Azomethines are also 
known as Schiff’s base and they are well known intermediates for the preparation of 
oxadiazoles, azetidinone, thiazolidinone, formazone, arylacetamide and many other 
derivatives. These are the compounds which contain characteristic -C=N group. D. R. 
Dabideen et al.1 have prepared Schiff’s base (I) containing indole moiety as potent 
inhibitors of macrophage migration inhibitory factor proinflammatory activity. 
 
 
 
 
  
   
 
 
Azomethines were discovered by Hugo Schiff2 by the condensation of 
carbonyl compounds with primary amines in presence of acid catalyst in 1864. 
However, it is more convenient to work in a solvent such as alcohol, dilute acetic acid 
or glacial acetic acid. Sometime the reaction is aided by trace of acid, in other cases 
the hydrochloride of the amines can be used in the synthesis. 
 In general Schiff’s bases do not react further with either of the reagents used 
in their preparation as do most of the other types of simple intermediates. 
 
SYNTHETIC ASPECT 
Azomethine derivatives can be prepared by various methods, which are described 
as under.   
1. General account of the summary of reaction of aldehydes with amine 
(aromatic or aliphatic) has been reviewed by Murray3. 
 
 
 
 
OH
N
OMeO
N
H
(I) 
CHOR + R' NH2 R CH N R'
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2. Strache4 and Van Alphen5 have prepared imine involving in two steps. 
(a) Addition of the amine to the carbonyl group of the aldehyde gives aldol. The 
aldol is rarely capable of isolation. 
 
 
 
(b) The loss of water to give an imine (azomethine), this corresponds to the 
“crotonaldehyde stage” of the aldol condensation. 
3. Oddo and Tognacchini6 have introduced the comparative rates of formation of 
Schiff’s base from aniline; substituted aniline and aromatic aldehyde using a 
cryoscopy method follow the course of reaction. 
4. P. L. Beaulieu and co-workers7 have synthesized (E)-N-phenyl methylene glycine 
ethyl ester by the cyclocondensation of glycine ethyl ester hydrochloride, t-butyl 
methyl ether (TBME), benzaldehyde was added followed by anhydrous Na2SO4 
and triethylamine. 
 
5. Amanda J. Gallant et al.8 have prepared Schiff’s bases by condensation of 
equimolar quantity of 3,6 diformyl catechol and substituted o-phenylenediamine. 
 
6.  Nataliya E. Borisova et al.9 have demonstrated metal-free methods in the synthesis 
of macrocyclic Schiff’s bases by the condensation of 2,6-dicarbonyl derivatives of 
phenols and thiophenols with diamines in the presence of acid. 
CHOR R' NH2 CHOHNHR R'
NH2
COOEt
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7.  Ina Bolz et al.10 have reported novel Schiff’s bases (II) derived from 5- amino 
barbituric acid with para-nitro and para-N,N-dimethylamino cinnamaldehyde in 
ethanol. 
 
 
 
 
 
 
 
 
 
 
 
 
8. H. S. Joshi et al.11 have synthesized several Schiff’s bases (III) from 4-amino-5-
(3-pyridyl)-4H-1,2,4-triazol-3-thiol and different aryl aldehyde by using glacial 
acetic acid as a catalyst. 
 
 
 
 
 
 
 
 
9. Takanori Tanaka et al.12 have developed new chiral Schiff’s base (IV) as a catalyst 
for the enantioselective addition of diethyl zinc reagents to aldehydes. 
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MECHANISM 
 
 
THERAPEUTIC IMPORTANCE 
Schiff bases exhibit a wide range of pharmacological activities like antifungal,        
antibacterial, antiviral, anti-inflammatory etc. B. Shivarama Holla et al.13 have 
prepared some new Schiff’s bases having anticancer activity. Ravindra V . Chambhare 
et al.14 have prepared some azomethine and tested for their antimicrobial activity. 
 Yadav Bodke and S. S. Sangapure15 have synthesized some azomethine and 
tested for their biological activity. Pawar et al.16 have synthesized azomethine by the 
condensation of iodovanillin with different substituted aromatic amines, and 
determined antibacterial activity. 
 N. Raman and co-workers17 have prepared Schiff’s bases of 4-amino 
antipyrine and reported as antimicrobial activity. R. Nair et al.18 have  prepared some 
4-ethyl-6-{(E)-1- [3-arylimino] ethyl} benzene-1,3-diol derivatives (I) from 
resacetophenone and reported their antibacterial activity. 
 
 
 
 
 
 
 
 
  
R
H
O
R
H
OH+
NH2 R1
+H2N
H
R1
R OH
+H2N
H
R1
R +OH2
R
H
N+
H
R1 R
N
R1
H
+
H+
-H+H2O+
- H2O
OHOH
H5C2
CH3
N
R
R=m-nitro-ph, o-nitro-ph   (I) 
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  Mehta R. H. et al.19 have synthesized coummarin Schiff’s base derivatives of 
(II) and examined for their antibacterial activity. Khalafallah A. K. and Hassan M. 
E.20 have prepared some styryl Schiff’s bases derivatives as potential antibacterial and 
antifungal activity. Sharaf El-Din, and Nabaweyal21 have synthesized some 
azomethine Derivatives (III) having good antibacterial activity. 
 
 
 
 
 
 
 
D. R. Shekawat et al.22 have reported in an earlier communication the 
synthesis and study of Schiff’s bases from substituted benzaldehyde N-mustards and 
various aryl amines. A number of compounds from this series displayed significant 
activity against dunning leukemia (solid), lymphoid leukemia (L1210), and walker 
carcinosarcoma (256) (intramuscular). S. Ren and co-workers23 have reported 
synthesis, biological evaluation, and quantitative structure-activity relationship 
analysis of new Schiff’s bases of hydroxy semicarbazide as potential antitumor 
agents. M. A. Castro et al.24 have synthesized Schiff’s base (IV) from pedophilic 
aldehydes and aliphatic, aromatic and heterocyclic primary amines, all of them 
maintained the main biological property the cytotoxic selectivity against the HT-29 
cell line. 
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Chohan et al.25 have synthesized azomethines, which have been screened and 
compared for their antibacterial action against bacterial species Escherichia coli, 
Pseudomonas aeruginosa and Klebisella pneumonias. Das Joydip26 have synthesized 
trans-N-refinylidene-n-butylamine (V) which found stabilized in liposome of 
phosphatidylcholine. The rate of formation of the Schiff’s base is found to decrease 
with increasing cholesterol concentration in the membrane. Patel V . M.27 have 
synthesized some new Schiff’s bases having good antibacterial activity. 
 
 
 
 
 
 
 
 
 
Lei Shi et al.28 have confirmed synthesis and antimicrobial and antifungal 
activities of Schiff’s bases derived from 5-chlorosalicylaldehyde and primary amines. 
Schiff’s bases also shows excellent fluorescent properties which is reported by 
different chemists.29-31 Schiff’s bases are also utilized as starting material in the 
synthesis of industrial.32 and biological compounds such as â-lactams.33 S. Samadhiya 
et al.34 have prepared some Schiff’s bases and reported as herbicidal and pesticidal 
activities. J. Jyh-Jia et al.35 have synthesized a series of chemically modified aryl-
aldehyde Schiff’s bases and tested for their antioxidant activity and radiation 
protection. J. Parikh and co-workers36 have demonstrated some 4-[(arylidene) amino] 
benzoic acid and screened as potential antibacterial agents against bacteria and fungi 
using the Agar Ditch method. Palwinder Singh et al.37 have reported syntheses and 
anti-cancer activities of 2-[1-(indol-3-yl)-but-3-enylamino]-2-phenyl-ethanols (VI). 
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Deshmukh M. D. and Doshi A. G.38 prepared some new Schiff’s bases showing 
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysentry 
and Salmonella typhi. Wang and Yangang39 have synthesized diazomethines having 
plant hormone activity. Das Arima et al.40 have prepared Schiff’s bases of 
aminohydroxyl guanidine (SB-AHG5) and tested for antiviral activity against Herpes 
Simplex virus (HSV-1) and adenovirus (Ad-5) along with eleve other heterocyclic 
SB-AHG5. 
Pawar R. P . et al.41 have synthesized azomethines by the condensation of 
iodovanillin with different substituted aromatic amines and tested for antibacterial 
activity. Ergenc and co-workers42 have synthesized azomethine derivatives having 
antifungal activity. Yadav Bodke43 have synthesized some azomethines and tested for 
their biological activity. B. Shivarama Holla et al.44 have prepared and reported 
anticancer activity of some new Schiff’s bases. 
Cascaval Alexandru et al.45 have synthesized azomethines, which have good 
analgesic and antipyretic properties. Pandeya S. N. et al.46 have synthesized Schiff’s 
bases showing good activity against Vibrio cholerae non-O., Shigella boydii, 
Enterococcus faecalis and Edwaredsiella torla with MIC in the rang of 10-25 μg/ml. 
Some compounds were found to be active against Salmonell typhi and Vibro 
cholerae-0, (MIC 25-150 μg/ml). 
Ali Yousif et al.47 have synthesized some Schiff’s base derivatives of glucose 
containing acetylenic bond and tested for their bactericidal activity against E. coli and 
Staphylococcus aureus. 
Ravindra V . Chambhare et al.48 have prepared some azomethines and tested 
for their antimicrobial activity. B. Shivarama Holla et al.49 have synthesized 
azomethines of (VII) having antibacterial and anti-inflammatory activity. 
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Ram Tilak et al.50 have synthesized some Schiff’s bases, thiazolidinones 4 -
triazolines, and formazones of 2-chloro phenothiazines and screened against 
carrageen induced edema in albino rats. The thiazolidinones showed promising anti-
inflammatory activity. 
S. K. Sridhar et al.51 and R. Mladenova et al.52 have separately synthesized 
some Schiff’s base derivatives and reported as antibacterial agents. P . Panneerselvam 
et al.53 and S. N. Pandeya et al.54-55 have been separately prepared some schiff’s base 
derivatives and reported as antifungal agent. M. N. Ibrahim et al.56 have reported 
synthesis and use of Schiff’s bases as fluorimetric analytical reagents. V . Alagarsamy 
et al.57 have been reported some Schiff’s base bearing quinazolin nucleus as 
analgesics and anti-inflammatory agents. S. B. Desai et al.58 and P . Pathak et al.59 
have separately reported Schiff’s bases as anticancer agents. K. Vashi et al.60 have 
synthesized a series of 2'-hydroxy-3'-chloro-5'-ethyl-N-(p-tolyl)-chalconimines and 
screened for their antibacterial activity against Staphylococcus aureus and Escherichia 
coli. Michael J. Hearn et al.61 have prepared isoniazide Schiff’s bases and evaluated as 
antitubercular activity against Mycobacterium tuberculosis. S. N. Pandeya et al.62 
have reported synthesis, antibacterial, antifungal and anti-HIV activity of Schiff’s 
base of isatin with N-[6-chlorobenzothiazol-2-yl] thiosemi carbazide. 
From above importance of Schiff’s bases we also studied the methyl-N-aryl 
amines by reduction of Schiff’s base. From literature survey it is proved that these 
derivatives have different variety of biological activities such as P2X7 receptor 
antagonists,63 HDM2- p53 protein-protein antagonists,64 MCH1 receptor antagonist,65 
NPY5 antagonists,66 dual Atk1/2 inhibitors,67 Selective (VIII) dopamine D3 
receptors,68 antiobesity (IX) and antidiabetic.69  
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Several methodologies are also reported for the synthesis of methyl-N-aryl 
amine derivatives like, Diels-Alder reaction,70 carbonylation/intramolecular 
amidation,71 phenol Ugi-Smiles condensation,72 based-induced cyclization,73 and 
Staudinger/aza-Wittig reaction,74 by using bifunctional reagents in MCRs,75,76 by 
Ullmann-Goldberg coupling77 by using transmetallating agents such as 
triarylbismuth,78 aryllead triacetates,79 arylboronic acids,80,81 hypervalent aryl 
siloxanes.82 
Looking to the interesting properties of azomethines, we have synthesized 
some new azomethines, which have been described as under. 
 
SECTION-1.1: SYNTHESIS AND STRUCTURE ELUCIDA TION OF  4-ISO 
  PROPOXY-N'-[(1E)–(ARYL) METHYLENE] BENZOHYDRAZIDE. 
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INTRODUCTION:    
 
Thermally stable neutral aromatic 1,3,4-oxadiazoles83 have been known for 
about 80 years. They have been subjected to intensive investigation particularly in the 
last decade because of their broad spectrum of uses as biologically active compounds 
in medicine, agriculture and dyestuff industries. 1,3,4-oxadiazoles also have been 
useful in diverse areas like drug synthesis, heat resistant ad UV absorbing polymers. 
The literature prior to 1965 is surveyed in comprehensive reviews84-86. The moiety is 
represented by the structure (I). 
 
 
 
 
 
 
 
 
2,5 di substituted 1,3,4-oxadiazole and its derivatives constitute an important 
class of heterocyclic compounds. Due to their remarkable biological activity, like 
anticancer152, antimicrobial153, antimalarial154, anticonvulsant155, anti-inflammatory156, 
anti-HIV-1157, 1, 3,4-oxadiazole and its derivatives have been frequently employed in 
drug synthesis, various commercial and industrial applications. In fact 1,3,4-
oxadiazole ring carrying substitution in an appropriate position and substituent with a 
nucleophillic centre, are excellent precursors for further synthesis of five and six 
membered heterocycles. A detailed account of biological activities, synthetic 
usefulness is described in this section.  
The work presented in the current section is concerned with the synthesis, 
characterization and antimicrobial activity studies of some novel 1,3,4-oxadiazoles. 
 
 
SYNTHETIC ASPECTS: 
Different methods for the preparation of 1,3,4-oxadiazole derivatives known 
in literatures are as follows. 
O
N N
R R'
 (I) 
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1. From N, N’- diacyl hydrazines: 
The common synthetic approaches to the oxadiazoles involve 
cyclization of diacyl hydrazines. A variety of reaction conditions and 
anhydrous reagents as mentioned below, have been used to induce cyclization 
of N-N’diacylhydrazines to their respective 1,3,4-oxadiazoles (I). The general 
reaction is represented below. 
 
 
 
 
 
(a) Iodobenzene has been found to be an excellent reagent for the oxidation of a 
variety of hydrazines to N,N’-diacyl hydrazines which undergo readily 
cyclization to yield 1,3,4-oxadiazoles.87 
(b) A novel and efficient means of affecting the cyclodehydration of N,N’-diacyl 
hydrazines is reported by Brain and coworkers88 by using polymer supported 
burgess reagent in combination with single mode microwave heating. 
(c) Pd-catalyzed cyclization of N,N’-diacylhydrazines is successfully done by 
Lutuns and his coworkers.89 
(d) N, N’-diacylhydrazines on reaction with bissylyl (Me2SiCl2) in the presence of 
traffic acid catalyst have been reported90 to yield 1,3,4-oxadiazoles. 
 
2.  From aldehydes: 
 
(a) Aldehydes have been used with trichloroacetic acid hydrazide in the presence 
of a base to yield 1,3,4-oxadiazoles91 (II). 
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3. From trichloromethylarenes92 
Symmetrical 2,5- diaryl-1,3,4-oxadiazoles (III) have been prepared by 
making use of trichloromethylarenes with excess of hydrazine hydrate in 
alcohol with 68-98% yield. 
 
 
 
 
 
4. From Acid Hydrazide: 
Four different routes from acid hydrazides are known to lead the 
formation of 1,3,4-oxadiazoles. 
(a) N-acylhydrazines are known to react with orthoformic ester to yield 
intermediate imino derivatives, which are at correct oxidation level to cyclize 
directly to the respective 1,3,4-oxadiazoles93 (IV). 
 
 
 
 
 
 
(b) Ladva94 and his coworkers have utilized the reaction of acid hydrazides with 
aromatic acids in the presence of phosphoryl chloride. This lead to the 
formation of corresponding 2,5-disubstituted-1,3,4-oxadiazoles (V). 
 
 
 
 
 
(c)     Chloroacetic acid reacts with phenol to give phenoxyacetic acid. This acid 
 after Conversion to phenoxy acetic acid hydrazide has been cyclized in the 
 presence of  cyanogen bromide to give 2-amino-5-substituted-1,3,4-
 oxadiazole95 (VI). 
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(d) Carboxylic acid hydrazides96 when treated with carbon disulphide in the 
 presence of potassium hydroxide in ethanol, yielded 5-substituted-2-mercapto-
 1,3,4- oxadiazoles (VII). 
 
  
 
 
 
 
(e) Lee et al.97 have reported the synthesis of 1,3,4-oxadiazoles (VIII) having 
phenol or thiophenol group. This was achieved by the treatment of suspension 
of salicylic acid hydrazide in toluene with acetic anhydride in the presence of 
equimolar methansulfonic acid. 
 
 
 
 
 
 
 
 
5. From heterocyclic esters  
 Due to biological importance of pyridazines and 1,3,4-oxadiazoles. 
E.A.Bakhite and coworkers98 synthesized derivatives containing both the entities in 
one molecule. Treatment of ethyl-5-hydroxyl-3,4-diphenylthieno [2,3-c]pyridazine -6-
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carboxylate with hydrazine hydrate in ethanol to carbohydrazide. Furthermore, 
refluxing of carbohydrazide in glacial acetic acid resulted in the formation of the 
corresponding 1,3,4-oxadiazole (IX). 
 
 
 
 
 
 
 
 
 
 
 
6. From Di(benzotriazole-1-yl)methanimine 
 A.R. Katritzky and coworkers99 synthesized 2-amino-5- phenyl-1,3,4-
oxadiazole (X) by the reaction of benzene carbohydrazide with di(benzotriazol-1-yl) 
methanimine in THF. 
 
 
 
 
 
 
 
7. From Trichloroacetic Acid hydrazones 
 El kaim and coworkers 100 developed novel route for the synthesis of new 
1,3,4,-oxadiazoles (XI) from hydrazones. This was achived by the reaction of 4-nitro 
phenol trichloro acetate with hydrazine and in situ tapping with carbonyl derivative. 
This was followed by the treatment of these hydrazones with potassium carbonate 
under phase transfer conditions to new 1,3,4-oadiazoles. 
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8. Microwave Assisted Oxidation of 1-Aryl-2-aroylidine hydrazines 
 Synthesis of 2,5-di substituted-1,3,4-oxadiazoles (XII) by oxidation of 1-
aroyl-2-arylidene hydrazines under microwave irradiation using potassium 
permanganate and mixture of acetone/water has been reported by S.Rostamizadeh and 
coworkers.101 
 
 
 
 
 
 
 
 
 
THERAPEUTIC IMPORTANCE 
 2,5-Disubstituted 1,3,4-oxadiazole derivatives have been tested for various 
pharmacological properties, which have been summarized in following sections: 
1. Antitubercular102-103 
2. Antimalarial104 
3. Hypnotic and sedative105 
4. Antithrombic106 
5.  Anticonvulsatant107 
6.  Hypoglycemic108 
7.  Anti-inflammatory109-110 
8.  MAO inhibitor111 
9.   Bactericidal112-113 
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10. Antitumor114 
11. Anticancer115 
12. Anti-HIV-1116 
13. Nematocidal117 
14. Herbicidal118-119 
15. Antihypertensive120 
 Beriger Ernst121 have synthesized a series of oxadiazoles bearing substituted 
furan ring system and reported them as nematocides. A variety of oxadiazoles have 
been synthesized and assessed for their anti-inflammatory122, antihypertensive and 
virucidal activity.159 Kazunori Oono et al.123 have prepared 2,5-disubstituted 1,3,4-
oxadiazoles (I) as anxiolytics and anticonvulsants. Andotra et al.124 have prepared 
some 2-amino -1,3,4-oxadiazoles as antibacterial agents. Antipyretic, anti-
inflammatory and analgesic activities of 1,3,4-oxadiazoles have been reported125. 
Moreover, in vitro pesticidal activity has been found in compound (II) having 
oxadiazole nucleus. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-Amino -1,3,4 – oxadiazoles act as muscle relaxant126 and showed 
antimicotic activity.127 Eduardo Cortes et al.128 have synthesized some 5-methyl -4H-
1-(p-R1-phenyl)-3a, (p-R2-phenyl)-3a, 4- dihydro [1,2,4] oxadiazole [4,5-a] [1,5] 
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benzodiazepines to confirm its pharmacological activity as an anticonvulsant drug 
(III). 
 
 
 
 
 
 
 
 
Moreover B. shivarama Holla et al.129 have also synthesized 1,3,4- oxadiazoles 
derivatives (IV) and tested for antibacterial activity. 
 
 
 
 
 
Sulabh Sharma and coworker130 have reported the anti-inflammatory activity 
of some new 1,3,4- oxadiazole derivatives (V). 
 
 
 
 
 
 
 
J. C. S. Kataky131 have reported 2-amino [4-(5-(2-chlorophenyl)-1,3,4-
oxadiazole)-2-yl] 6-aryl/substituted aryl -7-oxo-6,7- dihydro thiazolo [4,5-d] 
pyrimidine -5(H)- thiones  and evaluated for antimicrobial activity and fungitoxicity. 
Harendra singh et. Al.132 have synthesized 2-aryl-6-arylamino-1,2,4-thiadiazolo [3,2-
b]-1,3,4-oxadiazoles and screened for fungal toxicity. 
Parikh et al. have synthesized variety133 of 1,3,4-oxadiazoles bearing aryl 
sulphonamido aryl,134-135 mercapto,136 quinolinyl137 and amino moieties at 2-position 
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(Y) and 4’-pyridyl, benzenesulphonamidophenyl, diiodoquinolinoxy and aryl 
sulfonamido phenyl at 5-position (X) as antimicrobial agents. 
H.H.Parekh and co-workers have investigated 1,3,4-oxadiazoles having 
triazine,138-139 phenyl sulphonyl,140 2’- isopropyl -5-methyl phenoxy methyl,141-143 
dapson144-146 moieties at position (X) and aryl, aryl amino, arylsulphonamido, 
substituted benzalamino moieties at 2-position (Y) and evaluated their antimicrobial 
activity, General structure for above references is as under. 
 
Chan, Wai Ngor and et al.147 have synthesized 1,3,4-oxadiazole derivatives 
(VI) and reported as orexin receptor antagonists. Grover et al.148 have synthesized 
1,3,4-oxadiazole derivatives and tested for antibacterial activity. Khan and Akhtar149 
have reported the anti-inflammatory activity of some new 1,3,4-oxadiazole 
derivatives. Ayscough and co-workers150 have synthesized oxadiazoles (VII) and 
tested for anti-inflammatory activity. 
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K C Ravindra, H M V agdevi, V P V aidya & Basavaraj Padmashali151 have prepared 
1,3,4- oxadiazoles linked to naptho [2,1-b] furan (VIII) and evaluated for 
antimicrobial and anti-inflammatory. 
 
 
 
 
 
 
 
 
 
 
Vital contribution of 1,3,4-oxadiazole ring system to the medicinal chemistry 
as an active constituent of antibiotics made chemists to explore for its other 
derivatives as therapeutic agents. Accordingly, several derivatives of 1,3,4-
oxadiazoles have been designed as under. 
  
 
SECTION:-1.2:- SYNTHESIS AND STRUCURE ELUCIDATION OF 2 - (4 -
ISOPROPOXY- PHENYL)-5 (ARYL) - 1,3,4- OXADIAZOLES. 
O
N N
O R
(VIII) 
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SECTION-1.1 
 
SYNTHESIS & STRUCTURE ELUCIDATION OF 4-ISOPROPOXY- N'-[(1E) 
– (ARYL) METHYLENE] BENZOHYDRAZIDE. 
The increasing copyright literature of current years demonstrates that the 
azomethines derivatives are worn as superior therapeutic agents. In vision of these 
conclusion, it appeared of concentration to synthesize Schiff’s bases of the below 
mentioned compounds by the condensation of 4-isopropoxy benzoic acid hydrazide 
with different aromatic aldehydes. 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (Ia-j) have been screened for their in vitro 
therapeutic assay like Antibacterial activities towards Gram positive and Gram 
negative bacterial strain and Antifungal activities towards fungal strains at different 
concentrations (Minimum Inhibitory Concentration). The biological activities of 
synthesized compounds (Ia-j) have been compared with standard drugs viz. 
Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(Chapter-8). 
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IR SPECTRALSTUDIES OF 4-ISOPROPOXY BENZOICACID HYDRAZIDE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2973 2975-2950 158 
-CH3 C-H str. (sym)  2872 2880-2860 " 
 C-H def. (asym.) 1419 1470-1435 " 
 C-H def.(sym.) 1384 1390-1370 " 
Aromatic C-H str. 3043 3090-3030 159 
 C=C str. 1527 1540-1480 " 
 C-H i.p. def. 1120 1125-1000 " 
 C-H o.o.p. def. 840 835-810 " 
Moiety C-O-C (asym) 1101 1075-1010 160 
Amide -CONH- 1606 1660-1580 161 
Hydrazide -NH-NH2 3395 3380-3410 " 
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PMR SPECTRAL STUDIES OF 4-ISOPROPOXY BENZOICACID 
HYDRAZIDE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
(300 MHz).  
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 1.33 6H doublet (CH3)2 moiety 
2 4.17 2H singlet(broad) -NH2 
(Hydrazide) 
3 4.59 1H multiplet -CH-(isopropyl) 
4 6.86-6.88 2H doublet Ar-Ha,a’  
5 7.72-7.74 2H doublet Ar-Hb,b’  
6 8.13 1H Singlet -CONH- 
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IR SPECTRAL STUDIES OF 4-ISOPROPOXY-N'-[(1E)-(4-METHOXY 
PHENYL) METHYLENE] BENZOHYDRAZIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2978 2975-2950 158 
-CH3 C-H str.(sym)  2833 2880-2860 " 
  C-H def.(asym.) 1488 1470-1435 " 
  C-H def.(sym.) 1372 1390-1370 " 
Aromatic C-H str. 3071 3090-3030 159 
  C=C str. 1550 1540-1480 " 
 C-H i.p. def. 1057 1125-1000 " 
 C-H o.o.p. def. 842 835-810 " 
Moiety Ar-O-C (sym.) 1057 1075-1010 160 
Ether C-O-C (asym) 1287 1275-1200 158 
Amide -CONH- 1620 1660-1580 " 
Schiff 
base 
-N=CH- 1596 1600-1580 " 
Sec.amine -NH- 3199 3410-3380 " 
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PMR SPECTRAL STUDY OF 4-ISOPROPOXY-N'-[(1E)-(4-METHOXY 
PHENYL) METHYLENE] BENZOHYDRAZIDE. 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
(300 MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 1.30 6H doublet (CH3)2 moiety 
2 3.43 3H Singlet -N=CH-
(schief.) 
3 3.83 1H Singlet Ar-OCH3 
4 4.69 1H multiplet -CH-(isopropyl) 
5 7.03-7.98 8H multiplet Ar-H 
6 8.42 1H Singlet -CONH- 
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EXPERIMENTAL 
 
SYNTHESIS & STRUCTURE ELUCIDATION OF 4-ISOPROPOXY- N'-[(1E) 
– (ARYL) METHYLENE] BENZOHYDRAZIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 4-ISOPROPOXY BENZOIC ACID HYDRAZIDE. 
 A mixture of 4- isopropoxy benzoic acid ethyl ester (50gm, 0.24mol) and 
hydrazine hydrate (24gm, 2.0mol) was refluxed in ethanol (100ml) for 10 to 12 hrs, 
the completion of reaction was monitored by thin layer chromatography (TLC).after 
completion of reaction the reaction mass was cooled at room temperature and poured 
in ice water, the product was filtered and dried and finally crystallized with ethanol. 
Yield: 85%, m.p. - 112˚ C; [C10H14N2O2; required: C, 61.84; H, 7.27; N, 14.42 %; 
found: C, 61.80; H, 7.25; N, 14.39 %]. 
 
[B] PREPARATION OF 4-ISOPROPOXY-N'-[(1E)-(4-METHOXY PHENYL) 
METHYLENE] BENZOHYDRAZIDE. 
A mixture of 4-methoxy benzaldehyde (4.08 gm, 0.03 mol) in ethanol (30 ml) 
was added to a solution of 4-isopropoxy benzoic acid hydrazide (5gm, 0.025mol) 
ethanol, added glacial acetic acid (2 ml) as a catalyst. The reaction mass was refluxed 
for 5-6 hrs, the solvent was distilled out under reduced pressure and solid mass so 
obtained was isolated and purified by recrystallization from appropriate solvent, yield: 
90%, m.p.-185˚C; [C18H20N2O3; found: C, 69.20, H, 6.39, N, 8.90, requires C, 69.21, 
H, 6.45, N, 8.97 %]. 
Similarly, other 4-isopropoxy-N'-[(1E)-(aryl) methylene] benzohydrazide were 
prepared. The physical constants are recorded in Table No. -1. 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[C] BIOLOGICAL EVALUATION OF 4-ISOPROPOXY-N'-[(1E)-(ARYL) 
METHYLENE] BENZOHYDRAZIDE. 
Antimicrobial testing was carried out as described in Chapter-8. The zones of 
inhibition of test solutions are recorded in Graphical Chart-1a, Table-1a. Page No.-
357, 358. Result and discussion is given on page No.:-359. 
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SECTION-1.2 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2-(4-ISOPROPOXY- 
PHENYL)-5 (ARYL) - 1,3,4- OXADIAZOLES. 
 Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention 
in view of therapeutic applications. Looking to this, the synthesis of 1,3,4-oxadiazoles 
of  type-(II) was undertaken by two different method, in which reaction of Schiff base 
with Chloramine-T and KMnO4 was taken as shown in reaction scheme 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (IIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (IIa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations. 
(Chapter-8). 
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IR SPECTRAL STUDIES OF 2-(4-ISOPROPOXYPHENYL)-5-(p-METHOXY 
PHENYL)-1, 3, 4-OXADIAZOLE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2977 2975-2950 158 
-CH3 C-H str. (sym)  2830 2880-2860 " 
 C-H def. (asym.) 1497 1470-1435 " 
 C-H def.(sym.) 1380 1390-1370 " 
Aromatic C-H str. 3017 3090-3030 159 
 C=C str. 1518 1540-1480 " 
 C-H i.p. def. 1078 1125-1000 " 
 C-H o.o.p. def. 819 835-810 " 
Moiety Ar-O-C (sym.) 1067 1075-1010 160 
 C-O-C (asym) 1264 1275-1200 161 
Oxadiazole N-N str. 1040 1050-1010 " 
 C=N str. 1609 1660-1580 " 
 C-O-C str. 1264 1275-1200 " 
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PMR SPECTRAL STUDIES OF 2-(4-ISOPROPOXYPHENYL)-5-(p-
METHOXYPHENYL)-1, 3, 4-OXADIAZOLE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz) 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 1.38 6H doublet (CH3)2 moiety 
2 3.88 3H Singlet Ar-OCH3 
3 4.65 1H multiplet -CH-(isopropyl) 
4 6.98-7.02 4H Double doublet Ar-Ha, a’,b,b’  
5 8.02-8.06 4H Double doublet Ar-Hc, c’,d,d’ 
 
 
 
 
 
 
 
a
a'
b
b'
c
c'
d
d'
O
CH3
CH3
O
N N
O
CH3
Studies on some compounds…                                                                                     59 
 
Oxadiazoles… 
M
A
SS
 S
PE
C
T
R
A
L
 S
T
U
D
IE
S 
O
F
 2-
(4
-I
SO
PR
O
PO
X
Y
PH
E
N
Y
L
)-5
- 
(4
-M
E
T
H
O
X
Y 
PH
E
N
Y
L
) -
1,
 3
, 4
-O
X
A
D
IA
Z
O
L
E 
O
CH3
CH3
ON
N
O
CH3
m
/z
 =
 3
10
.3
4
 
 
 
 
 
 
 
 
 
 
Studies on some compounds…                                                                                     60 
 
Oxadiazoles… 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N N
O
O
CH3
CH3
O
CH3m/z = 310
N N
O
O
CH3
CH3
O-
+m/z = 295
N N
O
O-
O
CH3
+
m/z = 268
N N
O
O-+
m/z = 237
O-
N
O
+
m/z = 135
OH
O+
m/z = 121
+
O
m/z = 94
m/z = 78
++
+
0(M.I.P .)
0
0
0
0
0
0
( B.P .)
MASS FRAGMENTATION 
Studies on some compounds…                                                                                     61 
 
Oxadiazoles… 
EXPERIMENTAL 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2-(4-ISOPROPOXY- 
PHENYL)-5 (ARYL) - 1,3,4- OXADIAZOLES. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 4-ISOPROPOXY BENZOIC ACID HYDRAZIDE. 
Pls. refer Chapter-1, Section 1.1, Page No.52 
 
 [B] PREPARATION OF 4-ISOPROPOXY-N'-[(1E)-(4-METHOXY PHENYL) 
METHYLENE] BENZOHYDRAZIDE. 
 Pls. refer Chapter-1, Section 1.1, Page No.52 
 
[C] PREPARATION OF 2-(4-ISOPROPOXYPHENYL)-5-(4-METHOXY 
 PHENYL)   -1, 3, 4-OXADIAZOLE  
Route (01):- In the solution of 4-isopropoxy-N'-[(1E)-(4-methoxy phenyl) 
methylene] benzohydrazide. (3.12gm, 0.01 mole) in acetone (50ml), potassium 
permanganate (3.5gm) was added then reflux for 8 hrs., the reaction mass turns from 
pink to brown color during the reaction. TLC was observed during the reaction (if 
needed add extra potassium permanganate) after completion of the reaction filtered 
this hot solution through Buckner funnel. The product precipitated from acetone was 
filtered. Recrystallized it from proper solvent, m.p.-102◦c, yield: 70%.,[C18H18N2O3; 
found: C, 69.62, H, 5.87, N, 9.07, requires C, 69.66, H, 5.85, N, 9.03 %]. 
 Route (02):-In the solution of 4-isopropoxy-N'-[(1E)-(4-methoxy phenyl) 
methylene] benzohydrazide (3.12gm, 0.01 mole) and (2 gm) of Chloramine-T was 
added. It was refluxed for 2 to 3 hrs. TLC was observed of reaction mass during the 
reaction, after completion of the reaction filtered the reaction mass through Buckner 
funnel while hot to remove sodium salt. Collected the product from ethanol with 
chilling. Recrystallized it from proper solvent. 
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 Similarly, other 2-(4-isopropoxyphenyl)-5-(4-methoxyphenyl)-1,3,4-oxa        
diazoles  were synthesized, and their characterization data are recorded in Table-2.
  
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
  
[C] BIOLOGICAL EVALUATION 2-(4-ISOPROPOXYPHENYL)-5-
(ARYL) -1, 3, 4-OXADIAZOLE.  
Antimicrobial testing were carried out as described in Chapter-8. The zones 
of inhibition of test solutions are recorded in Graphical Chart-2a. Table-2a. Page 
No. - 360, 361. Result and discussion is given on page no.-362. 
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CHAPTER - 2 
STUDIES ON 
MANNICHBASES 
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INTRODUCTION 
 Mannich bases containing bridged N-atom exhibit pronounced biological 
activities. The study of mannich reaction attracted a great deal of attention to the 
chemists because it plays a vital role owing to their wide range of pharmacological 
and industrial applications. Mannich bases are also employed as intermediate in 
chemical synthesis.1-3 
 Mannich base derivatives with bridge N-atom have been found to be potent 
drug in medicinal science and possess wide range of biological activities like 
anticancer, antibacterial, antimalarial, analgesic etc. Mannich bases have gained 
important because of their technological applications in polymer chemistry4, 
especially as paints and surface active agents and exhibits complexation characteristic 
with many transition metal ions. 
 Mannich Reaction is one of simple strategy reported for preparing variety of 
various organic compounds of high medicinal and biological value. Its importance in 
organic synthesis is clearly evidenced from reviews of Blick, Karbe, Nobles and    
others5-10. Besides this, the chemistry of Mannich reaction has also been reviewed in a 
considerable number of publications and patents deals with the heterocyclic system 
based Mannich bases useful as chemotherapeutic agents as well as reactive 
intermediates for the synthesis of various organic compounds. As a result developing 
new synthetic methods for the construction of nitrogenous molecules has defined the 
frontiers of organic synthesis since its very beginning11. 
Mannich reaction is a classical method for forming carbon-carbon bond in 
organic synthesis. The versatility and potential to create both functional and structural 
diversity using this reaction have long stimulated the creativity of organic chemists. 
The increasing popularity of Mannich reaction has been fueled by the ubiquitous 
nature of nitrogen in drugs, natural products and biologically active compounds as 
well as by its multicomponent reaction to generate diversity. As a result it has 
stimulated researcher in both academic and industrial organic synthesis.  
 Jacobson, Tollens and co-workers 12,13 was first reported the classical method 
for the aminoalkylation of acidic proton present next to carbonyl group. Then in 1917 
Carl Mannich was initiated the detailed study of this reaction by preparing various β-
amino alkyl compounds viz. ethylenic, phenolic compounds, higher homologous of 
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ketones and heterocyclic compounds and recognized it as a general reaction for 
aminoalkylation 14. In its basic form, Mannich reaction is a condensation reaction of 
an aldehyde, usually formaldehyde with ammonia, a primary or secondary amine and 
a compound containing activated hydrogen called Substrate (R). The resulting 
product is β-amino alkylated compound having the N-atom linked to the substrate R 
through a methylene group and is known as Mannich base. The general aspect of this 
reaction is illustrated as below. 
 
 
 
A great deal of work on Mannich reaction has been reported by number of 
research workers15. Until 1965, considerable work has been reported regarding the 
synthesis of Mannich Bases derived from compounds containing acidic hydrogen on 
carbon but only a few examples of Mannich reaction of substrates having acidic 
proton on a Nitrogen atom were known16-19.  
R .S. Varma and W. L. Nobles20. have reported Mannich bases derived from 
substrates having active hydrogen atom on nitrogen. Tramontini Maurilio 21 reviewed 
many such reactions in which Mannich bases are employed as precursors for the 
synthesis of various organic compounds. From the literature survey Mannich bases 
represent a heterocyclic systems shows potential pharmaceutical activity viz. 
derivatives of oxadiazoles-2-thione, triazole, imidazole, thiazole, etc.22,23.  
Thus the present chapter of the thesis deals with the work based on synthesis 
and characterization of N-Mannich bases using Mannich reaction. Accordingly we 
have prepared different compounds of N-Mannich bases by Mannich reaction of 
heterocyclic moiety as secondary amine precursors with formaldehyde and ten 
different aromatic primary amines. In this chapter the brief review about the Mannich 
bases has been summarized in Section-2.1. 
 
Reactant, products and reaction condition in Mannich reaction: 
The substrate suitable for Mannich base synthesis is widely available among a 
number of α-XH acidic compounds. Where X being equal to C, N or other 
RH HCHO R'2NH R'2NH CH2 R+ +
-H2O
Substrate Amine Mannich base
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heteroatom. As a consequence a large number of substrate/amine combinations are 
possible to give enormous number of Mannich bases. On the other hand the amines 
employed include ammonia as well as common aliphatic and aromatic primary or 
secondary amines for the activation of formaldehyde. 
However very few limitations are found in the choice of amine reactants such 
as for tertiary amines as it lack a proton to form intermediate amine. Among these 
several amines, dimethyl and diethyl amine and the cyclic secondary amines like 
piperidine, morpholine, piperazine are by far the most commonly used as amino 
component in Mannich reaction. Nature of formaldehyde used in Mannich reaction 
may be provided by either aqueous formaldehyde solution, trioxymethylene or 
paraformaldehyde24,25. However aqueous formalin (37-40%) is generally a 
satisfactory source of formaldehyde due to favorable equilibrium position and 
formation of stable product. Choice of solvent is often important. In the reaction, 
when aqueous formalin is used, the condensation reaction is commonly carried out by 
shaking or stirring the reactants in the absence of organic solvents or in some cases 
methanol has been used as solvent. 
 
MECHANISM: 
In view of this conflicting evidence, Cummings and Shelton26 investigated the 
mechanism of Mannich reaction particularly in basic medium for which is reliable 
with the result for the basic medium. They also proposed a modification in 
mechanism of Mannich reaction for acidic medium which was in agreement of 
Alexander and Underhill.  
Over the years there has been much controversy about the mechanism of the 
mannich reaction. Studies of the reaction kinetics have led to the following 
mechanistic proposals. 
R.S.Varma and other have proposed27 the mechanism for aminomethylation of 
isatin as shown below, depending upon the order of addition of formaldehyde. 
According to them formaldehyde (ii) may react with dimethylamine (i) or isatin (iv) 
to generate aminomethylol derivative of dimethylamine (iii) or isatin (iv) to yield N-
Mannich base (v).  
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MECHANISM FOR THE FORMATION OF N-MANNICH BASE 
The mechanism of the synthesized Mannich base with current moiety 
oxadiazole-2-thione is described as under. 
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SYNTHETIC ASPECT: 
 Different methods have cited in literature to synthesize mannich bases by 
several Workers28,29 using various interesting substrates.  
1. Seshaiah Krishnan et al.30 have synthesized mannichbase (I) from the Schiff 
bases of isatin in presence of formaldehyde and diphenyl amine. 
 
 
 
 
 
 
 
 
 
 
2.  Rodolfo Quevedo et al31 have synthesized new macrocyclic compounds 
 having  two benzoxazine subunits joined by two ethylene bridges have been 
 prepared by  Mannich condensation of the appropriate 4-hydroxy phenyl 
 ethyl amine with an excess of formaldehyde. This is a general method for 
 synthesizing a new family of heterocyclophanes. (II) 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.  Hui Mao et al32 have synthesized facile and diastereoselective synthesis of β- 
acetamido ketones and keto esters via direct Mannich-type reaction (III). A 
Mannich type three-component reaction involving aldehydes, acetamide, and 
N
H
NR1
O
R
N
R
R2
O
NR1
HCHO
NH
H5C6
H5C6
R = H, Cl, Br
R1 = C6H5Br, C6H5CH3, C6H5OCH3
R2 = -CH2-(NC6H5)2
(I) 
OH
R
NH2
O
N
N
O
R
R
HCHO
R = COOC 2H5, H
(II) 
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enolizable ketones or β-keto esters for the preparation of β-acetamido carbonyl 
compounds in the presence of TMSCl is described.  
This newly developed protocol is operationally convenient, widely applicable, 
and highly diastereoselective. 
 
 
 
 
 
 
 
4. Rosaria Villano et al33 have synthesized a convenient approach to α-amino-β- 
 ketoesters by vinylogous Mannich reaction of masked acetoacetate. (IV) SiCl4 
 showed an efficient and selective catalyst for the vinylogous Mannich reaction 
 of linear and cyclic synthetic equivalents of acetoacetate dianion, leading to α-
 amino-β-ketoesters in moderate to high yields and complete γ-selectivity; anti-
 diastereoselective was observed by using a γ-methyl-substituted cyclic 
 silyloxydiene. 
 
5.  Chi and co-workers34 have synthesized mannich base using 1,4,10,13- 
tetraoxa-7,16-diazacyclooctadecane, formaldehyde and phenolic derivatives in 
benzene. 
6. Yung-son Hon et al.35 have prepared mannich base (V) from the reaction of 
phenolic compounds with a preheated mixture of dibromomethane and 
diethylamine. 
 
CHO
+ CH3CONH2
CH3 CH3
O O
O
CH3
O CH3
NHAc
TMSCl
CH3CN, Reflux
R = Aryl aldehyde
R R (III) 
CHO
PhNH2, CH2Cl2 CH2Cl2R-CH=N-C 6H4
3 Ao MS, SiO2, 1h/rt; DIPEA, SiCl 4
0.5h/-78 0C
R=Aryl aldehyde
N
CH3
O
COOMe
R
R
(IV) 
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7. Venkatesha Prabhu G. and V anappayya D.36 have synthesized 
aminobenzylated mannich bases (VI) by the condensation reaction between 
heterocyclic secondary amines and benzaldehyde. 
 
 
8. Pandeya and Sriram D. Dave37 have synthesized mannich bases by the 
condensation of the acidic group of isatin with formaldehyde and secondary 
amines.  
9. Christos A. Kontogiorgis et al.38 have synthesized mannich base of coumarine. 
10. G. Bryant and V . L. Heisey79 in 1965 have reported the synthesis of Mannich 
Bases derived from various nitrogen containing five membered ring systems 
such as pyrole, pyrazole, benzimidazole and benzotriazole. 
11.  A. H. El-masry and co-workers80 have made effort to incorporate a 
benzimidazole into a triazole moiety by Mannich reaction of oxadiazole with 
different secondary amines and paraformaldehyde to give Mannich base 
compounds. 
 
THERAPEUTIC IMPORTANCE 
The appearance of powerful and elegant Mannich reaction has stimulated 
major advances as pharmaceutical agents of remarkable significance in medicine, 
OH
N
CH3
CH3
OH
[CH2Br2, NH(Et)2]
(V) 
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+
NHX
X
CH3
OH
NH2
NH2 O NX
CH3
NH C
O H
XN
(VI) 
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biology and pharmacy. It would be more worthy to discuss in brief about the history 
and developments of these Mannich bases as pharmaceutical agents. 
Mannich bases are associated with a wide variety of biological activities and 
industrial applications such as, 
1. Anti-inflammatory39-41 
2. Antifungal42 
3. Antitumor43 
4. Analgesic44 
5. Cytotoxic and anticancer45 
6. Antibacterial46 
7. Antipsychotic47 
8. Tranquilizing48, 49 
9. Antileishmanial50 
10. Antimalarial51 
B. Shivarama Holla et al.52 have prepared mannich bases and tested them for 
anthelmintic activity (I) and all the newly synthesized compounds (II) were tested for 
their antibacterial and antifungal activity. 
 
 
 
 
 
 
 
 
 
 
 
Amodiaquine53,54,a mannich base derivatives (III) which shown an 
antimalarial activity superior than chloroquine in areas of high chloroquine resistance. 
M. L. Edwards et al.55 have prepared the mannich base of 4-phenyl-3-buten-2-one as 
an antiherps agent. Malcolm K. Scott and co-workers56 have prepared the pyrrole 
mannich base (IV) as a potent antipsychotic agent. 
O
N
N
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N N CH3
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J. Knoll et al.57 have prepared the mannich base (V) which was the most 
potent neuroleptic compound of a series of aryl substituted analogues. Molindone 
(VI) which has been reported to demostrate potent neuroleptic activity58. Jan Balzarini 
and co-workers59 have prepared the mannich bases of chalcone showing cytotoxic 
activities. 
 
H. S. Joshi et al.60 have been synthesized some new amino benzylated 
mannichbases and reported their antimicrobial activities. 
 Gul H. I. et al.61,62 have documented antifungal activity of bis mannich bases 
derived from acetophenones and some mono mannich bases evaluated for their 
anticonvulsant activity. Shingare M. S. et al.63 have described the synthesis and the 
antiviral activity of mannich bases (VII).  
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Movrin M. and Maysinger D.64 have synthesized mannich bases from 
nitroxoline and reported them as biologically active agents. Ojanen T. and 
coworkers65 have reported antifungal activity of some mono, bis and quaternary 
mannich bases derived from acetophenone. Li Y ., Yang Z. S. et al.66 have synthesized 
some mannich base derivatives and reported their antimalarial activity. 
Lorand T. and Kocsis B.67 have synthesized some new mannich ketones and 
reported their antibacterial activity. Erol D. D., Rosen A. et al.68 have synthesized 
some novel mannich base derivatives from 6-acyl-3-(3,5-dimethylpiperidinomethyl)- 
2(3H)-benzoxazolones and reported their biological activities. H. M. Hassan69 have 
synthesized some new mannich bases containing 1,8-napthyridine moiety and 
reported their antimicrobial activity. 
 K. C. Ravindra, H. M. Vagdevi and coworkers70 have documented 
antimicrobial and anti-inflammatory activity of N-mannichbases (VIII) derived from 
5-Naphtho [2,1-b]furan -2-yl-1,3,4-oxadiazole-2-(3H)-thione with different aromatic 
amines in presence of formaldehyde.  
 
 
 
 
 
 
  
 
 Ozair Alam, Mohd. Imran and S.A.Khan71 have synthesized annich base 
(IX) from some substituted 2-amino pyrimidine with morpholine in presence of 
formaldehyde and evaluated their antimicrobial and anticonvulsant activities. 
N
N
S
S
N
NH
S
N R
R
(VII)
R= H, 4-Me, 5-OMe, 5-Cl,  6-Br
O O
N N
NH R
S
(VIII)
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 Ashok kumar and co-workers72 have synthesized Mannichbase (X) of some 
anthranilic acid derivatives in presence of formaldehyde and different aromatic 
amines and evaluated for their anti-inflammatory activity. 
 
 
 
 
 
 
 
 
  
 Hassan A. Albar, and co-workers73 have synthesized Mannichbases (XI) from 
some unsaturated 1,3-diketoesters derivatives and studied their biological activity. 
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R1= Aromatic amines
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Senshaiah Krishnan Sridhar and Atmakuru Ramesh74 have synthesized a series 
of N- Mannich bases of isatin derivatives (XII)..The synthesized compounds were 
tested for their analgesic, anti-inflammatory and antipyretic activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Dharmarajan Sriram and co-workers75 have synthesized a series of 
aminopyrimidinimino isatin derivatives. These synthesized N-Mannich bases (XIII) 
were evaluated for non nucleoside HIV-1 reverse transcriptase inhibitors and also 
showed antibacterial activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M. Senthilraja and S. A. Thangadhurai 76 have synthesized N-Mannich bases 
by the reaction of Schiff bases of isatin with pyrimethamine (XIV). These synthesized 
N-Mannich bases were screened for antibacterial and antifungal activity.  
 
 
N
O
N
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N
N
CH2
OMe
OMe
OMe
R
NH
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NNH CH3 NNH Ph ONH
,, ,
Where, R=
(XIII) 
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Where, R= H, Cl, Br,
R1= Aromatic amnes
(XII) 
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V . K. Saxena and Rita Nigam77 have synthesized N-Mannich bases by the 
reaction of Schiffbases of isatin with 2-amino-4-phenyl-5-(4-substituted/unsubstituted 
-phenoxyphenylazo)-thiaxoles. These synthesized N-Mannich bases screen for 
cardiovascular, anti-inflammatory and antiviral activity (XV). 
  
 
 
 
 
 
 
 
 
 
 
 
 
T. K. Dave and V . A. co-workers78 have synthesized a of series 4-amino-3-
mercapto-5-pyridin-3´-yl-[1,2,4]-triazole which exhibit antimicrobial and anti 
tubercular activity.  
In view of the importance of mannich bases as versatile synthetic 
intermediates and the availability of scanty literature on therapeutic properties, we 
have undertaken the preparation of mannich bases in following section. 
 
SECTION-2.1:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-(4-
ISOPROPOXY PHENYL) 3-N-[(ARYL) AMINO METHYL]-1, 
3, 4 OXADIAZOLE -5 (4H) –THIONE. 
Where, R=
N
O
N
CH2
N
N
R
C2H5
NH2
Cl
Secondary amine (XIV) 
O N S
N
N
N
O
CH2 R1
NR
H5C6
Where, R = H, Cl.
R1 = Secondary amine
(XV) 
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SECTION-2.1 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-(4-ISOPROPOXY 
PHENYL) 3-N-[(ARYL) AMINO METHYL]-1, 3, 4 OXADIAZOLE -5 (4H) –
THIONE. 
In view of getting better therapeutic agent and considering the association of 
various biological activity with 2-(4-isoprpoxyphenyl)-1,3,4-oxadiazole-5(4H)-thione 
nuclei, the preparation of mannich bases of Type (III) have been undertaken from 2-
(4-isoprpoxyphenyl)-1,3,4-oxadiazole-5(4H)-thione with primary amines and 
formaldehyde in methanol. 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (IIIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and Gram 
negative bacterial strain and Antifungal activities towards fungal strains at different 
concentrations (Minimum Inhibitory Concentration). The biological activities of 
synthesized compounds (IIIa-j) have been compared with standard drugs viz. 
Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations, 
(Chapter-8). 
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Reaction scheme 
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IR SPECTRAL STUDIES OF 2-(4-ISOPROPOXYPHENYL)-3-[(4-METHOXY 
PHENYL) AMINO METHYL] - 1, 3, 4-OXADIAZOLE-5(4H) –THIONE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Instrument: SHIMADZU-FT-IR 8400-Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
 
 Type Vibration mode 
 
Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2964 2975-2950 81 
-CH3 C-H str.(sym)  2830 2880-2860 " 
 C-H def.(asym.) 1490 1470-1435 " 
 C-H def.(sym.) 1341 1390-1370 " 
Aromatic C-H str. 2996 3090-3030 82 
 C=C str. 1545 1540-1480 " 
 C-H i.p. def. 1088 1125-1000 " 
 C-H o.o.p. def. 841 835-810 " 
 CH2 str  1447 1500-1350 " 
Moiety Ar-O-C (sym.) 1238 1275-1200 83 
Oxadiazole C-O-C str 1088 1075-1010 84 
Thione  C=S 1191 1200-1050 " 
 C-N str 1212 1220-1020 " 
Ether C-O-C str 1238 1275-1200 " 
Sec.amine -NH- 3122 3410-3380 " 
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CH3
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PMR SPECTRAL STUDIES OF 2-(4-ISOPROPOXYPHENYL)-3-[(4-
METHOXYPHENYL) AMINO METHYL] - 1, 3, 4-OXADIAZOLE-5(4H) –
THIONE. 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
(300 MHz).  
 
  
 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 1.38 6H doublet (CH3)2 moiety 
2 2.22 1H Singlet -CH2- 
3 3.44 3H Singlet Ar-OCH3 
4 4.68 1H multiplet -CH- (isopropyl) 
5 5.98 1H Singlet -NH (mannich.) 
6 6.98-7.02 4H multiplet Ar-Ha,a’,b,b’  
7 7.68 2H doublet Ar-Hc, c’  
8 7.83 2H doublet Ar-Hd, d’ 
O
CH3
CH3
O
N
N
S
NH
O
CH3
a
a'
b
b'
c
c'
d'
d
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MASS SPECTRAL STUDIES OF 2-(4-ISOPROPOXYPHENYL)-3-[(4-
METHOXYPHENYL) AMINO METHYL] - 1, 3, 4-OXADIAZOLE-5(4H) –
THIONE.  
 
 
 
O
CH3
CH3
O
N N
S
NH
O
CH3
m/z = 371.45
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EXPERIMENTAL 
 
SYNTHESIS& STRUCTURE ELUCIDATION OF 2-(4-ISOPROPOXY 
PHENYL)-3-N-(ARYL) AMINO METHYL -1, 3, 4 OXADIAZOLE -5 (4H) –
THIONE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 4-ISOPROPOXY BENZOIC ACID HYDRAZIDE. 
 Pls. refer Chapter:-1, Section:-1.1, Page no. : - 52 
 
 [B] PREPARATION OF 2-(4-ISOPRPOXYPHENYL) - 1,3,4 – OXADIAZOLE 
-5(4H)-THIONE. 
To a cold stirred solution of 4-isopropoxy benzoic acid hydrazide (4 gm, 0.02 
mole) in ethanol (50ml) containing potassium hydroxide (1.5 gm, 0.02 mole), carbon 
disulfide (8 gm, 0.1 mole) was added gradually. The reaction mixture was heated 
under reflux on a steam-bath until hydrogen sulfide evolution ceased. Ethanol was 
recovered by distillation under reduced pressure and the residue was stirred with 
chilled water, filtered and the filtrate was neutralized with dilute hydrochloric acid. 
The product was filtered, washed with water & recrystallized from methanol. Yield: 
82%, m.p.167◦c., [C11H12N2O2S; found: C, 55.85, H, 5.15, N, 11.80, requires C, 
55.91, H, 5.12, N, 11.86 %].      
 
 TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
 
[C] PREPARATION OF 2-(4-ISOPROPOXYPHENYL)-3-N-[(4-METHOXY 
PHENYL) AMINO METHYL] - 1, 3, 4-OXADIAZOLE-5(4H) -THIONE. 
 A solution of the 4-methoxy aniline (1.5 gm, 0.01 mole) in the methanol 
(10ml) was added drop wise to a cold stirred solution of 2-(4-isoprpoxyphenyl) - 1,3,4 
– oxadiazole -5(4H)-thione (2.5 gm, 0.01 mole) in methanol (10ml) containing 
formaldehyde  (4 ml) and the reaction mixture stirred for 24 hrs at room temperature. 
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The precipitated product was filtered, washed with cold methanol, dried it and 
recrystallized it from DMF-ethanol solvent mixture to get pure product. Yield: 75%, 
m.p.154◦c., [C19H21N3O3S; found: C, 61.49, H, 5.78, N, 11.34, requires C, 61.44, H, 
5.70, N, 11.31 %]. 
 Similarly, other 2-(4-isopropoxyphenyl)-3-N-[(aryl)aminomethyl]-1,3,4-
oxadiazole -5(4H)-thione were prepared. The physical constants are recorded in 
Table No. -3. 
 
[D] BIOLOGICAL EVALUATION OF 2-(4-ISOPROPOXYPHENYL)-3-N-
[(ARYL) AMINO METHYL] - 1, 3, 4-OXADIAZOLE- 5(4H) –THIONE. 
Antimicrobial testing were carried out as described in Chapter-8. The zones 
of inhibition of test solutions are recorded in Graphical chart -3a, Table-3a. Page 
No. - 363, 364. Result and discussion is given on page no.:- 365. 
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CHAPTER - 3 
STUDIES ON 
PYRAZOLINES 
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INTRODUCTION  
 
The growing potent literatures of recent years demonstrate that Chalcone 
being a very active intermediate through which novel heterocycles with promising 
biological profile can be designed. The term Chalcone was first coined by Kotanecki 
and Tambor1 who did pioneering work in the synthesis of natural coloring 
compounds. They are characterized by their possession of C6 (A)-CO-CH=CH-C6 (B), 
structure in which two aromatic rings A and B, are linked by an aliphatic three carbon 
chain. 
 
 
 
 
 
 
 
Chalcones are phenyl styryl ketones containing reactive keto-ethylinic group        
(-CO-CH=CH-). Chalcones are also known as benzalacetophenones or benzylidene 
acetophenones the alternative name given to chalcones are β-phenyl acrylphenone  γ-
oxo-α , γ-diphenyl- α -propylene , α -phenyl- β -benzoethylene, 1,3-disubstituted-2-
propen-1-ones, 
 
SYNTHETIC ASPECT 
A considerable variety of methods are available in literature for the synthesis 
of chalcones. The most convenient method is the one that involves the Claisen-
Schmidt condensation of equimolar quantities of aryl methyl ketones with aryl 
aldehyde in presence of alcoholic alkali.2 
R C H
O
+ R1 C CH3
O
alkali
R CH
CH C
R1
O
O
A B
1
2
3
 (I) 
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 Several condensing agents are used such as alkali of different strength3,4 
anhydrous aluminium chloride,5 boron trifluoride,6 aqueous solution of borax,7 amino 
acids,8 phosphorousoxychloride,9 piperidine,10 hydrochloric acid,11-12 perchloric 
acid13, etc. Different methods of synthesis of 1,3-disubstituted-2-propen-1-ones can be 
quoted as below. 
1. By Fridel Craft cinnamoylation.14 
2. By Nencki reaction with cinnamic acid on aromatic compounds.15 
3. By Fries rearrangement of aryl cinnamates.16 
4. By diazo coupling of phenyl diazonium chloride with benzoyl acrylic acid.17 
Formation of 1,3-disubstituted-2-propen-1-ones proceeds through Claisen-
Schmidt type condensation and the process is catalyzed by the presence of alkali.18 
Following depicted steps are involved in the reaction mechanism. 
 
MECHANISM  
 
The intermediate aldol type products formed readily undergoes dehydration 
even under mild condition, particularly when R and R’ are aryl groups. 
CH3COR + OH- -CH2COR + H2O
R' C
O
H
R' C+
O-
H
R' C+
O-
H
+ R' C
O-
H
CH2 C
O
R
R' C
O-
H
CH2 C
O
R + OH2 R' C
H
CH2 C
O
R
OH
+ OH -
R' C
H
CH2 C
O
R
OH
R' CH CH C
O
R + OH2
-CH2COR
1.
2.
3.
4.
5.
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REACTIVITY OF CHALCONES 
 
The chalcones have been found to be useful for the synthesis of variety of 
heterocyclic compounds is as under. 
(a) Pyrazolines19 and their derivatives can be prepared by the condensation of 
chalcones with hydrazine hydrate and acetic acid. 
(b)  Chalcones on reaction with semicarbazide hydrochloride in ethanol affords 1-
carboxamide pyrazolines.20 
(c) Chalcones on condensation with malononitrile and ammonium acetate yields 
2-amino-3-cyanopyridines.21 
(d) Chalcones on reaction with 2-aminopyridine in glacial acetic acid affords 
pyrido pyrimidines.22 
(e) Isoxazoles23 can be prepared by the reaction of chalcones with hydroxylamine 
hydrochloride and sodium acetate. 
(f) Chalcones on treatment with urea in presence of alkali affords 2-oxo 
pyrimidines.24 
(g) Chalcones on reaction with thiourea in presence of alkali/acid yields 2-
thiopyrimidines.25 
(h) Chalcones on treatment with guanidine hydrochloride in presence of alkali 
affords 2-aminopyrimidines.26 
(i) Cyanopyridone27 derivatives can be prepared by the condensation of chalcones 
with ethyl cyanoacetate. 
(j) Chalcones react with monoethanolamine in ethanol gives 1,4-oxazipines.28 
(k) Oxirane29 can be prepared by the reaction of Chalcone with H2O2 in basic 
media. 
(l) Chalcones on reaction with barbituric acid gave barbitone30 derivatives. 
(m) Chalcone gives imine derivatives with amine in presence of sulfuric acid as 
catalyst.31 
(n) Chalcones on condensation with malononitrile in pyridine forms 2-amino-3-
cyanopyrans.32 
(o) Chalcones react with P2S5 yielded 2-isothiazolidines.33 
(p) Chalcones react with sodium nitrile in presence of glacial acetic acid in 
ethanol produces 2-1H-pyrimidines.34 
(q) Chalcones with 2-amino thiophenol in acetic acid produces 1,5-thiazepines.35 
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THERAPEUTIC IMPORTANCE 
1,3-Disubstituted-2-propen-1-ones and its derivatives are widely used in 
pharmaceutical field. Considerable interest has been shown in the chemistry of 1,3-
disubstituted-2-propen-1-ones due to their wide spectrum of therapeutic activities 
which are listed as under. 
1.  Antiallergic36 
2.  Antiinflammatory37-38 
3.  Antiviral39 
4.  Anti HIV40  
5.  Carboxygenase inhibitor41 
6.  Antitumor42-43 
7.  Antimalarial44 
8.  Anticancer45 
9.  Antileishmanial46 
10.  Insecticidal47-48 
11.  Antiulcer49 
12.  Bactericidal50-51 
13. Fungicidal52-53 
14.  Anthelmintics54 
 
Aldose reductase inhibitor activity of Chalcone derivatives have been reported 
by Okuyama et al.55 They are also associated with antitumor and antifungal activity as 
reported by A. Tsotitns and coworkers.56 Antifeedant activity of chalcones have been 
observed by Sharma and Sreenivasulu.57  
Ezico et al.58 have demonstrated that Chalcone possess a valuable 
antiproliferation activity both on sensitive cancerous cell and on cell which are 
resistant to common chemotherapeutic drugs. Some of the chalcones have been 
patented for their use in treatment of glucoma59 and showed antifungal,l60-61 aldose 
reductase inhibitors,62   anticancer63 and antimicrobial64-65activities. 
N. Liming et. al.,66 have synthesized 1,3-disubstituted-2-propen-1-ones and 
screened for their anti-inflammatory and cardiovascular activity. K. Srinivas et. al.,67 
have synthesized 1,3-disubstituted-2-propen-1-ones as a antitumor agent. Ko Horng-
Huey et. al.,68 have reported 1,3-disubstituted-2-propene- 1-ones as anti-inflammatory 
agent. N. Kazuhiko et. al.,69 have synthesized 1,3- disubstituted-2-propen-1-ones as 
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carcinogen inhibitors. Antitubercular activity of 1,3-disubstituted-2-propen-1-ones 
derivatives have been reported by L. Yuh- Meei et. al.,70 B. P . Das et. al.,71 have 
found that 1,3-disubstituted-2-propen- 1-ones possesses larvicidal properties. K. Min-
Young et. al.,72 have synthesized 1,3-disubstituted-2-propen-1-ones and tested for 
their matrix metallo proteinase inhibitor activity. 
L. Mei et. al.,73 have prepared antimalarial 1,3-disubstituted-2-propen- 1-ones. 
O. Veronika et. al.,74 have synthesized 1,3-disubstituted-2-propen-1- ones and 
screened as cardiovascular agents. Moreover, it has been found that 1,3-disubstituted-
2-propen-1-ones possess nitric oxide inhibitor,75-76 anti-HIV 77-78 and antiproliferative 
79-80 activities. H. H. Ko et. al.,81 have prepared some new 1,3-disubstituted-2-propen-
1-ones for potent inhibition of platelet aggregation. Z. H. L. et. al.,82 have reported 
some 1,3-disubstituted- 2-propen-1-ones as antiparasitic. G. M. L. et. al.,83 have 
documented the synthesis and biological activities of 1,3-disubstituted-2-propen-1-
ones as antiplasmodial. C. X. Xue et. al.,84 have documented 1,3-disubstituted-2- 
propen-1-ones as antimalarial agents. 
M. Satyanarayana et. al.,85 have synthesized 1,3-disubstituted-2- propen-1-
ones as antihyperglycemic agents (II). O. Sahzevari et al.86 have synthesized 1,3-
disubstituted-2-propen-1-ones as anticancer agent, which are particularly cytotoxic 
towards K562 leukemia cells. Furthermore, M. J. Alcaraz et. al.,87 have described the 
role of nuclear factor kappa-β and hemeoxygenase-1 in the action of an anti-
inflammatory 1,3-disubstituted-2-propen-1-ones in RAW 264.7 cells. 
 
 
 
 
 
 
 
O. Nerya et. al.,88 have prepared some new 1,3-disubstituted- 2-propen-1-ones 
as potent tyrosinase inhibitors. O. Sabzevari et. al.,89 have reported some new 1,3-
disubstituted-2-propen-1-ones as Molecular cytotoxic mechanisms of anticancer 
hydroxy chalcones (III). F. Hollosy et. al.,90 have prepared some new 1,3-
disubstituted-2-propen-1-ones as Plant-derived protein tyrosine kinase inhibitors.  
O
N
CH3
CH3 OH
O R
R=substituted phenyl
(II) 
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Recently, H. S. Ban et. al.,91 have reported some newer 1,3-disubstituted- 2-
propen-1-ones as inhibition of lipo poly saccharide-induced expression of inducible 
nitric oxide synthase and tumor necrosis factor-α by 2'-hydroxy chalcone derivatives 
in RAW 264.7 cells. S. Feldbaek Nielsen et. al.,92 have synthesized some 1,3-
disubstituted-2-propen-1-ones derivatives (IV) as antibacterial agent. 
 
 
 
 
 
 
 
 
P . P . Yadav et. al.,93 have synthesized nitrogen and sulfur containing furano 
flavonoids and thiophenyl flavonoids (V), which have been screened for antimicrobial 
activity. 
 
 
 
 
 
 
 
 J. N. Dominguez et. al.,94 have synthesized 1,3-disubstituted-2-propen- 1-ones 
and reported their activity as antimalarial agents. 
W. Duck Seo et. al.,95 have synthesized 1,3-disubstituted-2-propen-1- ones 
(VI) and reported as α-glucosidase inhibitors. 
O
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OMe
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H
N
NN
O
R
R=substituted phenyl
(IV) 
X OH
O
R
X= NCH3/S
R=H/OCH3(V) 
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M. Larsen and et. al.,96 have synthesized 1,3-disubstituted-2-propen-1- ones 
(VII) and reported their antiplasmodial activity. 
 
 
 
 
 
 
 
 
 
Moreover, S. Khatib et. al.,97 have reported some novel 1,3- disubstituted-2-
propen-1-ones as potent tyrosinase inhibitors (VIII). Seo et. al.,98 reported the 1,3-
disubstituted-2-propen-1-ones as α-glucosidase inhibitors. 
 
 
 
 
 
 
 
 
A. Araico et. al.,99 have synthesized 1,3-disubstituted-2-propen-1-ones as 
inhibitor of cyclo-oxygenase-2 and 5-lipoxygenase. 
S. H. L. et. al.,100 have designed and synthesized some new 1,3- disubstituted-
2-propen-1-ones and reported their anti-inflammatory activity. 
(VI) 
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R
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 P . Boeck et. al.,101 have synthesized some newer 1,3-disubstituted-2- propen-
1-ones (IX) with antileishmanial activity, in which analogues contain nitro, fluorine 
or bromine group respectively displayed increased selectivity against the parasites as 
compared with natural 1,3-disubstituted-2-propen-1- ones. X. Wu et. al.,102 have 
synthesized ferrrocenyl 1,3-disubstituted-2-propen-1-ones and reported their 
antiplasmodial activity. 
 
 
 
 
 
 
 
 
 
 
R. R. Kamble et. al.,103 have reported novel 1,3-disubstituted-2- propen-1-ones 
(X) having potent biological activity. 
 
 
 
 
 
 
M. S. Yar et. al.,104 have synthesized some 1,3-disubstituted-2-propen- 1-ones 
(XI) having antimicobacterial activity. 
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F. Jin et. al.,105 have reported structural requirements of synthetic derivative of 
butene, a natural 1,3-disubstituted-2-propen-1-ones (XII) for anti-inflammatory 
activity. 
 
 
 
 
 
 
 
These valid observations about the therapeutic applications of 1,3- 
disubstituted-2-propen-1-ones led us to explore chemistry and biological activities of 
1,3-disubstituted-2-propen-1-ones by synthesizing their several derivatives viz., 
pyrazolines, N-substituted pyrazolines,  which can be summarized in the following 
sections. 
 
 
SECTION-3.1:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3 -
DICHLORO N-(3-SUBSTITUTED STYRYL CARBONYL) 
BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OOMOM
OMOMMOMO
(XII)
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INTRODUCTION  
 
Pyrazoles are well known five membered heterocyclic compounds and several 
procedures for its synthesis have been extensively studied. Such studies have been 
stimulated by various promising applications, especially in the case of N-substituted 
pyrazole derivatives. In fact, certain N-substituted pyrazoles are used as analgesic, 
anti-inflammatory, antipyretic, agrochemicals whereas some others are being studied 
for their medicinal interest. 
The knowledge of such applications has pointed out that N-substituted 
pyrazoles are important target to be prepared to our interest on synthesis and 
molecular structure determination of some types of pyrazoles. 
The pyrazole ring system (I) consists of a doubly unsaturated five membered 
ring containing two adjacent nitrogen atoms. Knorr106 first synthesized a compound 
containing this system in 1883 by a reaction of ethylacetoacetate with phenyl 
hydrazine which yield 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (II). 
 
 
 
 
 
 
 
 
The discovery of pyrazole derivatives as antipyretic agents dates back to 1884, 
when the German chemist Ludwig Knorr107 attempted to synthesize quinoline 
derivatives with antipyretic activity and accidentally obtained antipyrine (2,3-
Dimethyl-1-phenyl-3-pyrazolin-5-one), which has analgesic, antipyretic and 
antirheumatic activity. Aminopyrine, a more potent analogue was synthesized there 
after and these drugs were widely used in market as antipyretics. In pyrazole ring if 
one carbonyl group comes at 5 position it is known as pyrazolone. The pyrazolone 
exists as a mixture of the three most probable tautomeric structures. Pyrazolone has 
been extensively explored for its importance in the field of pharmaceutical 
development. This five member heterocyclic ring has attracted attention word wide. 
N
N
Ph
CH3
O
N
H
N
N
N
R
R1
R2 R3
(I) (II) (III)
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Pyrazoles and their reduced forms pyrazolines are well known nitrogen 
containing five membered heterocyclic compounds (III) which possess widespread 
chemical and pharmacological applications108-110 such as analgesic, antipyretic and 
antirheumatic.111-112 These derivatives are also well known for their pronounced anti-
inflammatory properties113-114 and are used as potent antidiabetic agents.115-116 In 
addition, the pharmacological and antitumor activities of many compounds containing 
pyrazoline rings have been reviewed.117-119 Pyrazolines can be synthesized from α, β-
unsaturated carbonyl compounds and hydrazines. They are reported to be potential 
extractants and powerful drugs.120 The chemistry of pyrazoline was reviewed by Jorbe 
in 1967, which have been studied extensively for their biodynamic behaviour121 and 
industrial applications.122 
 
SYNTHETIC ASPECTS 
1. Pechmann H. V .123 has synthesized pyrazoles (I) by the reaction of acetylenes 
and diazomethane. 
 
 
 
 
 
 
2. Knorr L.124 has synthesized two structurally isomeric pyrazoles (II), (III) by 
the condensation of substituted hydrazines with 1,3-dicarbonyl compounds. 
 
 
 
 
 
 
 
 
3. Perumal P .T. et.al.125 have synthesized pyrazoles (IV) by the reaction of 
hydrazones with Vilsmeier reagent. 
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4. By the microwave assisted cyclocondensation of hydrazine derivatives with 
alkyl dihalides126 (V). 
 
 
 
 
 
 
5. Boruah R.C.et al.127 suggested one pot synthesis of pyrazoles (VI) from β- 
Formylenamides. 
 
 
 
 
 
 
6. Marica Theiszova et al.128 have synthesized pyrazoles by condensation of 2-
ethoxymethylene-3-oxobutanenitrile and hydrazines. 
7. 2-Pyrazolines (VII) can be constructed by the cyclocondensation of chalcones 
with hydrazine hydrate.129 
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8. 2-Pyrazolines can be prepared by condensation of Chalcone dibromide with 
hydrazines.130 
9. Epoxidation of chalcones gave epoxy ketones which reacts with hydrazine and 
phenyl hydrazine to give pyrazolines.131 
10. 2-Pyrazolines (VIII) can be prepared by cyclocondensation of γ-ketosulfone 
with refluxing hydrazines and KOH/methanol under nitrogen condition.132 
 
 
 
 
 
 
 
 
 
 
11. Dipolar Cycloaddition of nitrileimines of dimethyl fumarate, fumaronitrile and 
the N-aryl maleimides yielded the corresponding pyrazolines.133 
12. Epoxidation of chalcones with epoxy ketones on reaction with hydrazine 
hydrate and phenyl hydrazine to give pyrazolines.134 
REACTION MECHANISM 
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The above mechanism seems to be operable for the condensation of chalcones 
with hydrazines.135 
Nucleophillic attack by hydrazine at the β-carbon of the α, β-unsaturated 
carbonyl system (I) forms species (II), in which the negative charge is mainly 
accommodated by the electronegative oxygen atom. Proton transfer from the nitrogen 
to oxygen produces an intermediate end which simultaneously ketonises to ketoamine 
(III). Another intramolecular nucleophillic attack by the primary amino group of 
ketoamine on its carbonyl carbon followed by proton transfer from nitrogen to oxygen 
leads ultimately to hydroxyl amine (IV). The later with a hydroxy group and amine 
group on the same carbon loses water easily to yield the pyrazolines (V). 
 
THERAPEUTIC IMPORTANCE OF PYRAZOLINES 
 Compounds with a pyrazole structure are known to possess monoamine 
oxidase nhibitor136, antibacterial137, antidepressant138, hypotensive139, antipyretic and 
anti- inflammatory140 activities. Pyrazolines, bicyclic pyrazolines are nitrogen 
containing heterocyclic compounds are well known for their pronounced anti-
inflammatory activity.141-149 These compounds have been developed as nonsteroidal 
anti-inflammatory drugs. They block the formation of prostaglandins and having 
analgesic, antipyretic and anti-inflammatory activity.150 The discovery of this class of 
drugs provides an outstanding case history of modern drug development and also 
points out the unpredictability of biological activity from structural modification of a 
prototype drug molecule. 
 From the literature survey, it was revealed that 2-pyrazolines are better 
therapeutic agents. Some of the activities are mentioned below. 
1. Antiallergic.151 
2.  Anticonvulsant.151,152 
3. Antiimplantation.153 
4.  Antiinflammatory.154 
5.  Antitumor.155 
6.  Antineoplastic.157 
7. Antimicrobial.158 
8. Analgesic.159,160 
9. Bacteriocidal.161,162 
10. Cardiovascular.163 
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11. Diuretic.164 
12. Fungicidal.165 
13. Hypoglycemic.166 
14. Tranquilizer.167 
 Untawy, Atif and coworkers168 have patented 3-Methyl-4'-(substituted pheny 
lazo)-pyrazol-5-ones as antibacterial agent. K. Satyanarayana and MNA Rao169 
synthesized some 4-[5-(substituted aryl)-4,5-dihydro-lH-pyrazol-3-yl]-3-phenyl 
sydnones (VI) as anti-inflammatory, antiarthritic and analgesic agents. Essa H. Hu et 
al.170 have synthesized some pyrazoline derivatives (VII) of anthranilic acid and 
reported them as anti-inflammatory agents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Parikh et. al.171 have synthesized some antimicrobial pyrazolines. Shivananda 
M. K. and co-workers172 have prepared substituted pyrazolines and reported their 
antibacterial activity. Guniz Kacukguzel et al.173 have synthesized pyrazolines as a 
antimicrobial and anticonvulsant agents. Gulhan T. Z. and co-workers174 have 
prepared pyrazolines as a hypotensive agent. Nisha Singh and co-workers175 have 
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R
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synthesized 1- acetyl pyrazolines (VIII) and reported them as potent pesticides and 
fungicides. 
 
 
 
 
 
 
 
 
 E. Palaska et al.176 have prepared 3,5- diphenyl-2-pyrazolines (IX) and cited 
their antidepressant activity. Malhotra V . et al.177 have synthesized new pyrazolines as 
a cardiovascular agents (X). 
 
 
 
 
 
 
 
 
 
 Tejas Upadhyay et. al.178 and Sohit Rajvaidya et. al.179 have prepared 
pyrazolines as antimicrobial agent. Ashok Kumar et al.180 have synthesized 
pyrazolines as anticonvulsant agents (XI). 
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 A. V . Dobaria and co-workers181 have discovered pyrazolines bearing 
chloroquinoline nucleus as antimicrobial agents (XII). Berghot M. A. et. al.182 have 
prepared some pyrazoline derivatives of diazepam having antibacterial activity 
 
 
 
 
 
 
 
 Ahn J. H. et. al.183 have described the synthesis of cyano-pyrazoline 
derivatives as potent antidiabetic agents (XIII) and DP-IV inhibitor activity. Jeong T. 
S. et. al.184 have synthesized some novel 3,5-diaryl pyrazolines as human acyl-Co A: 
cholesterol acyl transferase inhibitors. 
 
 
 
 
 
 
 
 Novel analogs of linezolid (XIV) were synthesized by Stan D. Andrea,et. al.185 
and evaluated their antibacterial activity. 
 
 
 
 
 
 
 
 Y . Rajendra Prasad et. al.186 have synthesized some 1,3,5-triphenyl-2-
pyrazolines and 3-(2’-hydroxy naphthalen-1’-yl)-1,5-diphenyl-2-pyrazolines and 
reported as antidepressant (XV) & (XVI). 
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1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines (XVII) were 
synthesized by Gulberk Ucar et al.187 A novel cholinesterase and selective monoamine 
oxidase B inhibitors for the treatment of Parkinson’s and Alzheimer’s diseases. 
 
 
 
 
 
 
 
 Fedele Manna188 and co workers synthesized substituted pyrazoline (XVIII) 
and evaluated for their anticancer activity and for their ability to inhibit P-
glycoprotein mediated multidrug resistance by direct binding to a purified protein 
domain containing an ATP-binding site and a modulator interacting region. 
 
 
 
 
  
 
 
 D. G. Jones et al.189 have synthesized pyrazoline derivative (XIX) which 
possessing PR antagonist activity. Amir Azam and co-workers190 have synthesized 
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some 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline derivatives (XX) and 
tested their antiamoebic activity. 
 
 
 
 
 
 
 
 
  
Mohammad Abid and Amir Azam191 have synthesized 1-(thiazolo-[4,5- 
b]quinoxalin-2-yl)-3-phenyl-2-pyrazoline derivatives (XXI) and reported as 
antiamoebic agent. John R. Goodell. et al.192 have synthesized novel 1,3,5-
trisubstituted pyrazoline derivative which shows anti westnile virus activity (XXII). 
 
 
 
 
 
 
 
 
 
 Abd El-Galil E. Amr et. al.193 synthesized a series of androstano [17,16c] 
pyrazolines (XXIII). The compounds were evaluated for their antiandrogenic activity 
compared to that of Cyproterone. 
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 M. Shaharyar et al.194 the pyrazolines (XXIV) were synthesized and tested for 
their antitubercular activity in vitro against Mycobacterium tuberculosis H37Rv 
(MTB) and INH-resistant M. tuberculosis. (INHR-MTB). 
 
 
 
 
 
 
 
  
 
Richard A. Nugent,et al.197 synthesize pyrazoline bisphosphonate esters 
(XXV) which showed novel anti-inflammatory activity and are capable of inhibiting 
chronic arthritis and inflammation in animals. Such compounds might be useful in 
man for treating chronic issue injury associated with arthropathies such as 
inflammatory joint disease as well as other chronic inflammatory diseases. A novel 
pyrazoline (XXVI) compound that has potent cerebroprotective effects in the rat focal 
cerebral ischemia model was discovered by H. Kawazural,et al.195 David M. Ferguson 
and Pei-Yong Shi.196 Synthesized Triaryl pyrazoline {[5-(4-chloro-phenyl) – 3 – 
thiophen – 2 – yl-4,5-dihydro pyrazol-1-yl] -phenyl-methanone} (XXVII) inhibits 
flavivirus infection in cell culture. The inhibitor was identified through high-
throughput screening of a compound library using a luciferase-expressing West Nile 
(WN) virus infection assay. 
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Drug molecules having pyrazole nucleus with good pharmacological activities 
are listed below. 
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With an intention of preparing the compounds possessing better therapeutic 
activity, we have undertaken the synthesis of pyrazoles which have been described in 
following sections. 
 
SECTION:-3.2: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,  
     3-DICHLORO-N-[3-{3-ARYL-1[H]PYRAZOLINE-5-YL} 
PHENYL] BENZAMIDE. 
 
SECTION:-3.3: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 
 3 - DICHLORO-N- [3- {3- (ARYL)-1-PHENYL - 1[H] 
 PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
 
SECTION:-3.4: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,  
     3- DICHLORO-N– [3- {3- (ARYL)- 1- ACETYL - 1[H] 
     PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
 
SECTION-3.5: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,  
     3-DICHLORO-N – [3-{3-(ARYL)-1-THIOCARBAMIDO –  
     1[H] PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
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SECTION-3.1 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3 -DICHLORO N-(3-
SUBSTITUTED STYRYL CARBONYL) BENZAMIDE. 
 With the biodynamic activities of chalcones and as a fine synthon for different 
heterocyclic rings, the awareness has been paying attention on the creation of new 
chalcones. With a observation to obtained compounds having better therapeutic 
activity, we have synthesized 2,3–dichloro-N-(3-substituted styryl carbonyl) 
benzamide of Type-(IV) by the condensation of N-(3-acetylphenyl)-2,3-
dichlorobenzamide with various aromatic aldehydes by using alkali as catalyst. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (IVa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (IVa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations. 
Selected compounds have been also screened for their antitubercular activity, 
(Chapter-8). 
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IR SPECTRAL STUDIES OF 2,3 -DICHLORO N-(3-(p-METHOXY STYRYL 
CARBONYL) BENZAMIDE.  
  
 Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc.) 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2970 2975-2950 198 
-CH3 C-H str. (sym)  2835 2880-2860 " 
  C-H def. (asym.) 1417 1470-1435 " 
  C-H def.(sym.) 1319 1390-1370 " 
Aromatic C-H str. 3049 3090-3030 199 
  C=C str. 1550 1540-1480 " 
 C-H i.p. def. 1053 1070-1000 " 
 C-H o.o.p. def. 821 835-810 " 
Moiety C-Cl (str.) 790 800-600 200 
Carboxamide -CONH- 1660 1700-1650 201 
Ether C-O-C str. 1249 1260-1200 " 
Vinyl  CH=CH 3049 3050-3000 " 
Chalcone  C=O str 1620 1685-1640 " 
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PMR SPECTRAL STUDIES OF 2,3 -DICHLORO N-(3-(p-METHOXY 
STYRYL CARBONYL) BENZAMIDE.  
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer  
(300 MHz). 
Signal 
no. 
Signal position 
(δppm) 
Relative No. 
of protons 
Multiplicity Inference 
1 3.85 3H Singlet Ar-OCH3 
2 6.94 2H doublet -CH=CH-(venyl) 
3 7.22-7.42 4H Double dolublet Ar-Hg,g’,h,h’  
4 7.40-7.78 5H multiplet Ar-Ha,b,c,e,f 
5 7.80-7.82 2H doublet Ar-Hd, d’ 
6 8.25 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2,3-DICHLORO-N-[3-{3-(p-METHOXY 
PHENYL)-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
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Studies on some compounds…  130 
 
Pyrazolines… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASS FRAGMENTATION 
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2,3-DICHLORO N-[3-
(SUBSTITUTED STYRYL) CARBONYL] BENZAMIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF N-(3-ACETYLPHENYL)-2,3-DICHLORO  
 BENZAMIDE. 
A mixture of 2,3-dichloro benzoylchloride (50 gm, 0.23 mole) in benzene (200 
ml) was added in the mixture of 3-amino acetophenone (40 gm, 0.3 mole) in benzene        
(250 ml ) at 5-10˚C .Triethylamine was used as a quenching agent in catalytic amount. 
Then the reaction mass stirred at 30 to 35˚C for 4 to 5 hrs, reaction was monitored by 
T.L.C., after completion of reaction filtered the precipitated product and dry it, 
recrystallized the product from ethanol. Yield: 78%, m.p. 185˚C; [C15H11Cl2NO2; 
required C, 58.46, H, 3.60, N, 4.55 % found: C, 58.40, H, 3.58, N, 4.48].  
 
[B] PREPARATION OF 2,3-DICHLORO N-[3-(4-METHOXY STYRYL) 
 CARBONYL] BENZAMIDE. 
 A mixture of N-(3-acetylphenyl)-2,3-dichlorobenzamide (10 gm, 0.03 mole) and 
anisaldehyde (5.44 gm, 0.04 mole) in 150 ml of ethanol was stirred at room 
temperature for 24 hr in the presence of 5 ml of 40% NaOH, the reaction was 
monitored by T.L.C., after completion of reaction the mixture was poured on crushed 
ice; the separated solid was isolated and recrystallized from DMF-ethanol. Yield- 
68%, m.p. 199oC; [C23H17Cl2NO3; required: C, 64.80; H, 4.02; N, 3.29 %; found: C, 
64.78; H, 4.05; N, 3.27 %]. 
 Similarly, other 2,3-Dichloro-N-[3-(4-methoxy styryl) Carbonyl] Benzamide 
were prepared. The physical constants are recorded in Table No. – 4. 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[C] BIOLOGICAL EVALUATION OF 2,3-DICHLORO N-[3-
(SUBSTITUTED STYRYL)CARBONYL] BENZAMIDE. 
 Antimicrobial testing were carried out as described in Chapter-8, The zones of 
inhibition of test solutions are recorded in Graphical Chart-4a, Table-4a. Page. No.-
366, 367. Result and discussion is given on page no.:-368. 
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SECTION-3.2 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO- N- {3- 
[3-ARYL-1[H] PYRAZOLINE-5-YL} PHENYL] BENZAMIDE. 
 Pyrazoline derivatives represent one of the most active classes of compounds 
having a wide spectrum of biological activities. Looking to the interesting properties 
of pyrazolines it was considered worthwhile to synthesize a series of pyrazolines of 
Type- (V) for obtaining biologically potent agents which were prepared by reacting 
chalcones of Type-(IV) with hydrazine hydrate in Ethanol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (Va-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (Va-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations, 
Selected compounds have been also screened for their antitubercular activity. 
(Chapter-8) 
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IR SPECTRAL STUDIES OF 2,3-DICHLORO-N-[3-{3-(p-METHOXY 
PHENYL)- 1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
   
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2933 2975-2950 198 
-CH3 C-H str. (sym)  2835 2880-2860 " 
  C-H def. (asym.) 1492 1470-1435 " 
  C-H def.(sym.) 1348 1390-1370 " 
Aromatic C-H str. 3075 3090-3030 199 
  C=C str. 1515 1540-1480 " 
 C-H i.p. def. 1030 1125-1000 " 
 C-H o.o.p. def. 829 835-810 " 
Moiety C-Cl (str.) 788 800-600 200 
Carboxamide -CONH- 1651 1700-1650 201 
Ether C-O-C str. 1247 1260-1200 " 
Pyrazole ring C-N (str) 1174 1230-1020 " 
 N-H (str) 3330 3320-3140 " 
 C=N (str) 1602 1650-1550 " 
 C-H (CH2) str. 2835 2850-2790 " 
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PMR SPECTRAL STUDIES OF 2,3-DICHLORO-N-[3-{3-(p-METHOXY 
PHENYL)-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE.  
 
 Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER  Spectrometer (300 
 MHz). 
 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 3.25 1H Double doublet -CHa 
2 3.52 1H Double doublet -CHb 
3 3.94 1H singlet -OCH3 
4 5.12 1H triplet -CHX 
5 6.81-7.62 11H multiplet Ar-H 
6 7.38 1H singlet -NH (pyrazo.) 
    overlapped 
7 7.98 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2,3-DICHLORO-N-[3-{3-(p-METHOXY 
PHENYL)-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
Cl
Cl
O
NH
N
H
N
O
CH3
m/z = 440.32
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2,3-DICHLORO-N-[3-{3-
ARYL-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATIONOFN-(3-ACETYLPHENYL)-2,3-DICHLORO  
 BENZAMIDE. 
 Pls. refer chapter -3, Section-3.1, Page No.131 
 
 [B] PREPARATION OF 2,3-DICHLORO N-[3-(4-METHOXYSTYRYL) 
 CARBONYL] BENZAMIDE. 
  Pls. refer chapter-3, Section-3.1, Page No.131 
 
[C]  PREPARATION OF 2,3-DICHLORO-N-[3-{3-(4-METHOXYPHENYL)-         
1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
 A mixture of 2,3-dichloro-N-[3-(4-methoxy styryl) carbonyl] benzamide (4.26 
gm, 0.01 mole) and hydrazine hydrate (1.0 gm, 0.02 mole) in 25 ml ethanol was 
refluxed on an oil-bath for 10-11 hrs. The solution was poured on crushed ice. The 
product was isolated and crystallized from dioxane. Yield-65%, m.p.-116 0C; 
(C23H19Cl2N3O2; required: C, 62.74; H, 4.35; N, 9.54%; found: C, 62.71; H, 4.37; N, 
9.44%). 
 Similarly, other 2,3-Dichloro-N-[3-{3-(aryl)-1[H]pyrazoline-5-yl}phenyl] 
benzamide were prepared. The physical constants are recorded in Table-5. 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8). 
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[D]  BIOLOGICAL EVALUATION 2,3-DICHLORO-N-[3-{3-(ARYL)-1[H] 
PYRAZOLINE-5-YL}PHENYL] BENZAMIDE.  
  Antimicrobial testing were carried out as described in Chapter-8, The zones of 
inhibition of test solutions are recorded in Graphical Chart-5a, Table-5a. Page No.-
369, 370.Result and discussion is given on page no.:- 371. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies on some compounds…  142 
 
Pyrazolines… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
● 
S1
= 
Et
hy
le
ne
 d
ic
hl
or
id
e:
 E
th
yl
 a
ce
ta
te
 (8
:2
), 
S2
 =
 T
ol
ue
ne
: E
th
yl
 a
ce
ta
te
 (8
:2
) 
Studies on some compounds…  143 
 
Pyrazolines… 
SECTION-3.3 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO-N–[3-
{3-(ARYL)-1-PHENYL-1[H] PYRAZOLINE– 5-YL} PHENYL] BENZAMIDE. 
 Looking to the interesting therapeutic activities of pyrazoline, it was 
considered worthwhile to synthesize compounds bearing N-(3-acetylphenyl)-2, 3-
dichlorobenzamide moiety linked to the pyrazoline nucleus. Pyrazoline of Type (VI) 
have been prepared by the action of chalcones of Type-(IV) with phenyl hydrazine in 
presence of ethanolic sodium hydroxide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (VIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (VIa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations, 
Selected compounds have also been screened for their antitubercular activity 
(chapter-8). 
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IR SPECTRAL STUDIES OF 2,3-DICHLORO-N-{3-[3-(p-METHOXY 
PHENYL)-1-PHENYL-1[H] PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
 
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2951 2975-2950 198 
-CH3 C-H str. (sym)  2835 2880-2860 " 
  C-H def. (asym.) 1413 1470-1435 " 
  C-H def.(sym.) 1386 1390-1370 " 
Aromatic C-H str. 3061 3090-3030 199 
  C=C str. 1502 1540-1480 " 
 C-H i.p. def. 1031 1125-1000 " 
 C-H o.o.p. def. 840 835-810 " 
Moiety C-Cl (str.) 788 800-600 200 
Carboxamide -CONH- 1660 1700-1650 201 
Ether C-O-C str. 1247 1260-1200 " 
Pyrazole ring C-N (str) 1174 1230-1020 " 
 C=N (str) 1595 1650-1550 " 
 C-H (CH2) str. 2835 2850-2790 " 
 N-Ph 1502 1507-1495 " 
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PMR SPECTRAL STUDIES OF 2,3-DICHLORO -N- {3-[3-(p-METHOXY 
PHENYL)-1-PHENYL -1[H] PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE 
  
 Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER  Spectrometer (300 
 MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 3.18 1H Double doublet -CHA 
2 3.82 1H Double doublet -CHB 
3 3.68 1H singlet -OCH3 
4 5.45 1H triplet -CHX 
5 6.62-7.82 16H multiplet Ar-H 
6 8.22 1H singlet -NH (NHCO) 
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2,3-DICHLORO-N-[3-{3-
(ARYL)-1-PHENYL-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF N-(3-ACETYLPHENYL)-2,3-DICHLORO 
 BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
[B] PREPARATION OF 2,3-DICHLORO N-[3-(4-METHOXYSTYRYL) 
 CARBONYL] BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
 [C] PREPARATION OF 2,3-DICHLORO-N-{3-[3-(4-METHOXYPHENYL)-1-
PHENYL - 1[H] PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
 A mixture of 2,3-dichloro-N-[3-(4-methoxy styryl) carbonyl] benzamide (4.26 
gm, 0.01 mole) and phenyl hydrazine (2.16 gm, 0.02 mole) in acetic acid as a solvent 
was  refluxed on an oil-bath for 5-6 hrs. The solution was poured on crushed ice. The 
product was isolated and crystallized from DMF-ethanol. Yield-71%, m.p.-1960C; 
(C29H23Cl2N3O2; required: C, 67.45; H, 4.49; N, 8.14%; found: C, 67.43; H, 4.42; N, 
8.11%). 
  Similarly, other 2,3-dichloro-N- {3-[3-(aryl)-1-phenyl - 1[H] pyrazoline – 5 - 
yl} phenyl] benzamide were prepared. The physical constants are recorded in     
Table-6. 
 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[D] BIOLOGICAL EVALUATION OF 2,3-DICHLORO-N-[3-{3-(ARYL)-1-
PHENYL-1[H] PYRAZOLINE-5-YL}PHENYL] BENZAMIDE. 
   Antimicrobial testing were carried out as described in Chapter-8. The zones of 
inhibition of test solutions are recorded in Graphical Chart-6a, Table-6a. Page No.-
372, 373. Result and discussion is given on page no.:- 374. 
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SECTION-3.4 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO-   N – 
[3-{3-(ARYL)-1-ACETYL-1[H]PYRAZOLINE–5-YL}PHENYL]BENZAMIDE]. 
 Pyrazolines play a vital role owing of their wide range of biological activity 
and with an aim to getting better drug, it was considered worthwhile to synthesize 
some new acetyl pyrazolines. The preparation of 2,3-dichloro-N –[3-{3-(aryl)-1-
acetyl - 1[H] pyrazoline–5-yl}phenyl]benzamide] Type (VII) have been undertaken 
by cyclo condensation  of chalcones of Type (IV) with hydrazine hydrate in glacial 
acetic acid. 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (VIIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (VIIa-j) have been compared with standard 
drugs viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(chapter-8). 
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IR SPECTRAL STUDIES OF 2, 3-DICHLORO- N –[3-{3-(p-METHOXY 
PHENYL)-1-ACETYL-1[H]PYRAZOLINE–5-YL} PHENYL] BENZAMIDE]. 
 
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2930 2975-2950 198 
-CH3 C-H str. (sym)  2839 2880-2860 " 
  C-H def. (asym.) 1452 1470-1435 " 
  C-H def.(sym.) 1359 1390-1370 " 
Aromatic C-H str. 3086 3090-3030 199 
  C=C str. 1516 1540-1480 " 
 C-H i.p. def. 1033 1125-1000 " 
 C-H o.o.p. def. 829 835-810 " 
Moiety C-Cl (str.) 796 800-600 200 
Carboxamide -CONH- 1676 1700-1650 201 
Ether Ar-O-C (sym.) 1045 1075-1010 " 
Pyrazole ring C-N (str) 1178 1230-1020 " 
 C=N (str) 1606 1650-1550 " 
 C-H (CH2) str. 2839 2850-2790 " 
 N-COCH3 1637 1660-1650 " 
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PMR SPECTRAL STUDIES OF 2, 3-DICHLORO-   N – [3-{3-(p-METHOXY 
PHENYL)-1-ACETYL-1[H] PYRAZOLINE– 5 -YL} PHENYL] BENZAMIDE]. 
 
 Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
 (300 MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 2.41 1H singlet -COCH3 
2 3.14 1H Double doublet -CHA 
3 3.84 1H Double doublet -CHB 
4 3.78 1H singlet -OCH3 
5 5.50 1H triplet -CHX 
6 6.68-7.80 11H multiplet Ar-H 
7 8.28 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2, 3-DICHLORO- N – [3-{3-(p-METHOXY 
PHENYL)-1-ACETYL-1[H] PYRAZOLINE–5 -YL} PHENYL] BENZAMIDE]. 
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCURE ELUCIDATION OF 2, 3-DICHLORO-  N – [3-
{3-(ARYL)-1-ACETYL-1[H] PYRAZOLINE–5-YL} PHENYL] BENZAMIDE.] 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATIONOFN-(3-ACETYLPHENYL)-2,3-DICHLORO 
 BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
[B] PREPARATION OF 2,3-DICHLORO N-[3-(4-METHOXYSTYRYL) 
 CARBONYL] BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
[C]  PREPARATION OF OF 2, 3-DICHLORO-   N – [3-{3-(ARYL)-1-ACETYL 
-1[H]- PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE]. 
 A mixture of 2,3-dichloro-N-[3-(4-methoxy styryl) carbonyl] benzamide (4.26 
gm, 0.01 mole) and hydrazine hydrate (1 gm, 0.02 mole) in presence of glacial acetic 
acid on an oil-bath for 7-8 hrs. The solution was poured on crushed ice. The product 
was isolated and crystallized from dioxane. Yield-70, m.p.-2450C; (C25H21Cl2N3O2; 
required:  C, 62.25; H, 4.39; N, 8.71 %; found: C, 62.22; H, 4.44; N, 8.75 %). 
  Similarly, other 2, 3-dichloro-N- {3-[3-(aryl)-1-phenyl - 1[H] pyrazoline – 5 - 
yl}-phenyl] benzamide were prepared. The physical constants are recorded in     
Table-7. 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8). 
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[C]  BIOLOGICAL EVALUATION 2,3-DICHLORO-N–[3-{3-(ARYL)-1-
ACETYL -1[H]- PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE]. 
  Antimicrobial testing were carried out as described in Chapter-8. The zones of 
inhibition of test solutions are recorded in Graphical Chart-7a, Table-7a. Page No.-
375, 376. Result and discussion is given on page no.: - 377. 
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SECTION-3.5 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO-   N – 
[3-{3-(ARYL)-1-THIOCARBAMIDO - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE. 
 Pyrazolines are endowed with multipurpose biological activities. Looking 
at their versatile therapeutic importance and with an aim to getting better drug, it was 
considered worthwhile to synthesize some new pyrazole of Type (VIII). The 
preparation of pyrazolines of type (VIII) have been under taken by cyclocondensation 
of 2,3-dichloro-N-[3-(4-methoxy styryl) carbonyl] benzamide with thiosemicarbezide. 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (VIIIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (VIIIa-j) have been compared with standard 
drugs viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(chapter-8). 
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IR SPECTRAL STUDIES OF 2,3-DICHLORO-N–[3-{3-(p-METHOXY 
PHENYL)-1-THIOCARBAMIDO - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE.  
 
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2930 2975-2950 198 
-CH3 C-H str. (sym)  2865 2880-2860 " 
  C-H def. (asym.) 1435 1470-1435 " 
  C-H def.(sym.) 1354 1390-1370 " 
Aromatic C-H str. 3066 3090-3030 199 
  C=C str. 1540 1540-1480 " 
 C-H i.p. def. 1080 1125-1000 " 
 C-H o.o.p. def. 830 835-810 " 
Moiety C-Cl (str.) 710 800-600 200 
Carboxamide -CONH- 1664 1700-1650 201 
Ether C-O-C (sym.) 1251 1260-1200 " 
Pyrazole ring C-N (str) 1161 1230-1020 " 
 C=N (str) 1579 1650-1550 " 
 C-H (CH2) str. 2830 2850-2790 " 
 C=S 1556 1590-1550 " 
 -NH str 3269 3320-3140 " 
 
40060080010001200140016001800200024002800320036004000
1/cm
-15
0
15
30
45
60
75
90
105
120
%T
32
69
.4
5
30
66
.9
2
23
60
.9
5
16
6
4.
62
15
79
.7
5
15
56
.6
1
14
83
.3
1
14
35
.0
9
13
54
.0
7
12
51
.8
4
1
16
1.
19 1
08
0.
17
9
76
.0
1
88
1
.5
0
MM-05
Cl
Cl
O
NH
N
N
O
CH3
S
NH2
Studies on some compounds…  164 
 
Pyrazolines… 
 
PMR SPECTRAL STUDIES OF 2,3-DICHLORO-N–[3-{3-(p-METHOXY 
PHENYL)-1-THIOCARBAMIDO - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE. 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 3.20-3.22 1H Double doublet -CHA 
2 3.40-3.44 1H Double doublet -CHB 
3 3.81 1H singlet -OCH3 
4 5.98 1H Double doublet -CHX 
5 6.81-7.68 11H multiplet Ar-H 
6 7.98 2H Singlet (Broad) -NH2 
7 8.25 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2,3-DICHLORO-N–[3-{3-(p-METHOXY 
PHENYL)-1-THIOCARBAMIDO - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE. 
 
 Cl
Cl
O
NH
N
N
O
CH3
S
NH2
M/Z= 499.42
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO- N – [3-
{3-(ARYL)-1-THIOCARBAMIDO - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF N-(3-ACETYLPHENYL)-2,3-DICHLORO 
 BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
[B] PREPARATION OF 2,3-DICHLORO N-[3-(4-METHOXYSTYRYL) 
 CARBONYL] BENZAMIDE. 
 Pls. refer chapter-3, Section-3.1, Page No.131 
 
[C] PREPARATION OF 2,3-DICHLORO-N–[3-{3-(ARYL)-1-THIOCARBA  
MIDO-1[H] PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE. 
 A mixture of 2,3-dichloro-N-[3-(4-methoxy styryl) carbonyl] benzamide (4.26 
gm, 0.01 mole) and thiosemicarbazide (0.04 mole) in presence of ethanolic sodium 
hydroxide on an oil-bath for 10-11 hrs. The solution was poured on crushed ice. The 
product was isolated and crystallized from dioxan. Yield-65%, m.p.-1440C; 
(C22H19N3O4; required: C, 57.72; H, 4.04; N, 11.22 %; found: C, 57.82; H, 4.11; N, 
11.25%). 
  Similarly, other 2, 3-dichloro-N- {3-[3-(aryl)-1-phenyl - 1[H] pyrazoline – 5 - 
yl} phenyl] benzamide were prepared. The physical constants are recorded in    
Table-8. 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[C] BIOLOGICAL EVALUATION 2,3-DICHLORO-N–[3-{3-(ARYL)-1-
ACETYL -1[H]- PYRAZOLINE – 5 - YL} PHENYL] BENZAMIDE]. 
 Antimicrobial testing were carried out as described in Chapter-8. The zones of 
inhibition of test solutions are recorded in Graphical Chart-8a, Table-8a. Page No.-
378, 379. Result and discussion is given on page no.380. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies on some compounds…  169 
 
Pyrazolines… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
● 
S1
= 
Et
hy
le
ne
 d
ic
hl
or
id
e:
 E
th
yl
 a
ce
ta
te
 (8
:2
), 
S2
 =
 T
ol
ue
ne
: E
th
yl
 a
ce
ta
te
 (8
:2
) 
Studies on some compounds…  170 
 
Pyrazolines… 
 
REFERENCES:   (Chapter-3: Ref. No.:- 1-201) 
 
1.  S. V. Kostanecki and J. Tambor; 
Chem. Ber ., 32, 1921 (1899). 
2.  K. Kazauki, K. Htayama, S. Yokomor and T. Soki; 
Chem. Abstr ., 85, 5913 (1976). 
3. H. Rupe and D. Wasserzug;  
 Chem. Ber ., 34, 3527 (1901). 
4. T. Szell; Chem. Ber ., 92, 1672 (1959) ;  
 Chem. Abstr ., 53, 21913 (1959). 
5. C. Kurodo and T. Matsukuma; Sci. Papers Inst. Phys. Chem. Res. (Tokyo), 18,  
(1932); Chem. Abstr ., 26, 2442 (1932). 
6.  D. S. Breslow and C. R. Houser ; J. American Chem. Soc., 62, 2385 (1940) ; 
Chem.Abstr ., 34, 7875 (1940). 
7.  G. V. Jadav and V . G. Kulkarni;  
 Curr . Sci. (1944). 
8.  L. Reichel; Naturwissenschallen 32, 215 (1944);  
 Chem. Abstr ., 10, 2441 (1946). 
9 .A. A. Rawal and N. M. Shah;  
 Indian J. Chem., 21, 234 (1962). 
10.  P . L. Cheng, P . Fournari and J. Tirouflet;  
 Bull. Soc. Chim. France, 102248 (1963);Chem. Abstr ., 60, 1683 (1964). 
11.  R. B. Lyle and L. P . Paradis; J. American Chem. Soc., 77, 6667 (1955); Chem. 
Abstr .,50, 10057 (1956).11. T. Szell; Chem. Ber ., 
12.  S. A. Hermes; 
  Chem. Abstr ., 70, 96422h (1969). 
13.  V . M. Vlasov; Izu. Sib. Otd, Akad. Nauk. S. Ser . Khim. Nauk. 2, 96 (1971); 
Chem.Abstr ., 76, 140411d (1972). 
14.  Shinda and Sato; J.Pharm. Soc.,(Japan), 49, 797 (1929); 
  Chem. Abstr., 24,604(1903). 
15.  Bergellin and Morantonic Atti; Alad, Linli, 1968[V] 17, ii, 119-125; 
Brit.Chem.Abstr.,8(1) 801 (1908). 
16.  Christian and Amin; 
  J. Sci. Ind. Research., 14B, 421 (1955). 
Studies on some compounds…  171 
 
Pyrazolines… 
17.  Mehra and mathur;  
 J. Indian. Chem. Soc., 52, 801 (1975). 
18.  P . L. Nayak and N. K. Rout; 
  J. Indian Chem. Soc., 52, 801 (1975). 
19.  M. A. El. Hashan, M. El-Kady, M. A. Saiyed, A. A. Elsawy; 
Egypt. J. Chem., 27(6), 715-21 (1985) (Eng.); Chem. Abstr ., 105, 208684 
 (1986). 
20 . P . S. Utale, P . B. Raghuvanshi, A. G. Doshi; 
Asian J. Chem., 10(3), 597-99 (1998). 
21.  A. Sammour, Y . Akhnookh and H. Jahine; 
U.A.R. J. Chem., 13(4), 421-37, (1970); Chem. Abstr ., 77, 101348q (1972). 
22.  S. W. Pfleiderer and H. Mosthafa; 
Synthetic Org. Chem., B90, 738 (1957). 
23. L. S. Crawley and W. J. Fanshawe; 
J. Heterocycl. Chem., 14, 53, (1977). 
24.  A. Khalafallah; 
Asian J. Chem., 8(4), 951-96 (1996). 
25.  D. J. Brown; 
Heterocycl. Compd., 16. 
26.  E. C. Taylor and R.W. Morrison; 
J. Org. Chem., 32, 2379 (1967). 
27.  K. Folkers, S. A. Harris; 
J. Am. Chem. Soc., 61, 1245 (1939). 
28.  E. A. Mohamed, R. M. Abdel Rahman, A. A. Sayed and M. M. Ismail; 
Indian J. Chem., Soc., 69, 82 (1992). 
29.  Rasaki Abayomi Osisany, James Olabisi Oluwadiya; J. Heterocycl. Chem., 26, 
947 (1989). 
30.  M. R. Mahmoud, Awatef E. F. E., M. S. Abd-El-Halim, A. M. Radwan; 
Indian J. Heterocycl. Chem., 4, 131-36 (1994). 
31.  A. Y . Deshmukh, P . B. Raghuwanshi, A. G. Doshi; 
Oriental J. Chem., 18(1), 101-104 (2002). 
32.  A. Chan Seng H., Brimble Margaret; 
Aus. J. Chem., (1998); Chem. Abstr .; 129, 16105f (1998). 
33.  Ms. B. S. Hastak and B.J. Ghiya; 
Studies on some compounds…  172 
 
Pyrazolines… 
Indian J. Heterocycl. Chem., 2, 133-135 (1992). 
34.  P . A. Mehta and H. B. Naik; 
Oriental J. Chem., 14(1), 159-60 (1998); Asian J. Chem., 10(4), 1017-8 
 (1998). 
35.  K. P . Jadhav, D. B. Ingle; 
Indian J. Chem., 22B, 180 (1983). 
36.  E. T. Ogansyan et al.; 
Khim. Farm. Zh., 25(8), 18 (1991); Chem. Abstr ., 115, 247497n (1991). 
37.  H. Serre, J. Rey and J. P . tarayre; 
Fr . Demande, 2, 377, 201 (Cl A 61 K 37/48); Chem. Abstr ., 91, 9494a (1979). 
38.  A. E. Vanstone, G. K. Maile and L. K. Nalbantoglu; 
Ger . Offen. DE 3,537, 207 (Cl. 07 c 65/40) (1986); Chem. Abstr ., 106, 49778f 
(1987). 
39.  D. Binder, C. R. Noe, W. Holzer and B. Rosenwirth; 
Arch. Pharm., 318(1),48 (1985); Chem. Abstr ., 102, 149025u (1985). 
40. Sarot Cheenpracha, Chatehanok Karalai, Supinya Tewtrakul; 
Bioorganic & Medicinal Chemistry, 14(6), 1710-1714 (2006). 
41.  S. Satoshi, N. Yasunori, U. Hiroki; 
J. Med. Chem., 3904-9 (Eng.) (1993); Chem. Abstr ., 120, 133956j (1994). 
42.  Y . Satomi; 
Ind. J. Cancer , 55(3), 506 (1993); Chem. Abstr ., 120, 208071 (1994). 
43.  R. J. Auto et al.; 
J. Clin. Biochem. Nutr ., 17(2), 73 (1994); Chem. Abstr ., 123, 122487x (1995). 
44.  Li Rongshi, Chen. Xiawa., Gong Baogung, Qominguez, Jose N. et al.; 
J. Med. Chem., 38(26), 5031-7 (1995); Chem. Abstr ., 124, 232f (1996). 
45.  G. Zongru, H. Rui; 
Faming Zbuanli Shenquarg Gonku Shuominh Shu CN, 1, 113, 909; Chem. 
Abstr ., 125,10376r (1996). 
46.  F. S. Nielsen, S. B. Chirstensen;  
 J. Med. Chem., 41, 4819-4832 (1998). 
47.  Nissan Chemical Industries Ltd., 
Japan Kokai Tokkyo Koho Japan, 58, 08,035, (1983); 
Chem. Abstr .,98, 178947a (1983). 
48.  R. Seele et al.; 
Studies on some compounds…  173 
 
Pyrazolines… 
Eur . Pat. Appl. Ep., 337, 198 (Cl C07D, 249/08) (1989); Chem. Abstr ., 113, 
178990s (1990). 
49.  Tashio Pharmaceutical Co. Ltd.; 
Japan, kokai Tokkyo Koho Jp., 59, 12, 094 (84, 12, 094) (Cl A 61 K 31/215); 
Chem. Abstr ., 101, 54722j (1984). 
50.  K. Bowden, P . A. Dal and C. K. Shah; 
J. Chem. Res. Synop., 12, 2801 (1990); Chem. Abstr ., 114, 160570m (1991). 
51.  Y . Inamori et al.; 
Chem. Pharm. Bull., 39(6), 1604 (1991); Chem. Abstr ., 115, 105547c (1991). 
52.  V . M. Gaurav and D. B. Ingle; 
Indian J. Chem., 25B, 868 (1986); Chem.Abstr ., 107, 39321h (1987). 
53.  A. K. Pedersen and G. A. Fitz Gerald; 
J. Pharm. Sci., 74(2), 188 (1985); Chem. Abstr ., 103, 87592m (1985). 
54.  M. R. Bell; 
US Appl. , 637, 931 (1984); Chem. Abstr ., 113, 211828t (1990). 
55  Okuyama Torn, Okada Yoshihito, Shibato Shoji et al.; 
Jpn. Kokai Tokkyo Koho JP , 11, 349, 521 (1999); Chem. Abstr ., 132, 22752t 
(2000). 
56  A. Tsotitns, K. Theodara et al.; 
PCT Int. Appl. WO, 99, 54,278 (1999); Chem. Abstr ., 131, 28260e (1999). 
57 P . N. Sarma, B. Sreenivasulu; 
J. Indian Chem. Soc., (1997); Chem. Abstr ., 128, 88799n (1998). 
58  E. Bombardelli, V . Piero; 
PCT Int. Appl. WO, 98, 58, 913; Chem. Abstr ., 130, 95382r (1999). 
59  S. Elichi, K. Koji; 
PCT Int. Appl. WO, 99, 61, 403; Chem. Abstr ., 132, 12199d (2000). 
60 B. B. Kalashnikov, I. P . Kalashnikov; 
Russ. J. Gen. Chem., (1998); Chem. Abstr ., 130, 296596n (1999). 
61 S. Satoshi, N. Yasunori, V . Hiroki; 
J. Med. Chem., 3904-9 (Eng.) (1993); Chem. Abstr ., 120, 133956j (1994). 
62 P . B. Walavalkar, S. Pednekar; 
J. Heterocycl. Chem., (1999); Abstr ., 131, 257517p (1999). 
63 O. Toru, O. Yoshihito, S. Shaji; 
Jpn. Kokai Tokkyo Koho JP , 11, 349, 521; Chem. Abstr ., 132, 22752t (2000). 
Studies on some compounds…  174 
 
Pyrazolines… 
64 J. R. Dimmock, M. Elisk; 
U. S. US, 6, 017, 933; Chem. Abstr ., 132, 107880n (2000). 
65  T. M. Abdet Rahman; 
Bull. Chim. Farm., (1998); Chem. Abstr ., 132, 93276h (2000). 
66.  i Liming, Worsencrott K. J., Weingarten M. D., Meng C. Q., Sikorski J. A.; U. 
 S. 
US WO 02 41336 (2002); Chem. Abstr ., 139, 85160 (2003). 
67.  umar Srinivas K., Hager E., Pehit C., Gurulingoppal H., Davidson N. E., Khan 
S. R.; J. Med. Chem., 46(14), 2813-15 (2003);  
 Chem. Abstr ., 139, 117464 (2003). 
68.  Ko Horng-Huey, Tsao Lo-Ti, Yo Kum-Lung, Cheng-Tsung, Wong J. P ., Lin 
C. N.; Bioorg. & Med. Chem., 11(1), 105-111 (2003); Chem. Abstr ., 139, 
30144 (2003). 
69.  Nakahara Kazuhiko, Torakoontiwakon G.,Kaneyama M.,Ono Hiroshi, 
Yoshida Mitsuru; 
  Jpn. Kokai Tokkyo Koho JP ., 03 040829 (2003); Chem. Abstr ., 138, 158753 
(2003). 
70.  Lin Yuh-Meei, Zhou Yasheen, Flavin M. T., Zhou L. M., Nie, W., Cheng, F. 
C.; 
Bioorg & Med. Chem., 10(8), 2795-2802 (2002); Chem. Abstr ., 138, 66146 
(2003). 130, 296596n, (1999). 
71.  Das B. P., Chowdhary D. N., Ghosh K., Das G. K.; 
  Environ and Ecolo., 20(3), 649-55 (2002); Chem. Abstr ., 139, 129387 (2003). 
72.  Kim Min-Young, Park B. Y ., Kim K. M., Sung N. D. Myung P . K.;  
 PCT Int. Appl. WO 02 KR 2031 CA 61K031-03) (2002);Chem. Abstr ., 138, 
368613 (2003). 
73.  Liu, Mei, Wilairat Prapon, GO Mei-Lin; 
  J. Med. Chem., 45(8), 1735 (2002); Chem. Abstr ., 139, 94746 (2003). 
74.  Opletalova V eronika, Jahodar L., Jun D., Opletal L.;Ceska a Slovenska 
 Farmacie, 
52(1), 12-19 (2003); Chem. Abstr ., 138, 265043 (2003). 
75.  Rojas Javier, Dominguez J. N., Charris J. E., Lobo Gricela, Paya M., Ferrandiz 
M.L.; 
Studies on some compounds…  175 
 
Pyrazolines… 
 Eur . J. Med. Chem., 37(8), 699-705 (2002); Chem. Abstr ., 138, 122472 
(2003). 
76.  Rojas Javier, Paya M., Qominguez J. N., Luisa F. M.;  
 Bioorg. & Med. Chem. Letters, 12(15), 1951-54 (2002); Chem. Abstr ., 138, 
39068(2003). 
77.  Mateeva N. N., Kode R. N., Redda K. K.;  
 J. Heterocycl. Chem., 39(6), 1251-58 (2002); Chem. Abstr ., 138, 401568 
 (2003). 
78.  Wu Jiu-Hong, Wang Xi-Hong, Yi Yang-Huy, Lee Kuo-Hsiung; Bioorg. & 
Med. Chem. Jeff., 13(10), 1813-1815 (2003); Chem. Abstr ., 139, 
146483(2003). 
79.  Potter G. A., Butter P. C.;  
 PCT Int., Appl. WO, 03 028713 (2002) (Cl. A61K03100), Chem. Abstr ., 138, 
297623 (2003). 
80.  Potter G. A., Ijaz Taeeba;  
 PCT Int. Appl. WO, 03 029176 (Cl. C07 C049-84) (2002); Chem. Abstr ., 138, 
304053 (2003). 
81.  Ko H. H., Hsieh H. K., Liu C. T., Lin H. C., Teng C. M., Lin C. N.;  
 J Pharm Pharmacol., 56(10), 1333-7 (2004). 
82.  Ziegler H. L., Hansen H. S., Staerk D., Christensen S. B., Hagerstrand H.; 
AntimicrobAgents Chemother ., 48(10), 4067-71(2004). 
83.  Go M. L., Liu M., Wilairat P ., Rosenthal P . J., Saliba K. J., Kirk 
K.;Antimicrob Agents Chemother ., 48(9), 3241-5(2004). 
84.  Xue C. X., Cui S. Y ., Liu M. C., Hu Z. D., Fan B. T.; 
 Eur . J. Med. Chem., 39(9), 745-53(2004). 
85.  Styanarayana M and Tiwari P .;  
 Bioorg. Med. Chem. 12(5), 883-889, (2004). 
86.  Omid Sahzevari, Giuseppe Galati, Majid Y . Moridani, Arno Saraki and Peter  
 J. O’Brien; Che. Biological chemistry, 148(1-2), 57-67 (2004). 
87.  Alcaraz M. J., Vicente A. M., Araico A., Dominguez J. N., Terencio M. C.;  
 Br . J.Pharmacol., 142(7), 1191-9(2004). 
88.  Nerya O., Musa R., Khatib S., Tamir S., Vaya J.; 
  Phytochemistry. 65(10), 1389-95(2004). 
89.  Sabzevari O., Galati G., Moridani M. Y ., Siraki A., O’Brien P . J.;  
Studies on some compounds…  176 
 
Pyrazolines… 
 Chem Biol Interact., 148(1-2),57-67(2004). 
90.  Hollosy F., Keri G.;  
 Curr . Med. Chem. Anti-Cancer Agents, 4(2),173-97(2004). 
91.  Ban H. S., Suzuki K., Lim S. S., Jung S. H., Lee S., Ji J., Lee H. S., Lee Y . S., 
Shin K. H.; Biochem Pharmacol., 67(8), 1549-57(2004). 
92.  Simon Feldbaek Nielsen, Thomas Boesen, Mogens Larsen, and hasse 
 Kromann; 
Bioorganic & Medicinal Chemistry, 12(11), 3047-3054 (2004). 
93.  Prem P . Yadav, Prasoon Gupta, P. K. Shukla and Rakesh Mavrya; Bioorganic 
& 
Medicinal Chemistry, 13(5), 1497-1505 (2005). 
94.  Jose N. Dominguez, Caritza Leon, Juan Rodrigues, jiri Gut and Philip J. 
Rosenthal; Il Farmaco,60(4), 307-311 (2005). 
95.  Woo Duck Seo, Jin Hyo Kim, Ki Hun Park et al.; 
 Bioorganic & Medicinal Chemistry, 15(24), 5514-5516 (2005). 
96. Mogens Larsen, Hassa Kromann, Arsalan Kharazmi and Simon Feldbaek 
 nielsen; 
Bioorganic & Medicinal Chemistry, 15(21), 4858-4861 (2005) 
97. Khatib S., Nerya O., Musa R., Shmuel M., Tamir S., Vaya J.; 
 Bioorg MedChem., 13(2), 433-41(2005).. 
98.  W. D. Seo, J. H. Kim, J. E. Kang, H. W. Ryu, M. J. Curtis-Long, H. S. Lee, 
 M. S. 
Yang, and K. H. Park;  
Bioorg. Med. Chem. letters, 15(22), 5030-5034 (2005). 
99.  A. Araico, M. C. Terencio, M. J. Alcaraz, J. N. Dominguez C. Leon and M. L. 
Ferrandiz; 
  Life Science, 78(25), 2911-2918 (2006). 
100.  Sung Hee Lee, Xing Yu Jin et al.;  
 Eur . J. Pharmacology, 532(1-2), 178-186 (2006). 
101.  Paula Boeck,Camila Alves and Bartira Rossi-Bergmann; Bioorganic & 
 Medicinal 
Chemistry, 14(5), 1533-1545 (2006). 
102.  Xiang Wu, Edward R. T., Mei-Lin Go et al.; 
  Eur . J. Pharmacology, 532(1-2), 178-186 (2006). 
Studies on some compounds…  177 
 
Pyrazolines… 
103.  Kamble R. R., Sudha BS ;  
 Indian Journal of pharmaceutical Sciences, 68(2), 249-253 (2006). 
104.  M. Shahar Yar, A. Ahmad Siddiqui, M.Ashraf Ali and ;  
 J. Serb. Chem. Soc. 72 (1) 5-11 (2007). 
105.  Feng Jin,Ying Lan Jin, Dae Won Sohn, Soon-Ai Kim, Dong Hawn Sohn, 
Youn Chul and Kim, Hak Sung Kim;  
 Arch Pharm Res, 11(30), 1359-1367 (2007). 
106. Knorr; 
 Ger . Pat., 26, 429 (1983) [Friedander, 1, 208]. 
107 Knorr L.; 
 Justus Liebigs Ann. Chem., 379, 236 (1894). 
108.  El-Maphraby M. A., Khalafalla A. K., Hassan M. E., Soleiman H. A.; 
 J Indian Chem Soc 63, 910 (1986). 
 109. Krapcho J., Turk C.; 
  J Med Chem 22, 207 (1979). 
110.  Raiford C. C., Tanzer C. K.; 
  J Org Chem 6, 799 (1941). 
111. Hukki J., Laitinen P ., Alberty J.; 
  E. Pharm. Acta Helv. 43, 704 (1968). 
112. Jung J. C., Watkins E. B., Avery M. A.; 
  Heterocycles 65, 77 (2005). 
113. Bansal E., Srivastava V . K., Kumar A.; 
  Eur . J. Med.Chem. 36, 81 (2001). 
114.  Udupi R. H., Rao S. N., Bhat A. R.; 
  Indian J. Heterocycl. Chem. 7, 217 (1998). 
115. Ahn J. H., Kim H. M., Jung S. H., Kang S. K., Kim K. R., Rhee S. D., 
  Bioorg. Med. Chem. Lett. 14, 4461 (2004). 
116. Villhauer E. B., Brinkman J. A., Naderi C. B., Dunning B. E., Mangold B. L.; 
  J. Med. Chem. 45, 2362 (2002). 
117.  Amr A. E.; 
  Indian J. Heterocycl. Chem. , 10, 49 (2000). 
118.  Hammam A. G., Fahmy A. F. M., Amr A. E., Mohamed A. M.; 
  Indian J. Chem. , 42 1985 (2003). 
119.  Hammam A. G., Abdel Hafez N. A., Midura W. H.,Mikolajczyk M. Z.; 
Studies on some compounds…  178 
 
Pyrazolines… 
  Naturforsch., 55b, 417 (2000). 
120.  Kumar A.; 
  Indian J Chem 35A, 1018.(1996). 
121.  Elguero J.; In Comprehensive Heterocyclic Chemistry, eds.,  
  A. R. Katritzky and C.W. res., Vol 5, Ch. 404. 
122.  Theobald R. S.;Rodd’s Chemistry of Carbon Compounds, Ed. M. F.  
  Ansell, Vol. IV, Part C, Ch. 16 2nd Edition,(Elsevier Science Publishers B. 
  V .,Amsterdam) 59 (1998). 
123. H. V . Pechmann; 
 Ber ., 31, 2950 (1898). 
124.  L. Knorr; 
 Ber ., 16, 2587 (1883). 
125.  Paramasivam T. Perumal, Narayanasamy Mathivanan et.al.; 
 Bioorg. & med.chem. Lett., 14(24), 6035-6040 (2004). 
126. R. S. Varma and Yuhong Ju; 
 Tetrahedren Lett., 46(36), 6011-6014, Sept.(2005). 
127. Boruah R. C., Anil Saikia, Madan G. Barthakur, Chandan J. Saikia, Utpal  
  Bora; 
 Tetrahedren Lett., 47(1), 43-46, Jan.(2006) 
128.  Marica Theiszova, Petra Cernuchova, Giang Vo-Thanh, Viktor Milata, Andre 
 Loupy; Tetrahedron 61(22), 5379-5387, May(2005). 
129.  Fahmy A. M., Hassan M., Khalf A. A., Ahmed R. A.; 
 Rev. Roum. Chim., 33(7), 755-61 (1998); Chem. Abstr ., 111, 77898 (1989). 
130.  Hurst E. W., Hull R.; 
 J. Med. Pharm. Chem., 3, 215–229 (1961). 
131.  Matsuda T., Hirao I.; 
 Nippon Kag. Zass., 86, 1195–1197 (1965). 
132.  Yu Chen, Yulin Lam., Yee-Hing Lai.; 
 Org Lett. 5 No.7 1067-1069 (2003 ) 
133.  Hassaneen Hamdi M., Hamad A. E., Hiyam A. H. M.; 
 Salter Lett., 8(5), 27582 (1989); Chem. Abstr ., 111, 57611 (1989). 
134.  El. Hashsh M. A., El-Kady M., Saiyed M. A., Elsawy A. A.; 
 Egypt. J. Chem., 27(6), 715-21 (1985); Chem. Abstr ., 105, 20868u (1986). 
135. Kumsars K., Velena A., Duburs G., Uldrikis J., Zidermane A.; 
Studies on some compounds…  179 
 
Pyrazolines… 
 Biokhimiya, 36, 1201–1209 (1971). 
136.  Gokhan N., Yesilada A., Ucar G., Erol K., Bilgin A.A.; 
 Arch Pharm.Med.Chem. 336,362-371 (2003). 
137. Holla B. S., Akbarali P . M., Shivanada M. K., 
 IL Farmaco 55 256–263 (2000). 
138. Plaska E., Aytemir M., Uzbay T., Erol D.; 
 Eur . J. Med. Chem. 36 539–543 (2001). 
139.  Turan ZitouniG., Chevallet P ., Kilic F. S.; 
 Eur . J. Med. Chem. 35 635–641 (2000). 
140.  Bruno O., Ranise A., Bondavalli F., Schenone F., D’Amico M., Filipelli A., 
 Filipelli W.,IL Farmaco 48 949–966 (1993). 
141.  Manna F.; Chimenti F., Bolasco A., Cenicola M. L., de-Amico M. D.,Parrillo 
 C.; 
 Eur .J. Med. Chem. , 27, 633 (1992). 
142.  Jain S. M., Devi S., Bani S., Singh S., Singh G. B.; 
 Indian J. Chem. , 27B, 1019 (1988). 
143.  Kumar A., Saxena K. K., Lata S., Saxena R. S., Srivastava V . K.; 
 Indian Drugs 28, 111 (1990). 
144.  Udupi R. H., Rao S. N., Bhat A. R.; 
 Indian J. Heterocycl. Chem. 7, 217 (1998). 
145.  Paul S., Gupta R.; 
 Indian J. Chem. , 37B, 1279 (1998).130 
146.  Bansal E., Srivastava V . K., Kumar A.; 
 Eur . J. Med. Chem. 36, 81 (2001). 
147.  Nugent R. A., Murphy M., Schlachter S. T., Dunn C., Smith R., Staite N. D.; 
 J. Med. Chem. 36, 134 (1993). 
148.  Krapcho J., Turk C. F.; 
 J. Med. Chem. 22, 207 (1979). 
149.  Warner P . L., Luber J.; 
 U.S. Patent 4,172, 647, (1979); Chem. Abstr . 92, 58785a (1980). 
150.  Lombardino G.; 
 Nonsteroidal Anti-inflammatory Drugs; Wiley Interscience, John Wiley and 
 Sons: New York, 1985. 
151.  Roman B.; 
Studies on some compounds…  180 
 
Pyrazolines… 
 Pharmazie, 45, 214 (1990). 
152.  Brozozowsk Z., Pormarnacka E.; 
 Acta. Pol. Pharm., 37(4), 1378-80 (1980); Chem. Abstr ., 25, 80807 (1981). 
153.  Archana Shrivastava V . K., Chandra Ramesh, Kumar Ashok; 
 Indian J. Chem., 41B, 2371-75 (2002); Chem. Abstr ., 138, 271582 (2003). 
154. Reddy D. B., Senshuna T. and Ramma Reddy M. V .; 
 Indian J. Chem., 30B, 46 (1991). 
155. Ashok Kumar, Verma R. S. and Jagu B. P .; 
 J. Ind. Chem. Soc., 67, 120 (1990). 
156.  Ronald W. I., Adriano A.; 
 Chem. Abstr ., 126, 181346f (1997). 
157. Mokhtar H. M., Faidallah H. M.; 
 Pharmazie, 42, 482 (1987). 
158.  Panda J. Srinivas S. V ., Rao M. E.; 
 J. Indian Chem. Soc., 79(9), 770-1 (2002); Chem. Abstr ., 138, 153499n 
 (2003). 
159. Delay Francois, Patent Schrift ; 
 Chem. Abstr ., 117, 90276f (1992). 
160.  Aysel G., Seref D., Gultaze C., Kevser E., Kamil V .; 
 Eur . J. Med. Chem., 35, 359-64 (2000). 
161.  Desaea P ., Nunrich A., Carderny M. and Devaux G.; 
 Eur . J. Med. Chem., 25, 285 (1990). 
162.  Kalluraya Balakrishna, Chimabalkar R., Rai G., Gururaja R., Shenoy S.; 
 J. Indian Coun. Chemi., 18(2), 39-43 (2001); Chem. Abstr ., 138, 238061 
 (2003).131 
163.  Hiroyuti Y ., Mocoto O. et al.; 
 Eur . Pat. Appl. Ep 295695 (Cl. C07D 401/6) (1988); Chem. Abstr ., 111, 23510  
 (1989). 
164.  Zalgislaw K. and Seffan A.; 
 Acta. Pol. Pharm., 36(6), 645 (1979); Chem. Abstr ., 93, 204525e (1980). 
165.  Nayal S. S. and Singh C.P .; 
 Asian J. Chem. 11, 1, 207-212 (1999). 
166.  Trena K.and Zolzislaw; 
 Acta. Pol. Pharm., 36 (3), 227 (1979); Chem. Abstr ., 93, 4650r (1980). 
Studies on some compounds…  181 
 
Pyrazolines… 
167.  Hans B., Rolf R. and Rudolf R.; 
 US. Pat. 3, 822, 283 (1974); Chem. Abstr ., 81, 105494r (1974). 
168.  Untawy, Atif E. Fatema A., Abdela M.; 
 Chim Pharm. J., 47(1), 37-45 (1995); Chem. Abstr ., 123, 228016d (1995). 
169.  Satyanarayana K., Rao M. N. A.; 
 Eur J Med Chem 30,641-645 (1995). 
170.  Essa H. Hu, Daniel R. Sidler, Ulf H. Dolling; 
 J. Org. Chem., 63, 3454-3457 (1998). 
171.  Akhil Bhatt, Parekh H. H. and Parikh A. R.; 
 Heterocyclic Commun., 4(4), 361-66, (Eng.); Chem. Abstr ., 130, 25006x 
 (1999). 
172.  Shivananda M. K., Akberali P . M., Holla B., Shivarama, Shenoy M., Shalini; 
 Org. Chem. Incl. Med. Chem. 39B(6), 440-447 (Eng.); Chem. Abstr .,134, 
 86195n (2000). 
173.  Guniz Kacukguzel, Sevin Rollas, Habibe Erdeniz, Muammer Kiraz, A. 
 Cevdet Ekinci; Eur . J. Med. Chem., 35, 761-77 (2000). 
174.  Gulhan T. Z., Pierre Chevallet, Fatma S. K., Kevser Eral.; 
 Eur . J. Med. Chem., 35, 635-41 (2000). 
175.  Nisha Singh; Naresh K. Sangwan, Kuldip S. Phindsa & Haisor Indra; 
 J. Indian Chem. Soc., 78, 119-122 (2001). 
176.  Palaska E., Aytemir M., Uzboy I. T., Erol D.; 
 Eur . J. Med. Chem., 36(6), 539-543 (Eng), 2001; Chem. Abstr ., 136, 18374v 
 (2002). 
177.  Malhotra V., Pathak S., Nath R., Mukherjee D., Shanker K.; 
 Indian J. Chem., 41B, 1310-13 (2002); Chem. Abstr ., 137, 370021j (2002). 
178.  Tejas A. Upadhyay, Jawalant A. Shastri & Parekh H. H.; 
 Orient. J. Chem., 18(1), 175-76, (2002). 
179.  Sohit Rajvaidya, Jaladhi Vasavada & Parekh H. H.; 
 Ind. J. Chem., 42 B, 906-908, (2004).132 
180.  Archana V . K. Srivastava, Kumar Ashok; 
 Arzneimittel. Forschung, 52(11), 787-91 (2002); Chem. Abstr ., 138, 353758 
 (2003). 
181.  Dobaria A. V ., Patel J. R. & Parekh H. H.; 
 Ind. J. Chem., 42 B, 2019, (2003). 
Studies on some compounds…  182 
 
Pyrazolines… 
182.  Berghot M. A., Moawad E. B.; 
 Eur . J. Pharm. Sci. 20(2), 173-9 (2003). 
183.  Ahn JH, Kim HM, Jung SH, Kang SK, Kim KR, Rhee SD, Yang SD, Cheon 
 HG, Kim SS;Bioorg. Med. Chem. Letter 14(17), 4461-5 (2004). 
184.  Jeong TS, Kim KS, An SJ, Cho KH, Lee S, Lee WS; 
 Bioorg. Med. Chem. Letter 14(11), 2715-7 (2004). 
185.  Stan D. Andrea, Zhizhen Barbara Zheng, Kenneth DenBleyker, Joan C.; 
 Bioorg. & Med. Chem. Lett. 15 2834–2839 (2005). 
186.  Y . Rajendra Prasad, A. Lakshmana Rao, L. Prasoona, K. Murali and P . Ravi 
 Kumar; Bioorg. Med. Chem. letters 15(22), 5030-5034 (2005). 
187. Gulberk Ucar, Nesrin Gokhan, Akgul Yesilada, Altan Bilgin; 
 Neuroscience Letters 382 327–331 (2005). 
188. Fedele Manna, Franco Chimenti, Rossella Fioravanti; 
 Bioorganic & Medicinal Chemistry Letters 15 4632–4635 (2005). 
189.  Jones D. G. et al. 
 Bioorg. Med. Chem. Lett. 15 3203–3206 (2005). 
190.  Amir Azam, Asha Budakoti and Mohammad Abid; 
 E. J. Med. Chem., 41(1), 63-70 (2006). 
191.  Mohammad Abid and Amir Azam; 
 Bioorg. Med. Chem. letters, 16, 2812-2816 (2006). 
192.  Goodell J. R., Pulg Basagoiti F.; Forsley B. M. et. al.; 
 J. Med. Chem., 49, 2127-2137 (2006). 
193.  Abd El-Galil E. Amr et al. 
 Bioorg. Med. Chem. 14 373–384 (2006). 
194.  Shaharyar M. et al. 
 Bioorg. Med. Chem. Lett. 16 3947–3949 (2006). 
195. Kawazural H.et al. 
 Jpn.J. pharmacol 73. 317-327 (1997). 
196.  David M. Ferguson and Pei-Yong Shi; 
 Antimicreobial agents and chemotherapy. 50, 1320-1329 (2006)  
197.  Richard A. Nugent, Megan Murphy, Stephen T. Schlachter, Colin J. Dunn J. 
 Robert; J. Med. Chem. 36, 134-139 (1993). 
198. V. M. Parikh; “Absorption spectroscopy of organic molecule” Addition 
weslay Pub. Co. London, 243, 258 (1978). 
Studies on some compounds…  183 
 
Pyrazolines… 
199. A. R. Kartizky and R. Alan Jones;  
J. Chem. Soc., 294z (1960). 
200. F.V.Loffe; 
 Khim. Geterokeiki Sodein, 6, 1089 (1968); Chem. Abstr., 70, 72338 (1986). 
201. D.L.Paria, G. M. Lampman and G. S. Kriz; 
 Introduction to spectroscopy college publishing, Philadelphia, p-46 (1979). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
  
 
 
CHAPTER - 4 
STUDIES ON 
PYRIMIDINE-2-THIONES 
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INTRODUCTION  
 
 Pyrimidine is the most important member of all the diazine as this ring system 
occurs widely in living organisms. Pyrimidine (I) was first isolated by Gabriel and 
Colman in 1899. Pyrimidine and its derivatives represent one of the most active class 
of compounds possessing a wide spectrum of biological activities. 
 
  
 
 
 
 
Pyrimidine and its derivatives have gained prominence because of their 
potential pharmaceutical values. Many pyrimidine derivatives play vital role in many 
physiological actions. They are among those molecules that make life possible as 
being some of the building blocks of DNA and RNA. Pyrimidine is considered to be a 
resonance hybrid of the charged and uncharged canonical structures; its resonance 
energy has been found to be less than benzene or pyridine. 
From pyrimidine derivatives one of the important derivative Thiopyrimidine 
derivatives are an important class of pharmaceutically active pyrimidine compounds 
and their chemistry was extensively studied and continues to attract the attention of 
synthetic chemists. The thiopyrimidine derivatives and many heterocyclic compounds 
containing thiopyrimidine moiety are known to have major pharmacological 
activities. In addition to various pharmacological properties, thiopyrimidines are 
useful for the synthesis of tri and tetra–cyclic heterocyclic compounds. 
Pyrimidine is considered to be a resonance hybrid of the charged and 
uncharged cannonical structures; its resonance energy has been found to be less than 
benzene or pyridine. 
Some pyrimidines of physiologically as well as pharmacologically importance 
are as under: e.g., cytosine, bedmethrin (II) and trimethoprim (III). 
 
 
 
 
N
N
         (I) 
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SYNTHETIC ASPECT 
First primary synthesis of thiopyrimidine derivatives from aliphatic fragments 
was carried out by frankland and kolbs in 1848. Since than a many distinct primary 
synthetic methods has been devised.1-5Different methods reported are as under. 
1. The reaction of chalcones with thiourea in alkaline medium afforded 
corresponding mercapto pyrimidine derivatives.6 
2. Liu-Fang Ming et al.7 have synthesized mercapto pyrimidine by the reaction of 
1,3-diketones and thiourea. 
3. Mercapto pyrimidine can also be obtained by the condensation of β-dinitriles 
with thiourea and guanidines.8 
4. 2-Mercaptopyrimidines can be synthesized by Atul Kumar et al.9 through 
condensation of thiourea and substituted â-ketoester in presence of Ziegler-
Natta catalyst system under solvent free condition. 
5. Wei Yi Chen et al.10 have been prepared dihydropyrimidin-2(1H)-ones (I) by 
using HBF4 as catalyst under solvent free condition. 
 
 
 
 
 
 
 
 
 
 
6. By the controlled phase transfer catalysis conditions.11 
7. Wang Jinjun12 have prepared some new benzo[c]pyrano[4,3-d]pyrimidine 
derivatives (II). 
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MECHANISM 
 
 
Mechanism can be explained by the reaction between arylidene and thiourea 
in which thiourea react with α, β-unsaturated system and electron transfer take place 
due to the more electro negativity of oxygen atom than carbon atom. So, oxygen get 
negative charge, it condense with amine of thiourea and remove water molecule, so 
formation of thiopyrimidine is one type of Cycloaddition process. 
THERAPEUTIC IMPORTANCE 
 Thiopyrimidines are excellent reservoir of bioactive substance. In the past 
years, the literature enriched with progressive findings about the synthesis and 
pharmacological action of thiopyrimidine derivatives. The important activities are as 
under 
1. Antimicrobial.13-14 
2. Antitumor.15-16 
O
O
R
O
NHNH
X
R
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3. Anti-HIV.17-18 
4. Antiviral.19 
5. Anti-inflammatory and Analgesic.20 
6. Antagonist.21 
7. Antihistaminic.22 
8. Antitubercular.23 
9. Antiherpesvirus.24 
 S. S. Sangapure et al.25 have tested the antimicrobial activity of benzofuro 
[3,2- d]pyrimidine derivatives (I). El Sayed and co-workers26 have synthesized 
alkylated substituted mercapto pyrimidine derivatives (II) and studied their anticancer 
and antineoplastic activity. H. Y . Moustafa et al.27 have reported some pyrimidine 
derivativesand studied their biological activities. 
 
 
 
 
 
 
 
 N. V . Kaplina and co-workers28 shows herpes inhibiting activity of some 
mercaptopyrimidine derivatives (III). Mai A. et al.29 have synthesized 5-alkyl-2-
alkylamino-6-(2,6- difluorophenylalkyl)-3,4-dihydropyrimidin-4(3H)-ones, a new 
series of potent, broadspectrum non-nucleoside reverse transcriptase inhibitors 
belonging to the DABO family. 
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Michael D. V arney and co-workers30 have synthesized and evaluated 
biological activity of 5-thia-2,6-diamino-4(3H)-oxopyrimidines (IV) as potent 
inhibitors of glycinamide gibonucleotide transformylase with potent cell growth 
inhibition. Huang Y . L. et al.31 have synthesized non-classical antifolates, 5-(N-
phenylpyrrolidin-3-yl)-2,4,6-triaminopyrimidines and 2,4-diamino-6(5H)-oxopyri 
midlines as antitumor activity. 
 
 
 
 
 
 
 
 
Viney Lather and co-workers32 have been proposed to predict the anti-HIV 
activity of dihydro(alkylthio)(naphthylmethyl)oxopyrimidines. These models are 
capable of providing lead structures for development of potent but safe anti-HIV 
agents (V). H. S. Joshi et al.33 have sythesized some new pyrimidines and reported as 
antitubercular and antimicrobial agents. Agarwal A. et al.34 have synthesized 2,4,6-
trisubstituted pyrimidine derivatives as pregnancy interceptive agent. Sanmartin C. et 
al.35 have prepared new symmetrical derivatives as cytotoxic agents and apoptosis 
inducers. 
 
 
 
 
 
 
Marie Gompel and co-workers36 have showed that meridianins inhibit various 
protein kinases such as cyclin-dependent kinases, glycogen synthase kinase-3, cyclic 
nucleotide-dependent kinases and casein kinase. Alistair H. et al.37 have synthesized a 
novel series of pyrimidine IKK-2 inhibitors which show excellent in vitro inhibition 
of this enzyme and good selectivity over the IKK-1 isoform. L.G. Hammerland et al.38 
have been studied structure-activity relationship of thiopyrimidines as mGluR5 
N
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S (CH2)n
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antagonists. R. H. Wiley et al.39 have been synthesized some hydroxy-2-
thiopyrimidine- 5-carboxaldehyde derivatives used in cancer chemotherapy. Patil L. 
R. et al.40 have synthesized some new pyrimidines bearing paracetamol and 
imidazolyl moieties. Several thio analogues of pyrimidine were prepared based on the 
initial activity screening of several analogues of these heterocycles against 
Mycobacterium tuberculosis (Mtb) by Ashish K. Pathak et al.41 E. Ichikawa et al.42 
have prepared nucleoside analogues of constitute an important class of biologically 
active compounds, especially as antiviral and anticancer agents. Donn G. Wishka et 
al.43 have been synthesized furo [2,3-c] pyridine pyrimidine thioether as potent HIV-1 
non-nucleoside reverse transcriptase inhibitors. 
Morever, H. S. Joshi and co-workers44 have been synthesized some new series 
of thiopyrimidine bearing cinnoline nucleus and studied their antimicrobial against 
different microbes and antitubercular activity against MycobacteriumTuberculosis. R. 
A. Olmsted et al.45 have been reported some thiopyrimidine derivatives as potent, 
HIV-1 non-nucleoside reverse transcriptase inhibitor. 
Shigeta S. et al46 have been synthesized 5-alkyl-2-thiopyrimidine nucleoside 
analogues and examined for antiviral activities against Herps Simplex virus (HSV), 
Varicella-Zoster virus (SZV) and Human Cytomegalo virus (HCMV). H. S. Joshi et 
al.47have sythesized some new pyrimidines (VI) and reported as antitubercular and 
antimicrobial agents. 
 
 
 
 
 
 
 
 
A.S.noravyan at el.48synthesized some thienopyrimidine derivatives and 
reported them as anticonvulsant agent. Hozein Z. et al49 studied thienopyrimidine 
derivatives and evaluated for their antifungal and antibacterial activity. Moreover, M. 
et al.50 assessed some thienopyrimidine derivatives (VII) as Antitumer and 
antibacterial agent. 
 
NH
N
Br
SHR
(VI) 
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B.J.Ghiya et al.51 demonstrated some thienopyrimidine derivatives and 
screened for their anticancer, antitubercular and anti-HIV activities. Abou EI F. et 
al.52 synthesized thienopyrimidine derivatives (VIII) which showed anticancer 
activity. Erker T. et al.53 have prepared thienopyrimidine which have been shown to 
possess muscle relaxant activity. Breozowskil Z.54 found thienopyrimidine as anti 
HIV. Nakatsuka M.et al.55 prepared thienopyrimidines active against inflammation. 
 
 
 
 
 
 
 
 
 
 
 
Leone M. et al.56 have studied some thienopyrimidines showing antibiotic 
activity. Takatani M et al.57 and Scott K. et al.58 have synthesized thienopyrimidines 
associated with marked hypolipemics and hypoglycemic, anticonvulsant activities 
respectively. Schiafella F. et al.59 and Shafiee A. et al.60 prepared thienopyrimidines & 
evaluated for antifungal and anti-inflammatory activity respectively. Abdel R.61 
showed antimicrobial activity and He Xiao-Shu 62 evaluated for dopamine receptor 
activities. 
Sham M. Sondhi et al.63 have synthesized pyrimidine derivatives (IX) by an 
efficient, one-pot reaction of functionalized amines with either 4-isothiocyanato-4-
methyl-2-pentanone or 3-isothiocyanatobutanal. 
N
N SH
Ph
(VII) 
N NH
N
H
CH3
S
X
X(VIII) 
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Pratibha Sharma and co-workers64 have investigated the insertion of dimethyl 
vinylidene carbine into azo moiety was investigated in order to synthesize 4,6-
dimethyl-5-[2-(2-methylprop-1-enyl)-1H-benzimidazol-1-yl]pyrimidine-2(5H)-thione 
(X) under  kinetically controlled phase transfer catalysis conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methyl thiouracil (XI)65 and iodo thiouracil (XII)66 are well-known antithyroid drugs. 
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Thus, diverse biological activities have been encountered in compounds 
containing thiopyrimidine ring system. To further assess the potential of such type of 
compounds, studies of thiopyrimidine have been carried out as under. 
 
 
 
 
SECTION-4.1:-SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3- 
DICHLORO - N – 3-(4-ARYL-2-MERCAPTO -1,4,-DIHYDRO 
PYRIMIDINE- 6-YL)] BENZAMIDE. 
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SECTION-4.1 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO-N – 3-
(4-ARYL-2-MERCAPTO-1,4,-DIHYDROPYRIMIDINE- 6-YL)] BENZAMIDE. 
 Thiopyrimidines represent one of the most active classes of compounds 
possessing a wide spectrum of biological activities, such as significant in vitro activity 
against DNA and RNA viruses including polio viruses, diuretic, antitubercular 
spermicidal etc. Thiopyrimidine derivatives of type -(IX) have been prepared by the 
reaction of the chalcones of type (I) with thiourea in presence of basic catalyst in 
ethanol + DMF shown as under. 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (IX a-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (IXa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations. 
(Chapter-8). 
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IR SPECTRAL STUDIES OF 2,3-DICHLORO-N –[3-{4-(p-METHOXY 
PHENYL)-2-MERCAPTO-1,4,-DIHYDROPYRIMIDINE-6-YL)]BENZAMIDE.  
   
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration 
mode 
Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2937 2975-2950 67 
-CH3 C-H str. (sym)  2837 2880-2860 " 
  C-Hdef. (asym.) 1424 1470-1435 " 
  C-H def.(sym.) 1336 1390-1370 " 
Aromatic C-H str. 3047 3090-3030 68 
  C=C str. 1582 1540-1480 " 
 C-H i.p. def. 1048 1125-1000 " 
 C-H o.o.p. def. 811 835-810 " 
Moiety C-Cl (str.) 745 800-600 " 
Carboxamide -CONH- 1673 1700-1650 69 
Ether C-O-C (str..) 1213 1260-1200 70 
Thiopyrimidine C=S str 1582 1590-1550 " 
Amine -NH str 3219 3554-3350 " 
Vinyl CH=CH str 3021 3050-3000 " 
 
 
 
 
Cl
Cl
O
NH
N
NH
O
CH3
S
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PMR SPECTRAL STUDIES OF 2,3-DICHLORO -N– [3-(p-METHOXY 
PHENYL)-2-MERCAPTO-1,4,-DIHYDROPYRIMIDINE 6-YL)] BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 3.76 1H singlet -OCH3 
2 7.21-7.25 2H doublet Ar-Hf, f’  
3 7.41-7.62 6H multiplet Ar-Ha,b,c,d,e,g 
4 7.65-7.78 2H doublet Ar-Hh, h’  
5 8.12-8.18 2H doublet Ar-Hi, i’  
6 8.20 1H Sing let -NH (pyrimi.) 
7 8.52 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2, 3-DICHLORO-N–3-[{4-(p-METHOXY 
PHENYL)-2-MERCAPTO-1,4,-DIHYDROPYRIMIDINE-6-YL}]BENZAMIDE. 
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EXPERIMENTAL 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-DICHLORO-N – 3-
(4-ARYL-2-MERCAPTO-1,4,-DIHYDROPYRIMIDINE- 6-YL)] BENZAMIDE. 
 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A]  PREPARATION OF N-(3-ACETYLPHENYL)-2,3-DICHLORO 
BENZAMIDE. 
   Pls. refer Chapter-3, Section-3.1, page no.131 
 
[B]  SYNTHESIS AND STRUCTURE ELUCIDATION OF 2, 3-DICHLORO 
N-(3-SUBSTITUTED STYRYL CARBONYL) BENZAMIDE. 
  Pls. refer Chapter-3, Section-3.1, page no.131 
 
[C]  2,3-DICHLORO-N-3-[(4-(P-METHOXYPHENYL)-2-MERCAPTO-1,4- 
DIHYDRO PYRIMIDINE-6-YL)] BENZAMIDE. 
 A mixture of 2, 3-dichloro -N-(3-substituted styryl carbonyl) benzamide. (2.78 
gm, 0.01 mole) and thiourea (0.78gm, 0.01 mol) in ethanol (15 ml) was refluxed on a 
water bath in presence of alcoholic KOH for 12 hr. The solvent was distilled off and 
the residue was neutralized with dilute HCl, the separated solid was filtered out and 
crystallized from ethanol. Yield-58 %, m.p.-138oC; [C24H17Cl2N3O2S; found: C, 
59.72, H, 3.52, N, 8.65, requires C, 59.76, H, 3.55, N, 8.71%].  
 Similarly, other 2,3- dichloro-N-3-(4-aryl-2-mercapto-1,4- dihydropyrimidine-
6-yl)] benzamide were prepared. The physical data are recorded in Table No:-9. 
 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[D] BIOLOGICAL EVALUATION 2,3-DICHLORO-N-3-(4-ARYL-2-
 MERCAPTO-1,4- DIHYDROPYRIMIDINE-6-YL)] BENZAMIDE 
Antimicrobial testing were carried out as described in Chapter-8. The zones 
of inhibition of test solutions are recorded in Graphical Chart-9a, Table No. - 9a. 
Page No.-381,382. Result and discussion is given on page no.:- 383. 
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CHAPTER - 5 
STUDIES ON 
CYANOPYRIDINES 
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INTRODUCTION  
Pyridine is also called azabenzene and azine, is a heterocyclic aromatic tertiary 
amine characterized by six-membered ring structure composed of five carbon atoms 
and a nitrogen atom which replaces one carbon-hydrogen unit in the benzene ring 
(C6H5N).Most of the derivatives are prepared by manipulation of pyridine and its 
simple homologues in a manner similar to chemistry of the benzenoid chemistry. 
However, the simple pyridine compounds are prepared by the cyclization of aliphatic 
raw materials. Pyridine compounds are found in nature, for example nicotine from 
tobacco, ricinine from castor bean, alkaloids such as coniine, piperine and nicotine. 
Some pyridine system is active in the metabolism in the body. Pyridine can be parent 
component of targeted compounds such as insecticides, herbicides, medicines, 
vitamins, food flavoring, explosive and disinfectants. 
 
 
 
 
 
 
 
 
 Among a wide range of pyridines, 3-cyanopyridines (I) acquired a special 
attention due to their wide range of therapeutic activities. In our continuation of work 
in the chemistry of pyridine nucleus, we have undertaken the synthesis of some 3- 
cyanopyridine derivatives. 
 
SYNTHETIC ASPECTS 
Most of these derivatives are prepared by manipulation of pyridine and its 
simple homologues in a manner similar to chemistry of the benzenoid chemistry. 
However the simple pyridine compounds are prepared by the Cyclization of aliphatic 
raw materials. 
Preparation of 3-cyanopyridines is available in the literature1-5 with different 
methods. 
1. Samour and co-workers6 have prepared substituted cyanopyridines (II) by the 
condensation of chalcones with malononitrile in presence of ammonium acetate. 
 
   
N
CN
(I) 
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2. Feng Shi and co-workers7 have prepared 2-amino-3-cyanopyridine derivative 
by the reaction of aromatic aldehyde, ketone, malononitrile and ammonium 
acetate under microwave irradiation without solvent. 
3. Dao-Lin & Kimiaki8 have prepared 2-methoxy-3-cyanopyridine derivatives 
(III) by the condensation of α, β-unsaturated ketone with malononitrile in 
sodium methoxide. 
 
 
 
 
 
4. 2-Trihalomethyl 5-cyanopyridine (IV) have been synthesized by Jason WB 
Cooke.9 
 
 
 
 
 
 
5. Sakuri and Midorikaw10,11 have reported that malononitrile reacts with α, β-
unsaturated ketones to give 2-amino-3-cyano-4,6-disubstituted pyridines. 
6. By cyclocondensation of cyanoacetamide with ethyl acetoacetate in presence 
of base.12 
7. By the reaction of 3-substituted phenyl pyrazolone derivatives with 
malononitrile.13 
8. By the reaction of arylidene malononitrile with lithium isopropyl amide in 
dimethyl formamide-dichloromethane.14,15 
9. By the vapour phase air oxidation of nicotine over V2O516 or alkenyl 
substituted pyridines in presence of ammonia and V-Mo-P catalyat.17 
R1O
R
NCH3 NH2
CN
R1
CH3COONH4
CH2(CN)2 (II) 
R R'
O
N
N
N
R
R'
N
H3CO
NaOMe+
(III) 
EtO
CF2X
O
NC
NMe2
Toluene
NH4OAC
DMF
+
N
NC
CF2X
  (IV) 
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10. By the reaction of pyridine-3-carboxylic acid with ammonia in the presence of 
dehydrating catalyst at 275°C to 450 °C.18,19 
11. By heating potassium salt of 3-pyridine-sulphonic acid with sodium cyanide at 
350°C to 400 °C.20 
12. By heating pyridine-3-carboxamide in the presence of TiCl4 and a base 
trimethyl amine at 0 °C.21 
13. By the reaction of an alkali cyanide with 3-pyridine sulphonate22 or 3-bromo 
pyridine.23 
MECHANISM 
The reaction proceeds through conjugate addition of active methylene 
compounds to the, β unsaturated system as shown below. 
 
THERAPEUTIC IMPORTANCE 
 
Much research has been carried out with an aim to finding therapeutic values 
of pyridine skeleton since their discovery. The pyridine derivatives are reported to 
exhibit a wide variety of biological activities. 
1.   Antifungal.24 
2.   Antiepileptic.25 
3.   Antibacterial.26 
4.   Anticonvulsant.27 
5.   Antitubercular.28 
6.   Analgesic.29 
7.   Insecticidal.30 
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8.   Antisoriasis.31 
9.   Antihypertensive.32 
10. Bacteriostatic activity.33-35 
11. Antiphlogistic activity.36 
12. Anti-inflammatory activity.37 
13. Antiallergic activity.38 
Streightoff A.39 and Seydel J.40 have studied the bacteriostatic effect of some 
substituted 3-cyanopyridines. J. A. Van Allan et al.41 have prepared fused 
heterocyclic 3-cyanopyridine. (I) 
 
 
 
 
 
 
 
 
 
 
 
 
Barton et al.42 have reported fungicidal and insecticidal properties of 
cyanopyridines. J. J. Baldwin43-45 have prepared cyanopyridines exhibiting anti 
hypertensive activity. V . Scott and E. Joseph46,47 have prepared 2-amino-3- 
cyanopyridine derivatives which were found to be useful as antipsoriasis. Miertus et 
al.48 synthesized 2-formyl 3-cyanopyridine thiosemicarbazone as a carcinostatic agent. 
S. S. Verma et al.49 and M. D. Ankhiwala50 have synthesized 2-amino-3-cyano-2,6- 
disubstituted pyridines and studied their biological activities. F. Manna et. al.51 have 
prepared 3-cyanopyridine derivatives as anti-inflammatory, analgesic and antipyretic 
agents. Gadaginamath and co-workers52 have synthesized various cyanopyridine 
derivatives (II) and documented their biological activities. 
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The insecticidal activity of cyanopyridines has been screened by Y . Sasaki53  
and coworkers. Pankaj Patel & co-workers54 have synthesized cyanopyridines and 
evaluated their biological activity. Umed Ten et al.55 have prepared cyanopyridines as 
agro fungicides. 
The oxide activator bleaching activity of cyanopyridine has been proved by 
Rees W. M.56 Oshida M.57 prepared cyanopyridine derivatives which inhibited 
cerebral edema and delayed neuron death. Hence, they are useful as cerebral edema 
inhibitors or cerebrovascular disorder remedies. S. Guru et al.58 have synthesized 
various cyanopyridine derivatives (III) and documented their multiple biological 
activities. 
 
 
 
 
 
 
 
 
 
 
 
Some other new cyanopyridine derivatives are reported for their cholinesterase                
inhibitors,59 antihistaminic and adrenergic,60 herbicidal,61 anti-inflammatory62 & 
insecticidal63 activities. H. Yoshida et. al.64 have studied the antihistaminic & 
antiallergic activity of 3-cyanopyridine derivatives. John A. Tucker et al.65 have 
synthesized novel piperazinyl oxazolidinone containing cyanopyridine (IV) as an 
antibacterial agents. 
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El-Nabawia et al.66 have prepared new 2-amino-3-cyano pyridine derivatives 
(V) and studied their antimicrobial activity. 
 
 
 
 
 
 
 
 
 
 
Abdallah N. et al.67 have synthesized cyanopyridine derivatives which shows 
analgesic and anti-inflammatory activity. Adriano Atonso et al.68 have found that 
cyanopyridines are Farnesyl protein transferase inhibitors. Aivars Kruaze et. al.69 have 
synthesized 3-cyanopyridine derivatives & shown their neurotropic activity. Abu and 
co-workers70 have described novel fused cyanopyridines (VI) for the treatment of 
systemic fungal infection. 
 
 
 
 
 
 
 
 
 
 
 
Rajeev Doshi and co-workers71 have described some novel cyanopyridines as 
a new class of potential antitubercular agents. 
Abd El-Galil and co-workers72 have prepared 3-cyanopyridines (VII) and 
studied their pharmacological activity. Hammung E. and Abou and co-workers73 have 
studied the anticancer and anti-HIV activity of 3-cyanopyridines. 
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Edwin B. Villhauer and co-worker74 have synthesized the series of 
cyanopyridines as a DPP-IV inhibitor. One compound (VIII) is profiled as a potent, 
selective and short acting DPP-IV inhibitor that has excellent oral bioavailability and 
potent antihyperglycemic activity. S. V . Roman et. al.75 have investigated 2-amino-3-
cyanopyridine derivatives and reported their biological activity. 
 
 
 
 
 
 
 
 
El-Tawell and co-workers76 have described cyanopyridine derivatives (IX) and 
showed their significant biological activity. 
 
 
 
 
 
 
 
 
 
 
 
Pyachenko U. D. and co-workers77 have shown some cyanopyridines (X) 
useful in treatment of retroviral disease. Cyanopyridines have been screened by A. V . 
Dobaria et. al.78 and showed their significant biological activity. 
 
 
 
 
 
 
 
 
 
 
 
Hussain et al.79 have synthesized cyanopyridines as antimicrobial agent. Wu 
Wenxue et al.80 have synthesized cyanopyridines as histamine H3 antagonists. Harada 
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Hironori et al.81 have prepared cyanopyridines and screened for their large 
conductance calcium activated potassium channel opener activity. Marco J. L. et al82 
have synthesized cyanopyridines of acetyl cholinesterase inhibitors. 
Rosentreter Ulrich et al83 have synthesized a new cyanopyridine (XI) as 
receptor agonists in the treatment of cardiac disease, cancer, inflammation and 
neurodegenerative disease. Moustafa M. A. et al.84 have prepared cyanopyridine 
derivatives and evaluated for their antibacterial activity. 
 
 
 
 
 
 
 
 
 
Fatma Goda & co-workers85 have synthesized cyanopyridines (XII) and 
studied their antimicrobial activity. 
 
 
 
 
 
 
 
 
Ketan Hirpara & co-workers86 have discovered cyanopyridines as 
antitubercular agents (XIII). Eduardo H.S. Sousa et al87 have synthesized 
cyanopyridine derivatives as an antituberculosis. 
 
 
 
 
 
 
 
 
 
 
Henryk foks et al.88 investigated new 3-cyanopyridine derivatives showing an 
antibacterial activity. Abdel-Galil E. Amr and Mohamed M. Abdulla89 have 
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synthesized pyridine derivative (XIV) fused with steroidal structure. Initially the 
acute toxicity of the compounds was essayed via the determination of their LD50. 
 
 
 
 
 
 
 
 
 
Gary T. Wang and co-worker90 have synthesized 2’-trifluoromethylbiphenyl 
substituted 2-amino-nicotinonitrile (XV) as inhibitors of farnesyl transferase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
V . H. Shah et.al.91 have synthesized 2-amino-3-cyano-4-(m-phenoxy phenyl) - 
6-aryl-pyridines and evaluated for antimicrobial activity (XVI). 
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In light of wide varieties of biological activities exhibited by cyanopyridine, it 
appeared of interest to synthesize cyanopyridine derivatives in order to achieving 
compounds having better therapeutic activity described as under 
 
 
 
SECTION:-5.1: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-  
DICHLORO-N-[3-(2-AMINO,4-ARYL-3-CYANO PYRIDINE-
6-YL)] BENZAMIDE. 
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SECTION-5.1 
 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-DICHLORO- N- [3-
(2- AMINO, 4-ARYL-3-CYANO PYRIDINE-6-YL)] BENZAMIDE. 
The pyridine nucleus is found in a large number of commonly used drugs 
which have diverse pharmacological activities. To achieving better drug potency 
cyanopyridine derivatives of type-(X) have been prepared by the condensation of 
chalcones (compound-IV) and malononitrile as shown below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (Xa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (Xa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloremphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations, 
Selected compounds have been also screened for their antitubercular activity 
(chapter-8). 
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IR SPECTRAL STUDIES OF 2,3-DICHLORO -N- [3-2-AMINO-4-(p-
METHOXY PHENYL) -3-CYANO PYRIDINE-6- YL)] BENZAMIDE.  
 
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
   4000-400 cm-1 (KBr disc.) 
 
Type Vibration 
mode 
Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2928 2975-2950 92 
-CH3 C-H str. (sym)  2833 2880-2860 " 
  C-Hdef. (asym.) 1444 1470-1435 " 
  C-H def.(sym.) 1353 1390-1370 " 
Aromatic C-H str. 3020 3090-3030 93 
  C=C str. 1524 1540-1480 " 
 C-H i.p. def. 1032 1125-1000 " 
 C-H o.o.p. def. 850 835-810 " 
Moiety C-Cl str. 778 800-600 94 
Carboxamide CONH 1610 1680-1630 95 
pyridine C≡N str. 2220 2240-2220 " 
Nitrile  C=N str. 1582 1640-1500 " 
 C-N str. 1136 1220-1020 " 
Ether C-O-C 1221 1200-1260 " 
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PMR SPECTRAL STUDIES OF 2,3-DICHLORO -N- [3-(2-AMINO-4-(p-
METHOXY PHENYL) -3-CYANO PYRIDINE-6- YL)] BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
(300 MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 3.88 1H singlet -OCH3 
2 6.82 2H singlet (Broad) -NH2 
3 7.11-7.22 2H doublet Ar-Hf, f’  
4 7.44-7.96 8H multiplet Ar-
Ha,b,c,d,e,g 
5 7.98 4H double doublet Ar-Hh, h’,i, i’  
 8.38 1H singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 2,3-DICHLORO -N- [3-2-AMINO-4-(p-
METHOXYPHENYL) -3-CYANO PYRIDINE-6- YL)] BENZAMIDE. 
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2,3-DICHLORO- N- [3-
(2- AMINO, 4-ARYL-3-CYANO PYRIDINE-6YL)] BENZAMIDE. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A]  PREPARATION OF N-(3-ACETYLPHENYL)-2,3-DICHLORO 
 BENZAMIDE. 
 
  Pls. refer Chapter-3, Section 3.1, Page No.131 
 
[B] PREPARATION OF 2,3- DICHLORO -N- (3-SUBSTITUTED STYRYL  
CARBONYL) BENZAMIDE. 
 Pls. refer Chapter-3, Section 3.1, Page No.131 
 
[C]  PREPARATION OF 2,3-DICHLORO -N- [3-(2-AMINO, 4-(p-
 METHOXY PHENYL )-3-CYANO PYRIDINE-6YL)] BENZAMIDE. 
  A mixture of 2,3- dichloro -N- [3-(4-methoxy styryl carbonyl)] benzamide, 
(4.5 gm 0.01mole), malononitrile (1.5 gm, 0.01mole) and ammonium acetate (9 gm 
0.12 mole) dissolved in absolute alcohol (50ml) were heated under reflux for 12 hrs., 
cooled and poured in to crushed ice. The product was separated, filtered and 
crystallized from dioxane. Yield-62%, m.p.-235.C; [C26H18Cl2N4O2; required: C, 
63.81; H, 3.71; N, 11.45 %; found: C, 63.75; H, 3.66; N, 11.42%]. 
  Similarly, other cyanopyridines have been prepared by the same method. The 
physical data are recorded in Table No.-10. 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
 
 
[D]  BIOLOGICAL EVALUATION OF 2, 3-DICHLORO- N- [3-(2- AMINO, 
 4-(ARYL)-3-CYANOPYRIDINE-6-YL)] BENZAMIDE. 
Antimicrobial testing were carried out as described in Chapter-8. The zones 
of inhibition of test solutions are recorded in Graphical Chart-10a, Table-10a. Page 
No.-384,385.Result and discussion is given on page no.:-386. 
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INTRODUCTION 
 
 Dihydropyrimidine is the most important member in all the diazines. The 
chemistry of pyrimidines and their derivatives has been studied for over a century due 
to the association of these systems with a variety of biological properties. In 1893, the 
synthesis of functionalized 3,4-dihydropyrimidin-2(1H)-ones (DHPMs) via 
multicomponent reactions (MCRs) of an aromatic aldehyde, urea and ethyl 
acetoacetate was reported for the first time by P . Biginelli.1 This efficient approach to 
partly reduced pyrimidines was largely ignored in the following decades and 
therefore, the pharmacological properties of this interesting heterocyclic scaffold 
remained unexplored. Since the early 1980s, however, interest in dihydropyrimidones 
of type (I) has increased significantly 2. This was originally due to the apparent 
structural similarity of DHPMs to the well known dihydropyridine calcium channel 
modulators of the Hantzsch type3 (II). It was soon established that DHPMs exhibit a 
similar pharmacological profile to DHP calcium channel modulators of the nifedipine 
type and various activities have been observed in this area from 1980s to 1990s.4-5 
 Recently, the interest in the synthesis of these derivatives has been increased 
tremendously because they exhibit promising activities as calcium channel 
modulators, antihypertensive agents, α-1a receptor antagonists and neuropeptide Y 
(NPY) antagonists6,7 in anticancer drug capability of inhibiting Kinesinmotor protein.8 
Recently, interest has shifted from DHPM calcium channel modulators to other 
biologically active DHPM derivatives, e.g. α1a adrenoceptor selective antagonists 
which are useful for the treatment of benign prostatic hyperplasia.9 Again, the 
pharmacological activity in the area of α-1a adrenergic antagonists is based on 
activity found earlier in the DHP series of compounds. However, 
dihydropyrimidinones of type (I) represent much more than just being aza analogs of 
dihydropyridines of the Hantzsch type (II). 
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 The synthetic strategies for the dihydropyrimidine nucleus involve one-pot to 
multi step approaches. The production of dihydropyrimidinones via the well 
established Biginelli reaction certainly ranks as one of the most recognize and often 
used MCRs for the generation of novel pyrimidine scaffolds.10-13 The use of 
multicomponent reactions (MCRs) to generate interesting and novel drug like 
scaffolds is replete in the recent chemical literature.14-16 Multicomponent reactions 
(MCRs) are of increasing importance in organic and medicinal chemistry.17-22 When a 
premium is put on speed, diversity and efficiency in the drug discovery process,20,21 
MCR strategies offer significant advantages over conventional linear type  
synthesis.17-22 
 
SYNTHETIC ASPECTS 
 Literature survey reveals that several publications and patents have described 
the synthesis of dihydropyrimidines as under. 
1. Over 100 years ago, 4-Aryl-3,4-dihydropyrimidine-2(1H)-ones of type(I)  
 DHPMs) was reported for the first time. In 1893. The Italian chemist Pietro 
 Biginelli discovered a multicomponent reaction of aldehydes, urea or thiourea 
 and β-dicarbonyl compounds that produced these multifunctionalized 
 dihydropyrimidones1 in a simple one pot process. 
 
 
 
 
 
 
 
 
2.  DHPM-2(1H)-ones were prepared in high yield by Biginelli condensation of 
 an aldehyde, dicarbonyl compound and urea in ethanol using Mn(OAc)3 as a 
 catalyst23. 
3. Substituted 3,4-DHPM-2(1H)-ones were prepared in high yield by Biginelli 
 condensation of an aldehyde, dicarbonyl compound and urea in ethanol using 
 CoCl2.6H2O catalyst24. 
OH
NH2
NH2 O
R
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4. A simple effective synthesis of DHPM-2-(1H)-one derivatives, using boric 
 acid as a catalyst from an aldehyde 1,3-dicarbonyl compound and urea in 
 glacial acetic  acid is described by Tu Shujang et al.25 Compared with the 
 classical Biginelli reaction conditions, this new method has the advantage  of 
 excellent yield 86-97% and the short reaction time (0.5-2hr). 
5. Ethyl-2-(methylthio)-6-oxo-1,6-dihydro-pyrimidine-5-carboxylate (II) has 
 been investigated by M.A.Hassan et al.26 by the reaction of 5-carboethoxy-2-
 thiouracil, methyl iodide with the use of tetra butyl ammonium bromide (PTC) 
 as a catalyst with continuous efficient stirring for 4-6 hrs at 70˚C. 
  
BUILDING BLOCKS AND CATALYTIC DIVERSITY: 
 As the earlier examples of this cyclocondensation process typically involved 
β- ketoester, aromatic aldehyde and urea, the scope of this heterocyclic synthesis has 
now been extended considerably by variation of all three building blocks, allowing 
access to a large number of multifunctionalized pyrimidine derivatives.10, 12 
 
Diversity of aldehyde building blocks: 
 Out of the three building blocks in the Biginelli reaction it is the aldehyde 
component, which can be varied to the largest extent. In general, the reaction works 
best with aromatic aldehydes. These can be substituted in the o, m or p position with 
either electron-withdrawing or donating groups. Aliphatic aldehydes typically provide 
only moderate yields in the Biginelli reaction unless special reaction conditions are 
employed, i.e. Lewis acid catalysts/solvent free methods or using the aldehydes in 
protected form 27. In such transformations, DHPMs having a sugar-like moiety at 
position 4-(C-nucleoside analogs) (III), (IV) are obtained28,29. In a few cases, 
bisaldehydes have been used as synthon Biginelli reactions.30 
N
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O CH3
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N
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 Some of the aldehyde and protected aldehyde building blocks used in the 
Biginelli reaction is as under. 
 
Diversity of CH- acidic carbonyl building blocks : 
 Traditionally, simple alkyl acetoacetates are employed as CH-acidic carbonyl 
building blocks but other types of 3-oxoalkanoic esters or thioesters can also be used 
successfully10. 
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 Li-Wen Xu, et. al.31 described a synthesis of 5-unsubstituted 3,4- 
dihydropyrimidine-2(1H)-one (V),(VI) using acetophenone as a CH-acidic carbonyl 
and aromaticaldehyde and urea in the presence of FeCl3–TMSCl as catalyst. 
 
 4-Hydroxycoumarin on reaction with aldehydes in the presence of 
urea/thiourea using solid inorganic support under microwave irradiation (MWI) 
afforded 4-substituted benzopyrono [4,3-d]- pyrimidine (VII) derivatives in a few 
seconds.32 
 
 
 Ahmad Shaabani et. al.33 synthesized Spiro-fused heterocycles in good to high 
yields by a pseudo four-component reaction of an aldehyde, urea and a cyclic β-
diester or α,β-diamide such as Meldrums acid or barbituric acid derivatives using 
microwave irradiation under solvent-free conditions.(VIII) 
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 Different CH-Acidic carbonyl building blocks used in the Biginelli reaction 
are as under. 
 
 
 
 
 
 
 
 
 
 
 
Diversity of catalyst in the Biginelli synthesis : 
 The Biginelli condensation is strongly dependent on the amount of acidic 
catalyst present in the reaction medium. Traditionally, strong Bronsted acids such as 
hydrochloric or sulphuric acid have been employed but nowadays the use of Lewis 
acids such asBF3-OEt2 and CuCl34, FeCl335 or Yb(OTf)336 is preferred. In fact a 
plethora of different methods and conditions for synthesizing DHPMs according to 
the Biginelli principle is known today, ranging from mg to kg scale.37 
 Youquan Deng et, al.38 described a synthesis of 3,4-Dihydropyrimidine-2(1H)- 
ones (IX) in high yields by one-pot three-component Biginelli condensation in the 
presence of ionic liquids such as 1-n-butyl-3-methylimidazolium tetrafluoroborate 
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(BMImBF4) or hexafluorophosphate (BMImPF6) as catalysts under solvent free and 
neutral conditions at room temperature. 
 
 
 
 
 
 
 
 Silica gel supported sodium bisulfite catalyzes efficiently the three component 
condensation reaction of aldehyde, β-ketoester and urea in refluxing acetonitrile to 
afford the corresponding dihydropyrimidinones.39(X) 
 
 
 
 
 
 
 
  A simple and green chemistry procedure for the synthesis of 
dihydropyrimidi nones (XI) using heteropoly acid mediated cyclocondensation 
reaction is as under.40 
 
 
 
 
 
 
 
Diversity of Urea-type building blocks in the Biginelli synthesis: 
 The urea is the component in the Biginelli reaction that faces the most 
restrictions in terms of allowed structural diversity10. Therefore, most of the published 
EtO
O
CH3 O
R
O NH2
NH2 X
+
NH
N
H
X
R
EtO
O
CH3
ionic liquid
X= O, S
(IX)
EtO
O
CH3 O
R
O NH2
NH2 X
+
NH
N
H
X
R
EtO
O
CH3
X= O, S
SiO2- NaHSO4
CH3CN, Reflux
(X)
EtO
O
CH3 O
R
O NH2
NH2 X
+
NH
N
H
X
R
EtO
O
CH3
X= O, S
(XI)
HPA
 
Studies on some compounds…  239 
 
Dihydropyrimidines…  
examples involve urea itself as building block. However, simple monosubstituted 
alkyl ureas generally react equally well, in a regiospecific manner, to provide good 
yields of N1- substituted DHPMs.  
 Thiourea and substituted thiourea follow the same general rules as ureas, 
although longer reaction times are required to achieve good conversions. Yields are 
comparatively lower than the corresponding urea derivatives.  
 In some instances it is also possible to react protected urea or thiourea 
(isourea) or guanidine of type (XII) under weak basic conditions with the aldehyde 
and CH-acidic carbonyl component (or with a precondensed Knoevenagel type enone) 
to yield the corresponding protected DHPM41,42. This later method, using 
precondensed enones of type (XIII) has been frequently referred to as the “Atwal 
modification” of the Biginelli reaction. 10,12,43 
 Comparison and diversify analysis of the Biginelli and Atwal 
dihydropyrimidines (XIV) synthesis is as under. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
R4
OE
OR6
NH2
NH X
R1 NH
N X
R4
E
R6
R1
acid
R4
O
deprotectionbase
NH2
NH2 X
R
N
N
H
X
R4
E
R6
R
base
R4
O
E
R6
(XII)
(XIII)
R1, R4, R6 = H, alkyl, (het) aryl
X= O, S, NR
E= ester, amide, acyl, nitro
(XIV)
 
Studies on some compounds…  240 
 
Dihydropyrimidines…  
 
REACTION MECHANISM 
 Since the 1930s several mechanistic pathways have been proposed for the 
Biginelli reaction. In 1933, Folkers and Johnson reported that one of three 
intermediates (XV), (XVI) was likely present in this reaction44. These included 
bisureide (XV) which was formed by a condensation reaction between the 
arylaldehyde and the urea followed by subsequent attack of the resultant imine with 
another equivalent of urea.  Also, (XV) urido ethyl acrylate (XVI) arose from a 
condensation reaction between of the β-ketoester and urea finally, the reaction of the 
β-ketoester and the aldehyde delivered the aldol adduct (XVII). 
 
 
 
 
 
 
 
 
 
 Fourty years after the initial proposal, Sweet and Fissekis proposed a more 
detailed pathway involving a carbenium ion species45. According to these authors the 
first step involved an aldol condensation between ethyl acetoacetate (XVIII) and 
benzaldehyde (XIX) to deliver the aldol adduct (XX). Subsequent dehydration of 
(XX) furnished the key carbenium ion (XXI) which was in equilibrium with enone 
(XII). Nucleophilic attack of (XXI) by urea then delivered ureide (XXIII). 
Intramolecular cyclisation produced a hemiaminal which underwent dehydration to 
afford dihyropyrimidinone (XXIV). These authors demonstrated that the carbenium 
species was viable through synthesis. After enone (XXII) was synthesized, it was 
allowed to react with N-methyl urea to deliver the mono-N-methylated derivative of 
DHPM (XXIV). 
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 The mechanism was then reexamined 25 years later in 1997 by Kappe46. 
Kappe used 1H and 13CNMR spectroscopy to support the argument that the key 
intermediate in the Biginelli reaction was iminium species (XXVI).In the event, 
benzaldehyde reacted with urea to form an intermediat "hamiaminal" (XXV) which 
subsequently dehydrated to deliver (XXVI).Iminium cation (XXVI) then reacted with 
(XVIII) to give (XXIII), which underwent facile cyclodehydration to give 
(XXIV).Kappe also noted that in the absence of (XVIII), bisureide (XV) was 
afforded as a consequence of neucliophilic attack of (XXVI) by urea. This discovery 
confirmed the conclusion of Folkers and Johnson in 1933. As far as the proposal form 
25 years earlier by Sweet and Fissekis, kappe saw no evidence by 1H and 13C NMR 
spectroscopy that a carbenium ion was a required species in the Biginelli reaction. 
When benzaldehyde (XIX) and ethyl acetoacetate (XVIII) were mixed under 
Biginelli conditions the requisite aldol product (XX), which was necessary for the 
formation of carbenium ion (XXI), was not detected. 
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THERAPEUTIC IMPORTANCE 
 Dihydropyrimidine derivatives exhibit broad spectrum of therapeutic 
activities. Since 1980’s a number of publications and patents are published for the 
activity of DHPM derivatives which indicates the interest on the subject is 
tremendously increased.10,12 This is mainly due to the fact that the multifunctionalized 
dihydropyrimidine scaffold (DHPM, “Biginelli compounds”) represents a 
heterocyclic system with remarkable pharmacological efficiency. In the past decades, 
a broad range of biological effects, including antiviral, antitumor, antibacterial and 
anti-inflammatory activities has been described to these partly reduced pyrimidine 
derivatives47 Recently, appropriately functionalized DHPMs have emerged as orally 
active antihypertensive agents48-50 or α1a adrenoceptor- selective antagonists.51,52 
Mayer et al.53-55 have recently identified the structurally rather simple DHPM 
(monastrol) as a novel cell-permeable molecule. Monastrol is the only cell-permeable 
molecule currently known to specifically inhibit mitotic kinesin Eg5 and can therefore 
be considered as a leader for the development of new anticancer drugs. Apart from 
synthetic DHPM derivatives, several marine natural products with interesting 
biological activities containing the dihydropyrimidine-5-carboxylate core have 
recently been isolated.56 Most notably among these are the batzelladine alkaloids A 
Ph
O
H
NH2
O
NH2
Ph
OH
N
O
NH2
H
Ph N+
O
NH2
H
N
Ph
N
O
NH2
H
NH2
O
H
NH
Ph
EtOOC
OOCH3 NH2
NH
N
H
O
EtOOC
CH3
Ph
H+
-H2O
CH3
O
OEt
O
(XXV) 
(XXVI) 
 (XVIII) 
(XXIV) (XXIII) (XV) 
 
Studies on some compounds…  243 
 
Dihydropyrimidines…  
and B which inhibit the binding of HIV envelope protein gp-120 to human CD4 cells 
and therefore they are potentially new leading molecules for AIDS therapy.57 
 Dihydropyrimidines have attracted considerable attention as they appeared 
with Interest to possess wide range of therapeutic activities. Different activities are as 
under. 
1. Antiviral58-61 
2.  Antibacterial62 
3.  Antitumor63-65 
4. Cardiovascular66-68 
5.  Antiplasmal69 
6.  Anticarcinogenic70 
7. Calcium channel modulator71-73 
8.  Antihypertensive74-76 
9.  Vasodilative77 
10. Blood platelet aggregation inhibitor78,79 
11. Antiinflammatory80,81 
12.  Analgesic82 
13.  Antileukemic83 
14.  α1a-Adrenergic receptor antagonist.84,85 
15. Coronary dilatory86 
16.  Anti-ichemic87 
17.  Neuropeptide Y (NPY) antagonist88 
18.  Mitotic Kinesin inhibitor89 
19.  Metabotropic glutamate receptor antagonist90 
  
 Dhanapalan N. et al91 prepared dihydropyrimidinones such as compound (I) 
which exhibited high binding affinity and subtype selectivity for the cloned human 
α1a receptor. Systematic modifications of (I) led to identification of highly potent and 
subtype-selective compounds such as (II) with high binding affinity (K1) 0.2 Nm for 
α1a receptor and greater than 1500 fold selectivity over α1b and α1d adrenoceptors. 
The compounds were found to be functional antagonists in human, rat and dog 
prostate tissues. One compound exhibited excellent to inhibit intraurethral pressure 
(IUP) as compared to lowering diastolic blood pressure (DBP) in mongrel dogs 
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Kb(DBP)/ Kb(IUP) = 40 suggesting uroselectivity for α1a-selective compounds (I) & 
(II). 
 
 Calcium ion plays a vital role in a large number of cellular processes, 
including excitation-contraction and stimulus-secretion.92-94 In recent years interest 
has also focused on aza-analogs such as dihydropyrimidines (III) which show a very 
similar pharmacological profile to classical dihydropyridine calcium channel 
modulators.95-101 
  
 
 
 
 
 
 
 
 
 Hidetsura Cho et al.95 have synthesized the novel calcium channel antagonists 
3-N-substituted-3,4-dihydropyrimidines and 3-N-substituted-dihydropyrimidin-2(1H) 
-ones were regioselectively synthesized in good yields. Efforts of Atwal K. S. et al.102 
in this area have resulted in the discovery of dihydropyrimidines (IV) and (V) as 
potent AII receptor antagonists. 
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 Atwal K. S. et al.103 have described the potent antihypertensive activity of the 
modestly active dihydropyrimidine calcium channel blocker. Kappe C. O. et al.104 
synthesized the polycyclic DHPM derivatives. Muralidhar T. G. et al.105 have 
synthesized several DHPM-one analogues, among this (VI) and (VII) gave excellent 
selectivity (>880-fold) over a1b and a1d and also showed good selectivity over 
several other recombinent human G-protein coupled receptors. 
 
 Victor E.et al.106 synthesized 5’-triphosphates of (VIII) and (IX) evaluated 
directly as reverse transcriptase (RT) inhibitors using both a recombinant enzyme and 
enzyme obtained and purified directly from wild-type viruses. 
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 Sally-Ann P .et al.107 synthesized 4,6-Bis[(R-carbamoylethyl)thio]-1- 
phenylpyrazolo[3,4-d]pyrimidine and identified as a novel adenosine A1 receptor 
antagonist, antagonizing adenosine-stimulated cyclic adenosine monophosphate 
generation in guinea pig brain slices.108,109 
 James and coworkers110 reported the DHPM with 4-aryl dihydropyrimidinones 
attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective α1a receptor 
subtype antagonists. Many of these compounds were also evaluated in vivo and found 
to be more potent than terazosin in both a rat model of prostate tone and a dog model 
of intraurethral pressure without significantly affecting blood pressure. While many of 
the compounds tested, displayed poor pharmacokinetics, compound (X) was found to 
have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs.   
  
 
 
 
 
 
 
 
 
 Rakesh Kumar and coworkers111 synthesized, 5-substituted-6-azido-5,6-
dihydro- 2-deoxyuridine (XI & XII) and thymidine (XIII & XIV), which exhibited 
cytotoxic and antiviral activities. The compounds (XI) and (XIV) exhibited a broad 
spectrum of antiherpes activity against (HSV-1, HSV-2, HCMV, and VZV). 
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 Baldev Kumar et. al.112 have prepared some new oxo-pyrimidine derivative 
(XV) and reported them as potent calcium channel blockers. Abd. El-Galil and M. 
Abdulla93 have synthesized some fused steroidal oxo-pyrimidine derivative (XVI) and 
reported them as androgenic anabolic agent as well as anti-inflammatory agent. 
 
 
 
 
 
 
 
 
 
 Salvatore B. et al113 studied the stopped-flow fluorometry indicates that 
monastrol inhibits ADP release by forming an Eg5-ADP-monastrol complex. 
 Alessandro114 have studied molecular diversity in DHPM molecules by 
introducing sugar molecules at different position (XVII) and effect of chirality on 
activity. 
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 Recently, Vladimir N, Belov et. al.115 have documented enantioselective 
synthesis of the novel antiinfective TAN-1057A via aminomethyl-substituted 
dihydropyrimidinone 
heterocycle (XVIII). 
 
 
 
 
 
 
 
 
 Rajni Garg et. al.116 suggest that the balance of hydrophobicity and a volume 
dependent polarizability plays a key role in the inhibition of the viral protease by 
these (XIX) inhibitors. 
 
 
 
 
 
 
 
 
 
 
 Several potent, cell permeable 4-aryl-dihydropyrimidinones have been 
identified as inhibitors of fatty acid transporter FATP4. Christopher Blackburn et. 
al.117 described that lipophilic ester substituents at the 5-position and substitution at 
the para-position (optimal group -NO2 and CF3) of the 4-aryl group led to active 
compounds (XX), (XXI). 
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NEW DRUG MOLECULES UNDER CLINICAL STUDY: 
 Recently many new molecules which are under study from phase-I to Phase-
IV clinical trials for different pharmacological action have shown that the basic 
characteristic of morpholine to behave as hidden amine has attracted many medicinal 
chemists to incorporate this feature in drug design. Some interesting compounds are 
as under. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Moreover one compound119 is very active against Non-nucleoside inhibitor of 
human hepatitis B virus (IC50 = 53 nM for reduction of HBV DNA in human 
hepatoma HepG2.2.15 cells) with low cytotoxicity in uninfected cells (CC50 = 7 
mcM). Compound inhibited both viral DNA and viral cores in HepG2.2.15 cells and 
HBV-transfected cell lines, whereas it did not affect the activity of endopolymerase 
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and had no effect on other DNA or RNA viruses. In vivo in a transgenic mouse model, 
oral doses of 3-100 mg/kg b.i.d. or t.i.d. for up to 28 days dose-dependently. 
 Decreased viral DNA in the liver and plasma with efficacy comparable to 
lamivudine. However, unlike lamivudine, compound reduced cytoplasmic HBV core 
antigen (HBcAg) in the liver of mice. Pharmacokinetic studies in mice showed rapid 
absorption, 30% bioavailability and dose-proportional plasma levels. 
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 With an intention of preparing the compounds possessing better therapeutic 
activity, we have undertaken the synthesis of dihydropyrimidines which have been 
described in following sections. 
 
 
SECTION:-6.1 SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-
[ARYL-5-(3,4–DIMETHYL)-PHENYL AMINO CARBONYL] 
– 6 – PHENYL - 1, 4 -DIHYDROPYRIMIDINE-2(1H)-ONES. 
 
SECTION:-6.2 SYNTHESIS AND STRUCTURE ELUCIDATION OF N-
 PHENYL-4–[ARYL-5-(3,4 - DIMETHYL)-PHENYL AMINO 
 CARBONYL] – 6 – PHENYL - 1, 4 -DIHYDROPYRIMIDINE-
 2(1H)-ONES. 
 
SECTION:-6.3 SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-
[ARYL-5-(3,4–DIMETHYL)-PHENYL AMINO CARBONYL] 
–6 – PHENYL - 1, 4 -DIHYDROPYRIMIDINE-2(1H)-AMINO. 
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SECTION-6.1 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -[5-(3,4– 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-ONES. 
The broad spectrums of pharmacological properties have been demonstrated 
by the dihydropyrimidinone nucleus. Inspired by these facts, novel dihydropyrimidine 
derivatives of type (XI) have been synthesized by the condensation of N-(3,4-
dimethylphenyl)-3-oxo-3-phenylpropanamide with urea and aryl carboxaldehydes in 
the presence of catalytic amount of con. HCl. 
 
 
 
 
 
 
 
 
 
 
 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (XIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (XIa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations. 
(Chapter-8) 
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IR SPECTRAL STUDIES OF 4-[(p-METHOXYPHENYL) -5-(3,4– 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-ONES. 
   
 Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2958 2975-2950 126 
-CH3 C-H str.(sym)  2865 2880-2860 " 
  C-H def.(asym.) 1439 1470-1435 " 
  C-H def.(sym.) 1378 1390-1370 " 
Aromatic C-H str. 3081 3090-3030 127 
  C=C str. 1534 1540-1480 " 
Pyrimidine C=C str. 1572 1580-1520 " 
Moiety C-H i.p. def. 1057 1125-1000 " 
 C-H o.o.p. def. 842 835-810 " 
Amide -NH Str. 3397 3410-3380 126 
  -NH def. 1605 1635-1595 " 
Carbonyl -C=O Str. 1710 1700-1725 " 
Amide -C=O Str. 1677 1690-1660 " 
Ether Ar-O-C (sym.) 1068 1075-1010 " 
 
 
 
20.0
30.0
40.0
50.0
60.0
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80.0
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%T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cmdhpm(simple)
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 904.6
1058.0
1144.7
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1279.7
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1378.0
1439.8
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1605.0
1677.0
1710.7
2865.0
2958.6
3025.081.
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PMR SPECTRAL STUDIES OF 4-[(p-METHOXYPHENYL)-5-(3,4– 
DIMETHYL)  – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-ONES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer 
(300 MHz). 
Signal 
no. 
Signal position 
(δppm) 
Relative No. 
of protons 
Multiplicity Inference 
1 2.12 6H doublet 2 (CH3) moiety 
2 3.82 3H Singlet Ar-OCH3 
3 5.38 1H Singlet -CH (pyrimi.) 
4 6.82-7.22 12H multiplet Ar-H 
5 7.42 1H singlet -NH (pyrimi. 
    overlapped) 
6 7.78 1H singlet -NH (pyrimi.) 
7 8.82 1H singlet -NHCO 
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MASSS PECTRAL STUDIES OF 4-[(p-METHOXYPHENYL)-5-(3,4– 
DIMETHYL)  – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-ONES. 
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -[5-(3,4– 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-ONES. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A]  PREPARATION OF 3,4-DIMETHYL PHENYL) – 3 –OXO – 3 – PHENYL        
PROPANAMIDE. 
A mixture of Ethyl benzoyl acetate (20 gm, 0.1 mol) and 3,4-dimethylaniline 
(15 gm, 0.12 mole) in toluene was refluxed for 14 hr. ethanol was removed using 
Dean & Stark azeotropic assembly. The mixture was cooled to room temperature, 
washed the reaction mixture with dil HCl and than washed with water. Distilled out 
toluene under vaccume. The resulting residue was crystallized into the n-Hexane. 
Yield 80 %, m. p. 112˚ C. 
 
[B] PREPARATION OF 4 – METHOXY PHENYL [5 - (3,4 – DIMETHYL) – 
PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - DIHYDRO 
PYRIMIDINE -2(1H) –ONES. 
A mixture of urea (1.0 gm, 0.01 mole), 4-methoxy benzaldehyde (1.5 gm, 0.01 
mole) and N-(3,4-dimethylphenyl)-3-oxo-3-phenylpropanamide (3.0 gm, 0.01 mol) in 
25 ml of ethanol containing few drops of concentrated hydrochloric acid was refluxed 
for 10 hrs. The solution was allowed to stand for 12 hrs. at room tempeture and the 
resulting solid mass separated was filtered and crystallized from DMF-ethanol 
mixture. Yield - 68%, m.p.252˚ C, [C26H25N3O3; required: C, 73.05; H, 5.89; N, 9.83 
%, found:  C, 73.09; H, 5.95; N, 9.88 %. 
  Similarly, other 4 - aryl [5 - (3,4 – dimethyl) – phenyl amino carbonyl] – 6 – 
phenyl- 1,4 - dihydropyrimidine -2(1H) –ones were, prepared. The physical data are 
recorded in Table No.11 
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TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
 
 
[C] BIOLOGICAL EVALUATION OF 4 - ARYL [5 - (3,4 – DIMETHYL) – 
PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - DIHYDRO 
PYRIMIDINE -2(1H) –ONES. 
  Antimicrobial testing were carried out as described in Chapter-8. The zones of 
inhibition of test solutions are recorded in Graphical Chart-11a, Table-11a.Page 
No.-387, 388. Result and discussion is given on page no.:- 389. 
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SECTION:-6.2 
 
 SYNTHESIS AND STRUCTURE ELUCIDATION OF N-PHENYL, 4 -ARYL-
[5-(3, 4 -DIMETHYL)-PHENYL AMINO CARBONYL] – 6 – PHENYL - 1, 4 -
DIHYDROPYRIMIDINE- 2(1H)-ONES. 
Much interest have been focused around dihydropyrimidines derivatives 
because of their wide variety of pharmacological properties and industrial 
applications. In view of these findings and achieve to better drug potency, we have 
synthesized novel dihydropyrimidine derivatives of type- (XII) by the condensation of 
N-(3,4-dimethyl phenyl)-3-oxo-3-phenylpropanamide with N-phenylurea and aryl 
carboxaldehydes in the presence of catalytic amount of HCl. 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (XIIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (XIIa-j) have been compared with standard 
drugs viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(chapter-8). 
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 IR SPECTRAL STUDIES OF N-PHENYL- 4-[(p-METHOXYPHENYL -5-(3, 4 -
DIMETHYL)-PHENYL AMINO CARBONYL]–6 – PHENYL - 1, 4 –DIHYDRO 
PYRIMIDINE-2(1H)-ONES. 
 
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency 
range:4000-400 cm-1 (KBr disc). 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2958 2975-2950 126 
-CH3 C-H str.(sym)  2874 2880-2860 " 
  C-H def.(asym.) 1456 1470-1435 " 
  C-H def.(sym.) 1388 1390-1370 " 
Aromatic C-H str. 3047 3090-3030 127 
  C=C str. 1513 1540-1480 " 
Pyrimidine C=C str. 1578 1580-1520 " 
Moiety C-H i.p. def. 1101 1125-1000 " 
 C-H o.o.p. def. 814 835-810 " 
Amide -NH Str. 3396 3410-3380 126 
  -NH def. 1625 1635-1595 " 
Carbonyl -C=O Str. 1706 1700-1725 " 
Amide -C=O Str. 1689 1690-1660 " 
Ether Ar-O-C (sym.) 1090 1075-1010 " 
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70.0
80.0
90.0
100.0
%T
400.0600.0800.01000.01200.01400.01600.01800.02000.03000.04000.0
1/cm
 445.5
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 634.5
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 751.2
 814.9
1101.3
1252.7
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1388.7
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PMR SPECTRAL STUDIES OF N-PHENYL- 4-[(p-METHOXYPHENYL) - 5-
(3, 4 -DIMETHYL)-PHENYLAMINO CARBONYL] – 6 – PHENYL - 1, 4 –
DIHYDRO PYRIMIDINE-2(1H)-ONES.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 2.15 6H doublet 2 (CH3) moiety 
2 3.86 3H Singlet Ar-OCH3 
3 5.35 1H Singlet -CH (pyrimi.) 
4 622-8.25 17H multiplet Ar-H 
5 9.01 1H singlet -NH (pyrimi.) 
6 10.12 1H singlet -NHCO 
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MASS SPECTRAL STUDIES OF N-PHENYL- 4-[(p-METHOXYPHENYL) - 5-
(3, 4 -DIMETHYL)-PHENYLAMINO CARBONYL] – 6 – PHENYL - 1, 4 –
DIHYDRO PYRIMIDINE-2(1H)-ONES.  
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF N-PHENYL-4-ARYL - 
[5-(3,4– DIMETHYL) – PHENYL AMINO CARBONYL]– 6–PHENYL-1,4-
DIHYDRO PYRIMIDINE - 2(1H)-ONES. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 3,4-DIMETHYL PHENYL) – 3 –OXO – 3 – PHENYL        
PROPANAMIDE. 
 Pls. refer chapter-6, Section-6.1, Page No.-260 
 
 [B] PREPARATION OF N-PHENYL- 4 – METHOXYPHENYL [5 - (3,4 – 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - 
DIHYDRO PYRIMIDINE -2(1H) –ONES. 
A mixture of n-phenyl urea (1.36 gm, 0.01 mole), 4-methoxy benzaldehyde (1.5 
gm, 0.01 mole ) and N-(3,4-dimethylphenyl)-3-oxo-3-phenylpropanamide (2.67 gm, 
0.01 mole) in 15 ml of ethanol containing few drops of concentrated hydrochloric acid 
was refluxed for 7 hrs. The solution was allowed to stand for 12 hrs. at room 
temperature and the resulting solid mass separated was filtered and crystallized from 
dioxane., Yield- 60%, m.p.185˚ C, [C32H29N3O3; required: C,76.32; H, 5.80; N, 
8.34%, found:  C, 76.35; H, 5.78; N, 8.32 %]. 
  Similarly, other N-phenyl-4 - aryl [5 - (3,4 – dimethyl) – phenyl amino 
carbonyl] – 6 – phenyl- 1,4 - dihydropyrimidine -2(1H) –ones, were prepared. The 
physical data are recorded in Table No.12 
 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8) 
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[C] BIOLOGICAL EVALUATION OF N-PHENYL- 4 - ARYL [5 - (3,4 – 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - 
DIHYDRO PYRIMIDINE -2(1H) –ONES. 
Antimicrobial testing were carried out as described in Chapter-8. The zones 
of inhibition of test solutions are recorded in Graphical Chart-12a, Table-12a. Page 
No. - 390, 391. Result and discussion is given on page no. - 392. 
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SECTION:-6.3 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL - [5 - (3, 4 – 
DIMETHYL)-PHENYL AMINO CARBONYL]–6 – PHENYL - 1, 4 –DIHYDRO 
PYRIMIDINE-2(1H)-AMINO.  
 Pyrimidine derivatives have been reported to possess various pharmacological 
activities like antibacterial, antifungal, etc. In order to achieve better drug potency, we 
have synthesized pyrimidine derivatives of type (XIII) by the condensation of N-(3,4-
dimethylphenyl)-3-oxo-3-phenylpropanamide with guanidine and aryl carboxaldehy 
des in the presence of catalytic amount of potassium carbonate. 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (XIIIa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (XIIIa-j) have been compared with standard 
drugs viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(Chapter-8). 
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Reaction Scheme 
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 IR SPECTRAL STUDIES OF 4-(-p-METHOXY PHENYL) -5 - (3, 4– 
DIMETHYL) -PHENYL AMINO CARBONYL] –6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE-2(1H)-AMINO. 
  
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
  4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2921 2975-2950 126 
-CH3 C-H str.(sym)  2840 2880-2860 " 
  C-H def.(asym.) 1441 1470-1435 " 
  C-H def.(sym.) 1401 1390-1370 " 
Aromatic C-H str. 3075 3090-3030 127 
  C=C str. 1509 1540-1480 " 
Pyrimidine C-H i.p. def. 1088 1125-1000 " 
Moiety C-H o.o.p. def. 828 835-810 " 
Amide -NH Str. 3314 3410-3380 " 
  -NH def. 1631 1635-1595 126 
Carbonyl -C=O Str. 1677 1700-1725 " 
Amide -C=O Str. 1654 1690-1660 " 
Ether Ar-O-C (sym.) 1088 1075-1010 " 
 
 
 
NH
N
H
NH
NH
O
CH3
CH3
O
CH3
H
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PMR SPECTRAL STUDIES OF -4-[(p-METHOXYPHENYL)-5-(3,4-
DIMETHYL)-PHENYLAMINO CARBONYL] – 6 – PHENYL - 1, 4 –
DIHYDRO PYRIMIDINE-2(1H)-AMINO.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300  
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 2.08      6H doublet 2 (CH3) moiety 
2 3.88 3H Singlet Ar-OCH3 
3 5.25 1H Singlet -CH (pyrimi.) 
4 6.12 1H Singlet -NH (guanidi.) 
5 6.31-7.80 12H multiplet Ar-H 
6 7.88 1H doublet -NH (pyrimi.) 
7 8.22 1H Singlet -NH (pyrimi.) 
8 9.85 1H Singlet -NH (-NHCO) 
 
 
 
 
 
 
NH
N
H
NH
NH
O
CH3
CH3
O
CH3
H
 
Studies on some compounds…  276 
 
Dihydropyrimidines…  
MASS SPECTRAL STUDIES OF-4-[(p-METHOXYPHENYL)-5-(3,4-
DIMETHYL)-PHENYLAMINO CARBONYL]– 6 – PHENYL - 1, 4 –DIHYDRO 
PYRIMIDINE-2(1H)-AMINO.  
 
 
N H
N
H
O
CH3
O
N H
CH3
CH3
N H
m/z = 426
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CH3 +
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O
NH
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+
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N
H
O
NH
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+
OH +
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+
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EXPERIMENTAL 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL -[5-(3,4– 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6–PHENYL-1,4-DIHYDRO 
PYRIMIDINE - 2(1H)-AMINO. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 3,4-DIMETHYL PHENYL) – 3 –OXO – 3 – PHENYL        
PROPANAMIDE. 
 Pls. refer chapter-6, Section-6.1, Page No.-260 
 
 [B] PREPARATION OF N-PHENYL- 4 – METHOXYPHENYL [5 - (3,4 – 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - 
DIHYDRO PYRIMIDINE -2(1H) –AMINO. 
A mixture of Guanidine-HCl (2.0 gm, 0.02 mole), 4-methoxy benzaldehyde 
(1.36 gm, 0.01 mole) and N-(3,4-dimethylphenyl)-3-oxo-3-phenylpropanamide (2.67 
gm, 0.01 mole) in 15 ml of DMF containing pinch of potassium carbonate was 
refluxed for 14 hrs. The solution was allowed to stand for 12 hrs. at room tempeture 
and the resulting solid mass separated was filtered and washed with dil. HCl then 
crystallized from dioxane.Yield-58%, m.p.-166˚C, [C26H26N4O2; required: C, 73.22; 
H, 6.14; N, 13.14 %, found:  C, 73.20; H, 6.18; N, 13.12 %]. 
  Similarly, other N-phenyl-4 - aryl [5 - (3,4 – dimethyl) – phenyl amino 
carbonyl] – 6 – phenyl- 1,4 - dihydropyrimidine -2(1H) – amino, were prepared. The 
physical data are recorded in Table No.13 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8). 
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[C] BIOLOGICAL EVALUATION OF N-PHENYL- 4 - ARYL [5 - (3,4 – 
DIMETHYL) – PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - 
DIHYDRO PYRIMIDINE -2(1H) –AMINO. 
Antimicrobial testing were carried out as described in Chapter-8,The zones of 
inhibition of test solutions are recorded in Graphical Chart-13a, Table- 13a. Page 
No.-393, 394. Result and discussion is given on page no. - 395. 
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CHAPTER - 7 
STUDIES ON 
THIAZOLOPYRIMIDINES
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INTRODUCTION 
  
 Thiourea itself was one of the first new drug employed to depress, the 
clinically over active thyroid in thyrotoxicosis1 but some of the cyclic thioureides 
have been found better suited. All of these are prone of produce adverse reduction in 
susceptible patients and found more potent and less likely to produce side effect and is 
being used widely.2   
  Generally pyrimidine derivatives such as 2-hydroxy pyrimidine, 2-mercapto 
pyrimidine and 2-amino pyrimidine are studied. Pyrimidines have been isolated from 
the hydrolysis of the nucleic acid. 
 Pyrimidines are among those molecules that make life possible, have been 
some of the building blocks of DNA and RNA. Several analogs of pyrimidines have 
been used as compounds that interfere with the synthesis and functioning of nucleic 
acids e.g. fluorouracil, which has been used in cancer treatment. Also there are some 
thiouracil derivatives, which produce adverse reduction in susceptible patients and 
found more potent and less likely to produce side effects and is being widely used. 
There are several other important groups of pyrimidines with medicinal uses. 
 Pyrimidine ring carrying various substituents may be built up from two or 
three aliphatic fragments by the principle synthesis or by a variety of other synthesis, 
which are complimentary rather than alternative to it. A second type of synthesis is 
the isomerisation or break down of another heterocycles such as hydration of purine 
but such roots are frequently used.  
 Pyrimidine is best considered as a resonance hybrid to which the uncharged 
equivalent Kekule   structures 1 and 1a and charged structures 1b and 1g contribute. 
The self consistent p (pi) electron densities required for the ground state of pyrimidine 
are 0.776, 0.825 and 1.103 for positions 2, 4 and 5 respectively. Despite considerable 
localization of p (pi) electrons at nitrogen atoms of pyrimidines, the ring system is 
still sufficiently aromatic to possess substantial stability. This is great advantage in the 
primary synthesis of pyrimidines. 
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From the theoretical view point, it is essential to predict the structure, binding 
properties, chemical reactivity, etc. of dihydro compounds from the number and 
positioning of nitrogen atoms in the ring, as well as from the disposition of double 
bonds. Such quantum mechanical calculations also enable an evaluation of the degree 
of aromatic character in potential “homoaromatic” and “antiaromatic” isomers. 
Availability of novel model compounds for verifying these predictions would open up 
new horizons in theoretical heterocyclic chemistry, particularly in clarifying the 
structures leading to spontaneous isomerization of a derivative or in verifying its 
redox properties. 
From the biochemical point of view, 1,4-dihydropyrimidines are of intense 
interest because of presence of this group at the active site of the “hydrogen 
transferring coenzyme” NADH (reduced nicotinamide adenine dinucleotide). This 
nucleotide, a central participant in metabolic processes in living organisms, 
participates in the reduction of various unsaturated functionalities. 
Despite the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine moiety3 for clarifying a wide range of 
theoretical, medicinal and biological problems, the chemistry of this group of 
compounds is still extremely spotty.4-8 A deeper knowledge of the behavior of this 
class of compounds is, therefore, desirable. From the theoretical view point, it is 
essential to predict the structure, binding properties, chemical reactivity, etc. of 
dihydro compounds from the number and positioning of nitrogen atoms in the ring, as 
well as from the position of double bonds. 
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In the area of drug development, dihydroazines show great promise, 
particularly since the 4-aryldihydropyridines exhibit powerful vasodilation activity via 
modifying the calcium ion membrane channel,9-13 additionally; dihydropyridines have 
been found to actively transport medication across biological membranes.14 
 Until recently, most of the information available on dihydroazines centered 
around dihydropyridines, with very little data extending to the related 
dihydropyrimidines. 
 This lacuna has motivated our deep involvement in developing 
dihydropyrimidines chemistry, particularly dihydropyrimidines containing no 
substituents on the ring nitrogen.15 
 
SYNTHETIC ASPECT 
 Literature survey reveals that several publication and patents described the 
synthesis of dihydropyrimidinethiones as under. 
1. Polyphosphate ester (PPE) was utilized for the Biginelli's condensation. PPE 
serves as an excellent reaction mediator in the three component Biginelli reaction.16 
PPE is one of the phosphate-based reagents that are related to polyphosphoric acid 
(PPA). In contrast to PPA, PPE is aortic and soluble in organic media.(I) 
 
 
 
 
 
 
 
 
 
2. Indium (III) chloride was emerged as a powerful Lewis catalyst imparting 
high region and chemo selectivity in various chemical transformations. Ranu C. et 
al.17 described a simple synthesis of DHPM-2-(1H)-thione derivatives, (II) using 
indium (III) chloride (10 mol %) as a catalyst from an aldehyde, b-dicarbonyl 
compound and thiourea in THF. 
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3. DHPM was prepared from three component b-diketone, aldehyde and thiourea 
coupling in ethanol catalyze by indium(III) tribromide (InBr3)18,19   This modified 
one-pot Biginelli condensation provided not only simple preparation but also this 
modified Biginelli reaction was oxygen-bridge (III). 
4. Silica Sulfuric acid efficiently catalyzes the three component Biginelli reaction 
between an aldehyde, a,b-cabonyl compound, and thiourea in ethanol  to afford the 
corresponding dihydropyrimidines in high yield.20  The catalyst is reusable and can be 
applied several times without any decrease in the yield of the reaction (IV). 
 
 
 
 
 
 
 
5. Subhas D. Bose et al.21 describe a general and practical route for the Biginelli 
cyclocondensation reaction using cerium (III) chloride (CeCl3) heptahydrate as the 
catalyst.  Three different sets of reaction conditions were examined (i) traditional 
ethanol reflux (ii) water reflux and (iii) solvent-free conditions.  This is a novel, one-
pot combination that not only preserves the simplicity of Biginelli’s one-pot reaction 
but also consistently produces excellent yields of the DHPM-2(1H)-thiones (V). 
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6. Shrinivas et al.22 developed iodine catalyzed one-pot synthesis of 3,4-6. 
dihydropyridin-2(1H)-thiones (VI) This procedure involves three component 
cyclocondensation of aldehydes, 1,3-dicarbonyl compounds and thiourea to afford the 
corresponding dihydropyrimidinethiones in high yield. 
 
7. De. S. K. et al.23 synthesized novel one pot Biginelli-type reaction. Aromatic 
aldehydes with b-dicarbonbyl compound and thiourea in presence of catalytic amount 
of 5 % of Sc (OTf) 3 at 100oC (VII). 
 
8. John Mabry et al.24 synthesized different DHPMs via enamine intermediates 
using L-praline methyl ester hydrochloride found to be an effective catalyst for 
assembling dihydropyrimidine (VIII) thiones under mild condition. 
 
9. Zhang X et al.25 developed a novel series of 4-substituted 3,4-
dihydropyrimide-2(1H)-thiones (IX) employing magnesium perchlorate as an 
efficinet catalyst under ultrasound irradiation. 
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10. Some Biginelli compounds were synthesized by using a photochemistry 
method.  The Biginelli three component cyclocondensation reaction in THF medium 
using a mixture of b-ketoesters or b-diketone, aryl aldehyde and thiourea under 
irradiation with a tungsten lamp light to gave DHPM-2-(1H)-thiones26 (X). 
11. A practical and green chemistry approach towards synthesis of DHPM-2-
(1H)-thione without any solvent or catalyst.  This method was developed by  Ranu C. 
et al.27  Title compound was prepared from three component b-diketone, aldehyde and 
thiourea was heated under stirring at 100-105 0C afford the corresponding DHPM-2-
(1H)-thione (XI) in high yield (82%) and purity (> 95%). 
 
 
12. Recently, Wang L. et al.28-30 developed novel one pot Biginelli-type reaction. 
Aromatic and aliphatic aldehydes with b-dicarbonbyl compound and thiourea in 
presence of catalytic amount of 5 % of Yb (OTf) 3 at 100 0C for 60-90 minute under 
solvent free condition proceeded smoothly to afford the corresponding DHPM thione 
(XII). 
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ATWAL MODIFICATION  
 Apart from the traditional Biginelli condensation, there are only a few other 
synthetic methods available that lead to DHPMs. Since most of these protocols lack 
the experimental and conceptual simplicity of the Biginelli one-pot, one-step 
procedure, none of these have any significance today or can compete with the original 
Biginelli MCR approach. One noticeable exception is the so-called “Atwal 
modification” of the Biginelli reaction.31-33 Here, an enone first condensed with a 
suitable protected urea or thiourea derivative under almost neutral conditions. 
 
STRUCTURAL VARIATION OF REACTION 
 The original cyclocondensation reaction has been extended widely to include 
variation in all three components. If these, the aldehydes component has been varied 
to the largest extent and now includes not only many aromatic34-48 but also aliphatic35, 
36, 43, 49-52 and heterocyclic aldehydes 35,43,50, 53-56 can also be used. Particular interest is 
reaction where the aldehydes component is derived from a carbohydrate. In such 
reaction dihydropyrimidines having a sugar-like moiety at position four (C-nucleoside 
analogs) i.e. (I) or (II) are obtained. 
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Apart from common alkyl acetoacetates which are employed frequently as the 
b-ketoester components, other acetoacetic acid such as benzyl acetoacetate,49,57(-)-
methyl acetoacetate,57 b-chloroethyl acetoacetate,58 2-furanylmethyl acetoacetate,59 
and ethylthio acetoacetate59 have been used successfully in the Biginelli reaction; 
benzoylacetic acid esters react analogously to form (III). Similarly, ethyl 4-bromo 
acetoacetate55 and ethyl trifluoromethyl acetoacetate afford the corresponding 6-
functionalized dihydropyrimidines (IV). 
 
 
 
 
 
 
 
 
 Primary, secondary and tertiary acetoacetamides have been used in place of 
ester to produce pyrimidine-5-carboxamides (V).38,48,60-63 It should be emphasized that 
monosubstituted thioureas from exclusively N-1 substituted dihydropyrimidines of 
type (VI).35,40, 49,50,54,59,61,63-67  
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 In addition to solid-phase adaptions of the traditional three-component 
Biginelli condensation, solid-phase variations of the “Atwal modification” of the 
Biginelli reaction  have also been reported. Robinett et al.68 have disclosed the 
synthesis of a 648-member combinatorial library of 1,4-dihydropyrimidines 
(IX).Towards this end, polymer-bound acetoacetate (VII) was subjected to 
Knoevenagel condensation with aromatic aldehydes, followed by condensation with 
isothioureas. The resulting polymer-bound 1,4-dihydropyrimidines (VIII) were 
cleaved from the resin with 50% TFA to produce carboxylic acid (IX). 
 
 
 One other novel approach to DHPMs has been described by Shutalev et al.69 is 
outlined below. This synthesis is based on the condensation of readily available R-
tosyl-substituted thioureas (X) with the (in situ prepared) enolates of acetoacetates or 
1,3-dicarbonyl compounds. The resulting hexahydropyrimidines (XI) need not to be 
isolated and can be converted directly into DHPMs (XII). This method works 
particularly well for aliphatic aldehydes and thioureas and produces high overall 
yields of the desired target compounds. 
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THERAPEUTIC IMPORTANCE 
 Dihydropyrimidines of Biginelli-type have come a long way since their 
discovery in 1893 and the first patent on DHPM derivatives in 1930, describing 
agents for the protection of wool against moths70. 
 Dihydropyrimidinethiones have attracted considerable attentions as they 
appeared of interest to possess wide range of therapeutic activities. Different activities 
are as under. 
1. Antiviral71-73 
2.  Antimicrobiall74 
3. Antitumor75,76 
4.  Cardiovascular77 
5.  Antiplasmal78 
6.  Anticarcinogenic79 
7.  Calcium channel modulator80,81 
8.  Antihypertensive82,83 
9.  Vasodialative84 
10.  Blood platelet aggregation inhibitor85 
11.  Antiinflammatory86 
12.  Analgesic86 
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13.  Antilukemic87 
14.  a1a-Adrenergic receptor antagonist.88,89 
 Atwal K. et al.90 synthesized the 3-substituted 1,4-dihydropyrimidine (I)      
and show that vasorelaxant activity was critically dependent on the size of the C5 
ester group, isopropyl ester being the best, a variety of substituents (carbamate,      
acyl, sulfonyl, alkyl) were tolerated at N3. The dihydropyrimidines (I) are          
significantly morepotent than corresponding 2-heteroalkyl-l,4–dihydropyrimidines. 
 Dihydropyridine enantiomers usually show 10-15-fold difference in activity, 
the enantiomers of dihydropyrimidine (II) show more than a 1000-fold difference in 
activity. These results strengthen the requirement of an enamino ester for binding to 
the dihydropyridine receptor and indicate a nonspecific role for the N3-substituent. 
 
 
 
 
 
 
   
 
  
Biginelli compound show a diverse range of biological activities. As early as 
1930 simple derivatives (III) were patented as agent for the protection of wool against 
moths.91 Later, interest focused on the antiviral activity of Biginelli compounds.92 
 Pyrimidine-5-carboxamides derivatives of type (IV) were reported to possess 
anticarcinogencic activity,93 anti-inflammatory,48,94 analgesic48, and blood platelet 
aggregation inhibitory activity.45 
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 The main interest in Biginelli compounds, however, is due to the strong 
antihypertensive activity exhibited by certain derivatives. This is not surprising, since 
these dihydropyrimidines can be regarded as aza-analogs of dihydropyridines of the 
nifedipine type. Dihydropyridines have found widespread use in cardiovascular 
medicine and have served as important tools for the study of calcium channel 
structure and function.95 
Simple modification of the aromatic ring are reported to give substances with 
only moderate cardiovascular activity, e.g. (III),46 (VI),40,96,97 (VII) were shown to be 
potent calcium channel blockers,98-100 but they do not shown any significant anti-
hypertensive activity in vivo.98 This is also the case for bicyclic dihydropyrimidines 
(V).101,102  
 
Among the most potent derivatives are Biginelli compounds bearing an ester 
group at N-3 (VIII), thereby closely resembling the nifedipine structure.103-106 
Although the calcium channel  blocking activity of these compounds, e.g.(IX), is 
comparable to dihydropyridines, most of them are devoid of antihypertensive activity 
in vivo.104 
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Atwal K. S. et al.107 synthesized the 2-[[(4-methoxyphenyl) methyl] thio]-
dihydropyrimidines (X) and investigated that pyrimidines are integral parts of such 
biologically important compounds as antiviral, 108,109 antitumor 110 and cardiovascular 
agent.111 
 A very recent highlight in this context has been the identification of the 
structurally rather simple DHPM monastrol (XI) as a novel cell-permeable molecule 
that blocks normal bipolar spindle assembly in mammalian cells and therefore causes 
cell cycle arrest.112 Monastrol specifically inhibits the mitotic kinesin Eg5 motor 
protein and can be considered as a new lead for the development of anticancer 
drugs.112,113 
 
 
 
 
 
 
 
  
 
Out of a library of 16,320 diverse small molecules, Mayer et al.112 identified 
monastrol as a lead compound for the development of new anticancer drugs.  By 
using an innovative combination of two phenotype- based screens, one based on a 
mitosis-specific posttranslational modification and the other visualizing microtubules 
and chromatin, monastrol was recognized as the only cell-permeable compound that is 
capable of affecting mitosis in mammalian cells without targeting tubulin. 
 The design, synthesis and screening of libraries of small organic molecules 
possessing privileged structures has become a successful strategy in the drug 
discovery process.114 The term privileged structures is generally used to describe those 
classes of small organic molecules (<600-700 molecular weight) that have been 
shown to possess the ability to bind to a wide range of receptors.115  An efficient 
approach in medicinal chemistry relies on the identification of this type of scaffolds 
and their elaboration in a combinatorial manner with a set of pharmacophoric 
substituents to generate libraries of structurally related compounds. The biological 
screening of these collections then allows the identification of drug candidate 
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compounds.116 The dihydropyrimidine (DHPM) ring represents a heterocyclic 
structure of remarkable biological efficiency, as well established through the 
pharmacological activities exhibited by various DHPM derivatives that have been 
identified as potent calcium channel modulators, orally active antihypertensive agents, 
antidiabetic and a1a-adrenoreceptor-selective antagonists.117 
 Incidentally, DHPM derivatives are readily accessible products via the 
ketoester-aldehyde-urea (or thiourea) cyclocondensation known as the Biginelli three 
component.Reaction.118 Quite recently, the DHPM derivative monastrol (XI) was 
demonstrated to arrest mitosis in mammalian cells by causing the bipolar mitotic 
spindle to form a monoastral microtubule array surrounded by a ring of 
chromosomes.112 This novel action of monastrol differentiates it from all other known 
mitotic inhibitors ranging from colchine to taxol, which instead affect microtubules, 
the main structural element of the mitotic spindle.  
Since its discovery in 1999, several papers have appeared in the literature 
reporting on the synthesis,119,120 activity,121-127  and enantiomeric separation 119,120,128 
of monastrol and its analogues.129 Focusing on factors important for bipolar spindle 
formation, it has been demonstrated that monastrol specifically inhibits in vitro and 
and in vivo, the motoractivity of the mitotic kinesin Eg5, a motor protein required for 
spindle bipolarity.112, 123  
The rapid reversibility of monastrol inhibition activity allows for an exact 
temporal control over the cell cycle arrest in mitosis, thus confirming this small 
organic molecule as a new and powerful research probe of cellular processes.130 
Furthermore, since compounds that cause mitotic arrest have shown antitumor activity 
in humans,130 monastrol may serve as a lead for the development of new anticancer 
drugs. A recent study established that, in the case of monastrol, the (S)-enantiomer is 
more active than both the (R)-enantiomer and the racemate.123,124 Both (S)- and (R)-
monastrols abolished basal Eg5ATPase activity, with the (S)-enantiomer 
demonstrating a 15-fold higher potency.124 
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 George C. et al.131 prepared dihydropyrimidine (XII) was equipotent to 
nifedipine and amlodipine in vitro. In the spontaneously hypertensive rat, 
dihydropyrimidine (XII) is both more potent and longer acting than nifedipine and 
compares most favorably with the long-acting dihydropyridine derivative amlodipine. 
Dihydropyrimidine (XII) has the potential advantage of being a single enantiomer. 
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 Edward J. et al.132 employ difference infrared spectroscopy to probe structural 
changes that occur in the motor protein with monastrol in the presence of either ADP 
or ATP. 
 Sally Ann P .et al.133 synthesized 4,6-Bis [(R-carbamoylethyl)thio]-1-
phenylpyrazolo[3,4-d] pyrimidine (XIII) was identified as a novel adenosine 
A1receptor antagonist, antagonizing adenosine-stimulated cyclic adenosine mono 
phosphate generation in guinea pig brain slices.134,135 
 
 
 
 
 
 
 
 
 
 
 Salvatore B. et al.136 studied the stopped-flow fluorometry indicates that 
monastrol inhibits ADP release by forming an Eg5-ADP-monastrol ternary complex. 
Monastrol reversibly inhibits the motility of human Eg5. Monastrol has no inhibitory 
effect on the following members of the kinesin super family: MC5 (Drosophila 
melanogaster Ncd), HK379 (H. sapiens conventional kinesin), DKH392 (D. 
melanogaster conventional kinesin), BimC1-428 (Aspergillus nidulans BimC), Klp15 
(Caenorhabditis elegans C-terminal motor), or Nkin460GST (Neurospora crassa 
conventional kinesin). 
 Atwal K. et al.104 synthesized the 3-substituted 1,4-dihydropyrimidine (XIV) 
and show that vasorelaxant activity was critically dependent on the size of the           
C5 ester group, isopropyl ester being the best, a variety of substituents (carbamate, 
acyl, sulfonyl, alkyl) were tolerated at N3. The dihydropyrimidines (XIV) are 
significantly more potent than corresponding 2-heteroalkyl-l,4-dihydropyrimidines. 
Dihydropyridine enantiomer usually shows 10-15-fold difference in activity, the 
enantiomers of dihydropyrimidine (XV) show more than a 1000-fold difference in 
activity. These results strengthen the requirement of an enamino ester for binding to 
the dihydropyridine receptor and indicate a nonspecific role for the N3-substituent. 
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Atwal K.S.98 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5 
pyrimidinecarboxylic acid esters which lack the potential C, symmetry of 
dihydropyridine calcium channel blockers, were prepared and evaluated for biological 
activity. Biological assays using potassium-depolarized rabbit aorta and radioligand 
binding techniques showed that some of these compounds are potent mimics of 
dihydropyridine calcium channel blockers. The combination of a branched ester (e.g. 
isopropyl, sec-butyl) and an alkylthio group (e.g. SMe) was found to be optimal for 
biological activity.  Dihydropyrimidines (XVI) were found to be 30-fold less active. 
The solid-state structure of dihydropyrimidine analogue (XVI) shows that these 
compounds can adopt a molecular conformation which is similar to the reported 
conformation of dihydropyridine calcium channel blockers. 
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As a demonstration of this new concept in the Biginelli reaction, the synthesis 
of two C4 epimer monastrol analogues bearing the ribofuranosyl moiety at C6 
(XVII), (XVIII), (XIX) has been synthesized by Alessandro D. et al.137 
 
Novel compounds related to 2-(cyclohexylthio)-3,4-dihydro-5-methyl-6-(3-
methylbenzyl)-4- oxopyrimidine (XX) ( MC 639) have been synthesized by Antonello 
M. et al.138 and tested as inhibitors of human immunodeficiency virus (HIV-1). 
 
 
 
 
 
 
 
 
O
OR
OR OR
NH
N
H
EtOOC
S
OH
O
OR
OR OR
NH
N
H
EtOOC
S
OH
O
OR
OR OR
NH
N
H
EtOOC
S
OH  (XVII) 
  (XVIII) 
(XIX) 
NH
N
O
S
CH3
CH3
  (XX) 
Studies on some compounds…  308 
 
Thiazolopyrimidines… 
Numerous classes of non nucleoside reverse transcriptase inhibitors (NNRTIs) 
have been discovered by Antonello Mai et al.139 with dihydro-alkyloxy-benzyl-
oxopyrimidines (DABOs) being one of them. The lead compound, an isotrimethoprim 
derivative (XXI), (XXII), (XXIII) has been synthesized as a possible dihydrofolate 
reductase inhibitor, and when tested against HIV-1 because of its tructural similarity 
with HEPT, 140,141 it was a selective, although not very potent, HIV-1 inhibitor.142 On 
the basis of these findings, various oxopyrimidines have been synthesized and found 
to be specific HIV-1 inhibitors targeted at the reverse transcriptase.143-146 
  
Various 2-thiopyrimidine derivatives have been synthesized by Sondhi  S.M. 
et al.147 One of the compound, 7,7,8a-trimethyl-hexahydro-thiazolo[3,2-c]pyrimidine-
5-thione (XXIV) showed good anti-inflammatory (37.4% at 100mg/kg p.o.) and 
analgesic activity (75% at 100mg/kg p.o.). 7-(1-Mercapto-3,3,4a-trimethyl-4,4a,5,   
9b-tetrahydro-3H-pyrido[4,3-b]indol-7-yl)-3,3,4a-trimethyl-3,4,4a,5-tetrahydro-benzo 
[4,5] imidazo [1,2-c]pyrimidine-1-thiol (XXV) showed moderate activity against 
CDK-1 (IC(50)=5muM). The other compounds showed moderate anti-inflammatory 
(5-20%), analgesic (25-75%) and protein kinase (CDK-5, GSK-3) inhibitory activities 
(IC(50)>10muM). 
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Massey A. et al.148 report that growing human cells extensively incorporate the 
thiopyrimidine nucleoside 4-thiothymidine (XXVI) (S4TdR) into their DNA. The 
incorporated thiopyrimidine (S4T) can also undergo facile S-methylation to 4-
thiomethylthymine (S4meT). The rate of methylation of S4TdR in model substrates is 
similar to that for the conversion of S6G to S6meG indicating that the DNA of cells 
grown in S4TdR will contain significant levels of S4meT. 
 
 
 
 
 
 
 Twenty 5-alkyl-2-thiopyrimidine nucleosides were newly synthesized by 
Shigeta S. et al.149 and examined for antiviral activities against herpes simplex virus 
(HSV), varicella-zoster virus VZV) and human cytomegalovirus (HCMV). In this 
study, 2'-deoxy-5-alkyl-2-thiocytidine (XXVII) analogues had lower 50% effective 
concentration (EC50) values against HSV-1, and 2'-deoxy-5-alkyl-2-thiouridine 
(XXVIII) analogues showed lower. 
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New thiopyrimidine derivatives have been synthesized by Bassleer R. et al.156 
Among them, several inhibit the multiplication of Chick embryo cells cultivated in 
vitro they provoke strong nucleoli alterations, prevent the cells from entering into 
mitosis and can give rise to cell polyploidisation as to DNA. 
 EC50 against VZV than their congeners of arabinoside form. Among the 
compounds examined, 2'-deoxy-5-ethyl and 5-propyl-2-thiocytidine (XXIX), (XXX) 
were most potent and selective anti-HSV compounds. Their EC50s were 0.04 and 
0.15 microM, and selectivity indexes were more than 7,215 and 1,849, respectively. 
On the other hand, 2'-deoxy-5-propyl-2-thiouridine, 5-bromovinyl-2-thiouracil 
arabinoside and 5-styryl-2-thiouracil arabinoside (XXXI)) were most potent and 
selective anti-VZV compounds. Their EC50s were 3.1, 3.8 and 2.6 pM for CaQu 
strain of VZV, respectively, and 2.1 to 3.0 times lower than that of acyclovir. All 2-
thiopyrimidine nucleoside analogues did not show antiviral activities against 
thymidine kinase (TK) negative strains of HSV-1 and VZV. Only three 2-thiocytosine 
arabinoside compounds showed marginal anti-CMV activities (EC50s were 57-159 
pM). 
 
 Attia A. M. et al.150 synthesized N3-beta-D-glucopyranosyl, galactopyranosyl 
and xylopyranosyl 6-methyl-2-methylthiouracil (XXXII) and their 5-bromo 
derivatives by coupling an a-acetobromosugar with the corresponding thiouracil. The 
new modified thiouridine analogues were evaluated for their inhibitory activity 
against Human Immunodeficiency Virus (HIV) replication in MT-4 cells as well as 
for their cytotoxicity 
. 
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 Twenty 2-thiopyrimidine nucleoside analogues were synthesized by Shigeta S. 
et al.151 and examined for inhibitory activity against herpes simplex virus (HSV) type 
1 and 2, varicella-zoster virus (VZV), human cytomegalovirus (HCMV) and 
thymidine kinase-deficient HSV (HSV-TK-) replication in vitro. 
 2-thiouracil (thymine) arabinoside, 2'-deoxy-2-thiouridine (XXXIII) and their 
5-halogenated derivatives showed anti-HSV activity in both RPM18226 (human B-
lymphoblastoid cells) and MRC-5 (human embryo lung cells). 2'-Deoxy-5-
halogenated-2-thiocytidines (XXXIV) were also inhibitory against HSV, whereas 2-
thiocytosine arabinoside and its derivatives were not inhibitory against HSV 
replication, except 5-bromo and 5-iodo congeners. 
 
 
 
 
 
 
 Massey A. et al.152 described the thiopurines, 6-thioguanine (XXXV) and 6-
mercaptopurine, (XXXVI) are antileukemic agents that are incorporated into DNA 
following retrieval by the purine salvage pathway. 
 
 
 
 
 
 
  
N
NH N
H
N
S
NH2
(XXXV) 
N
N N
H
N
SH
(XXXVI) 
N
H
N
S
O OH
OH
O
(XXXIII) 
N
N
S
NH2
O OH
OH
X
(XXXIV) 
O
OH
OH
OH
N
N
H
C
O
CH3
CH3
SH
(XXXII) 
Studies on some compounds…  312 
 
Thiazolopyrimidines… 
Their toxicity requires active DNA mismatch repair (MMR) and thiopurine 
resistance is an acknowledged phenotype of MMR-defective cells. In addition to these 
direct cytotoxic effects, DNA thiobases have distinctive photochemical properties, the 
therapeutic potential of which has not been extensively evaluated. 
 Novel D- and L-2'-azido-2',3'-dideoxy-4'-thionucleosides were synthesized by 
Jeong L.S. et al.153 and evaluated for antiviral activity. When the final nucleosides 
were tested against HIV-1, HSV-1, HSV-2 and HCMV they were found to be only 
active against HCMV without cytotoxicity up to 100 micrograms/ml. 
 A new thiopyrimidine derivative has been synthesized by Bassleer R. et al.154 
It can inhibit cell multiplication in Chick embryo fibroblasts, in Mouse Ehrlich ascites 
tumor cells and in Rat hepatoma cells (line Rueber) cultivated in vitro. 
 Transfer RNAs isolated by Kwong L. K. et al.155 from Escherichia coli B 
grown in the presence of 2-thiouracil are deficient in pseudouridine. Much of this 
deficiency is from the T psi C region, which has only about 50% of its normal 
pseudouridine content. The other modified nucleoside from this region, ribothymidine 
is reduced by only about 10%. Studies showed that 2-thiouracil is incorporated into 
the RNA of E. coli during growth in the presence of the analog. 
 With an intention of preparing the compounds possessing better therapeutic 
activity, we have undertaken the synthesis of dihydropyrimidinthiones which have 
been described in following section. 
 
 
SECTION-7.1:- SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-
ARYL-5-(3,4–DIMETHYL)-PHENYLAMINOCARBONYL]-6 
–PHENYL-1,4-DIHYDROPYRIMIDINE-2(1H)-THIONES. 
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INTRODUCTION 
Biginelli reaction is not only important to synthesize analogs of DHPM ring 
using different building block as potent bioactive heterocycles, but also various 
scaffolds can   synthesized from this heterocyclic scaffold. 
Tetrahydro/dihydropyrimidine-2-thiones are the key intermediate for the 
synthesis of fused pyrimidines. They have become of considerable interest during the 
last forty years157-169.Many of these compounds have proved to be active anticancer161-
166, antipyretic and anti-inflammatory agents,164-168 calcium antagonist,169-171 
analgesic,172 antitumor,173-174 antidepresant,175 antibacterial and antifungal 176-178 
agents. 
The parent ring systems of known thiazolopyrimidine derivatives are shown in 
structures (I-IV). 
 
   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
SYNTHETIC ASPECT 
The following routs have been employed for the synthesis of thiazolo 
pyrimidines. 
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Azole Approaches 
Starting from the thiazole ring and subsequent construction of the pyrimidine 
ring in the terminal step. 
1. Thiazolo [3,2-a]pyrimidine (7) was prepared in 30% yield by the reaction of 
2-aminothiazole (5) with ethyl cyanoacetate (6) in a sodium ethoxide/ethanol 
mixture or using polyphosphoric acid 179 or acetic acid.180-181 
2. However, oxothiazolopyrimidine (9) was obtained upon treatment with 
phosphorous pentoxide and methanesulfonic acid (8).179 
3. The reaction of (5) with ethyl acetoacetate (10) at 140–150 0C resulted in the 
formation of (11) that was then converted to the Z-isomer upon heating at 250 
0C and cyclized to give (12).182  
4. 2-Aminothiazole (5) cyclized with acetyl acetone (13) at 1000C, in the 
presence of methane sulfonicacid-phosphorus pentoxide or formic acid–
phosphorus pentoxide, followed by treatment with 70% perchloric acid, to 
give the thiazolopyrimidin-4-ium salt (14).183 
5. The ester (16) was obtained from 2-aminothiazole (5) with an excess of 
methyl methanetricarboxylate (15) in 61% yield.184 
6. Cyclocondensation of (5) with diethyl ethoxymethylene malonate (17) in 
acetic acid followed by hydrolysis of the ester (18) gave (19).185-186 
7. Similarly, 2-aminothiazole (5) reacted with (20) in ethanol to give (21).187 
8. Stanovink et al.188-192 reported the synthesis of a series of thiazolopyrimidine 
derivatives upon reacting 2-aminothiazole with a variety of different reagents. 
Thus, dimethylaminobut-2-enoate (or pentenoate), (22), reacted with 5 to give 
thiazolopyrimidine (23). (Chart 1). 
9. The reaction of 2-aminothiazole (5) with 2-hydropolyfluoroalk-2-enoate (24) in 
basic medium gave two isomers, 7-oxo (25) and its isomeric 5-oxo (26).       
The structure of both (25) and (26) was established through 1H NMR, 19F 
NMR and mass spectra.193 
10. 2-Aminothiazole derivatives (5), (R1¼H, CO2Et; R2¼Ph, aryl, Me), reacted 
with the acetylenic derivative (27) and ester derivative (28) in ethanol and 
polyphosphoric acid, respectively, to give the isomeric oxothiazolopyrimidine 
derivatives (29) and (30), in 5–32% and 8–97% yield, respectively.194 
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11. Condensation of 2-aminothiazole (5) in absolute ethanol with the sodium salt 
of ethyl oximinocyanoacetate (31) gave after acidification (pH 6) with diluted 
hydrochloric acid, the nitroso derivative (32) in 92% yield.195 
12. Treatment of the 2-aminothiazaole derivatives (5) with the hydrazone 
derivatives (33) gave the oxothiazolo [3,2-a] pyrimidine derivatives (34).196 
13.  Compound (37) was prepared in 70–95% yield by thermal (160 0C) 
condensation of arylamino bisthiazole (35) with two equivalents of bis (2,4,6-
trichlorophenyl) methyl malonate (36).197(Chart 2). 
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Azine Approaches 
Starting from pyrimidine ring and subsequent construction of the thiazole in 
the terminal step. Pyrmidinethione derivatives (37-39) were alkylated with 
monochloroacetic acid or chloroacetyl chloride and then cyclized to give 
thiazolopyrimidine derivatives.198-212 Thus, pyrimidine thione (37) reacted with (40) 
or (41) in DMF or in an acetic anhydride/ pyridine mixture200-202 to gave thiazolo-
pyrimidines (42) and (43). Alkylation with (40) in the presence of an aromatic 
aldehyde198-200,203,205-208,210 gave the arylidene derivatives (44). Similarly, 
pyrimidinethione derivatives (38) and (39) reacted with monochloroacetic acid in 
acetic acid/acetic anhydride/sodium acetate mixture203-204 or with chloroacetyl 
chloride in dry dioxane to give the corresponding thiazolopyrimidines. (Chart-3) 
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summarizes the pyrimidine-thione derivatives (37-39) used in the synthesis of various 
thiazolopyrimidine. 
 
 
 
 
 
 
 
  
 The Hantzsch-type condensation of dihydropyrimidines (39) with a substituted 
2-bromophenylacetaldehyde (45) led to the thiazolopyrimidine derivatives (46).213-214 
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  Thiazolo[3,2-a]pyrimidine derivatives (48) were prepared by refluxing 
pyrimidinethione derivative (38) with phenacylbromide (47) in glacial acetic acid.215-
217 
 
 
 
 
 
 
 
Reaction of pyrimidine thiones (37) with 1,2-dibromoethane (49) gave the 
oxothiazolopyrimidine derivatives (50) in the presence of DMF/K2CO3 at 70–80 
0C.218-221 
 
 
 
 
 
 
 
 
Retro Diels-Alder reaction 
 
Both azole and azine approaches were considered as major methods for 
synthesis of the thiazolopyrimidine. Whereas, the retro Diels-Alder reaction was 
considered a minor method. Other reported methods include: (i) cyclization of 
propargyl thiopyrimidines in the presence of Pd (II) salts, (ii) metabolism of a N-
allylpyrimidine and (iii) reaction of thiazole derivative with isocyanate. 
 
THERAPEUTIC IMPORTANCE 
Thiazolo [3,2-a] pyrimidines have generated recent interest due to their 
interesting biological and pharmaceutical activities. Thus, these ring systems have 
following significant activities.  
Various derivatives of thiazolo [3,2-a]pyrimidine (I) have been synthesized by 
B. Tozkoparan et al.222 and tested for their anti-inflammatory activities at the 100 
mg/kg dose level compared with indomethacin. Krzysztof Danel and co-workers223 
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have been synthesized substituted 2,3-dihydro-7H-thiazolo[3,2-a]pyrimidin-7-ones 
and considered as annulated analogues of HEPT. 2,3-Dihydro-5-[(3,5-
dimethylphenyl)methyl]-3- ethoxy-6-ethyl-7H-thiazolo[3,2-a]pyrimidin-7-one (II) 
were found most active against HIV-1. 
 
Antimicrobial activity of thiazolo [3,2-a]pyrimidine (III) and (IV) have been 
screened by H. M. Sayed et al.224 against various gram positive, gram negative 
pathogens and fungi. 
 
Nargues S. Habib, Raafat Soliman, and co-workers225 have synthesized some 
thiazolo [4,5-d] pyrimidine (V) derivatives and evaluated for their antimicrobial 
activity studies. 
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 Chun Hu, Huang-quan Lin and co- workers226 have synthesized 5H-thiazolo 
[3,2-a]pyrimidine derivatives (VI) and studied their biological activities, they have 
evaluated thiazolo pyrimidine compounds as an acetyl cholinesterase inhibitors.   
 
 
 
 
 
 
 
 
 
Thus interesting biological activities of a novel heterocyclic derivative like 
thiazolopyrimidine have stimulated considerable research work in recent years 
leading to the synthetic utility of the derivatives of this ring system. In our search for 
new potential antimicrobial compounds, the reaction series of thiazolopyrimidine with 
different arylaldehyde under proper conditions has been investigated and the 
pharmacological profile of the compounds have been studied and described as under. 
 
 
 
SECTION-7.2: SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-
ARYLIDENE-4(4′-METHOXYPHENYL)- 5 - (3,4-DIMETHYL 
PHENYLAMINO) CARBONYL - 6-PHENYL - 4,7 DIHYDRO 
THIAZOLO [3,2-α] - PYRIMIDINE 3-ONES. 
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SECTION-7.1 
 SYNTHESIS AND STRUCTURE ELUCIDATION OF 4-ARYL-5-(3,4– 
DIMETHYL)-PHENYL AMINOCARBONYL] – 6 –PHENYL-1,4-DIHYDRO 
PYRIMIDINE-2(1H)-THIONES. 
 Compounds containing pyrimidine ring are widely distributed in nature. Many 
of these derivatives are reported to possess different biological activities. In view of 
these report, we have synthesized pyrimidine derivatives of type- (XIV) by the 
condensation of 3,4-dimethyl phenyl) - 3-oxo-3-phenylpropanamide, thiourea and aryl 
aldehydes in presence of catalytic amount of HCl. 
 
The structure elucidation of the synthesized compounds has been 
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (XIVa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (XIVa-j) have been compared with standard 
drugs viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(chapter-8). 
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 IR SPECTRAL STUDIES OF 4-[(p-METHOXYPHENYL)-5-(3,4–DIMETHYL) 
-PHENYL AMINO CARBONYL] –6– PHENYL-1,4-DIHYDRO PYRIMIDINE-
2(1H)-THIONES. 
  
  Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
  4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str.(asym.) 2958 2975-2950 227 
-CH3 C-H str.(sym)  2875 2880-2860 " 
  C-H def.(asym.) 1472 1470-1435 " 
  C-H def.(sym.) 1386 1390-1370 " 
Aromatic C-H str. 3079 3090-3030 228 
  C=C str. 1512 1540-1480 " 
Pyrimidine C=C str. 1530 1580-1520 " 
Moiety C-H str 3068 3090-3030 " 
 C-H i.p. def. 1100 1125-1090 229 
Amide -NH str 3398 3410-3380 230 
  -NH str 1607 1635-1595 " 
Carbonyl -C=O str. 1706 1700-1725 " 
Amide -C=O str. 1651 1690-1660 " 
Ether C-O-C str 1015 1075-1010 " 
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PMR SPECTRAL STUDIES OF 4-[(p-METHOXYPHENYL)-5-(3,4-
DIMETHYL)-PHENYL AMINO CARBONYL]–6–PHENYL- 1,4 –DIHYDRO 
PYRIMIDINE-2(1H)-THIONES.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 2.10 6H doublet 2 (CH3) moiety 
2 3.80 3H Singlet Ar-OCH3 
3 5.30 1H Singlet -CH (pyrimi.) 
4 6.91-7.50 12H Multiplet Ar-H 
5 9.10 1H Singlet -NH (pyrimi.) 
6 9.62 1H Singlet -NH (pyrimi.) 
7 10.21 1H Singlet -NH (-NHCO) 
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MASS SPECTRAL STUDIES OF 4-[(p-METHOXYPHENYL)-5-(3,4-
DIMETHYL)-PHENYL AMINO CARBONYL]–6 – PHENYL - 1, 4 –DIHYDRO  
PYRIMIDINE-2(1H)-THIONES.  
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EXPERIMENTAL 
 
SYNTHESIS & STRUCTURE ELUCIDATION OF 4-ARYL [5-(3,4– 
DIMETHYL)–PHENYL AMINOCARBONYL] –6 – PHENYL - 1,4 - DIHYDRO 
PYRIMIDINE -2(1H) –THIONES. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A]  PREPARATION OF 3,4-DIMETHYL PHENYL) – 3 –OXO – 3 – PHENYL        
PROPANAMIDE. 
 Pls. refer chapter no. 6- Section -6.1:- page no.-260 
 
 [B] PREPARATION OF 4 –[(p-METHOXYPHENYL)-5 - (3,4 – DIMETHYL) 
–PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 -DIHYDRO   
PYRIMIDI NE -2(1H) –THIONES.  
A mixture of thiourea (1.2gm, 0.015mole), 4-methoxy benzaldehyde (1.5gm,  
0.01mole) and N-(3,4-dimethylphenyl)-3-oxo-3-phenylpropanamide (2.67gm, 0.01 
mole) in 15 ml of ethanol containing few drops of concentrated hydrochloric acid was 
refluxed for 8 hrs. The solution was allowed to stand for 12 hrs. at room temperature 
and the resulting solid mass separated was filtered and crystallized from dioxane. 
Yield 67%, m.p.265˚ C, [C26H25N3O2S; required C, 70.40, H, 5.68, N, 9.47 % found: 
C, 70.43, H, 5.62, N, 9.42 %].  
  Similarly, other 4 - aryl [5 - (3,4 – dimethyl) – phenyl amino carbonyl] – 6 – 
phenyl- 1,4 - dihydropyrimidine -2(1H) –thiones were prepared. The physical data are 
recorded in Table No.14. 
 
 
 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8). 
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[C] BIOLOGICAL EVALUATION OF 4 -ARYL [5 -(3,4 – DIMETHYL) – 
PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - DIHYDRO 
PYRIMIDINE -2(1H) –THIONES   
 Antimicrobial testing were carried out as described in Chapter-8.The zones of 
inhibition of test solutions are recorded in Graphical Chart-14a, Table-14a. Page 
No.-396, 397. Result and discussion is given on table no.: - 398. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies on some compounds…  329 
 
Thiazolopyrimidines… 
 
 
 
 
 
● 
S1
= 
Et
hy
le
ne
 d
ic
hl
or
id
e:
 E
th
yl
 a
ce
ta
te
 (8
:2
), 
S2
 =
 T
ol
ue
ne
: E
th
yl
 a
ce
ta
te
 (8
:2
) 
Studies on some compounds…  330 
 
Thiazolopyrimidines… 
SECTION-7.2 
 
SYNTHESIS AND STRUCTURE ELUCIDATION OF 2-ARYLIDENE -N-(3,4-
METHYLPHENYL)-3,5-DIHYDRO-7-METHYL-3-OXO-5- PHENYL -2H-
THIAZOLO [3,2-a]  PYRIMIDINE - 6 -CARBOXAMIDES. 
Compounds containing pyrimidine ring are widely distributed in nature. Many 
of these derivatives are reported to possess different biological activities. In view of 
these report, we have synthesized 2-arylidene -N-(3,4-dimethylphenyl)-3,5-dihydro-7-
methyl-3-oxo-5- phenyl -2H-thiazolo [3,2-a]  pyrimidine - 6 –carboxamides of Type-
(XIII) by the condensation 1,2,3,4 tetrahydro - 4-(4-metrhoxy phenyl )-N-(3,4-
dimethyl phenyl )-6-phenyl -2- thioxo pyrimidine -5-carboxamide and different 
aromatic aldehyde.   
The structure elucidation of the synthesized compounds has been   
characterized by using elemental analysis, infrared and 1H-Nuclear magnetic 
resonance spectroscopy and further supported by Mass spectrophotometry. 
All the purified organic compounds (XVa-j) have been screened for their in 
vitro therapeutic assay like Antibacterial activities towards Gram positive and 
Gram negative bacterial strain and Antifungal activities towards fungal strains at 
different concentrations (Minimum Inhibitory Concentration). The biological 
activities of synthesized compounds (XVa-j) have been compared with standard drugs 
viz. Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, Norfloxacin 
(antibacterial) Nystatin, and Greseofulvin (antifungal) at different concentrations 
(Chapter-8). 
Compound-(XV) N
N S
O
R
N H
O
CH 3
CH 3
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CH 3
N H
N
H
S
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O
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IR SPECTRAL STUDIES OF 2-(p-METHOXYPHENYL)-4-(4’-METHOXY 
PHENYL) – N - (3,4-DI METHYLPHENYL) - 3,5 – DIHYDRO – 7 - METHYL 
– 3 – OXO - 5-PHENYL-2H -THIAZOLO [3,2-a]PYRIMIDINE - 6 –
CARBOXAMIDE.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Instrument: SHIMADZU- FT-IR -8400 Spectrophotometer; Frequency range: 
4000-400 cm-1 (KBr disc). 
 
Type Vibration mode Frequency in cm-1 Ref. 
Observed Reported 
Alkane C-H str. (asym.) 2967 2975-2950 227 
-CH3 C-H str. (sym)  2831 2880-2860 " 
  C-H def. (asym.) 1457 1470-1435 " 
  C-H def.(sym.) 1375 1390-1370 "  
Aromatic C-H str. 3082 3090-3030 228 
  C=C str. 1536 1540-1480 " 
 C-H i.p. def. 1024 1070-1000 " 
 C-H o.o.p. def. 834 835-810 " 
Thiazolo C=C str. 1553 1580-1520 229 
pyrimidine C-H str. 3082 3080-3030 " 
moiety C-H i.p. def. 1112 1125-1090 " 
 C-H o.o.p. def. 834 900-650 " 
Amine -NH str. 3302 3410-3380 230 
 C-N str. 1327 1360-1310 " 
Carbonyl -C=O str. 1673 1700-1725 " 
Amide -C=O str. 1660 1690-1660 " 
Ether C-O-C str. 1000 1000-950 " 
 
N
N S
O
NH
O
CH3
CH3
O
CH3
O CH3
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PMR SPECTRAL STUDIES OF 2-(3,4-DIMETHOXYPHENYL)-4(4’-
METHOXY PHENYL) – N - (3,4-DI METHYLPHENYL) - 3,5 – DIHYDRO – 7 
- METHYL – 3 – OXO - 5-PHENYL-2H -THIAZOLO [3,2-a]PYRIMIDINE - 6 
–CARBOXAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Internal Standard: TMS; Solvent: DMSO: Instrument: BRUKER Spectrometer (300 
MHz). 
Signal  
no. 
Signal position 
(δppm) 
Relative No.  
of protons 
Multiplicity Inference 
1 2.18 6H doublet 2 (CH3) moiety 
2 3.72 3H Singlet Ar-OCH3 
3 3.82 6H doublet 2(OCH3) 
3 6.25 1H Singlet -CH (pyrimi.) 
4 6.81-7.78 15H Multiplet Ar-H 
5 7.85 1H Singlet -NH (-NHCO) 
6 9.62 1H Singlet -CH (Vinyl) 
 
 
 
 
 
N
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O
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CH3
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MASS SPECTRAL STUDIES OF 2-(3,4-DIMETHOXYPHENYL)-4(4’-
METHOXYPHENYL) – N - (3,4-DI METHYLPHENYL) - 3,5 – DIHYDRO – 7 - 
METHYL – 3 – OXO - 5-PHENYL-2H -THIAZOLO [3,2-a]PYRIMIDINE - 6 –
CARBOXAMIDE. 
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MASS FRAGMENTATION 
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EXPERIMENTAL 
 
SYNTHESIS AND BIOLOGICAL SCREENING OF 2-ARYLIDENE -N-(3,4-
METHYLPHENYL)-3,5-DIHYDRO-7-METHYL-3-OXO -5- PHENYL -2H-
THIAZOLO [3,2-a]  PYRIMIDINE - 6 -CARBOXAMIDES. 
Melting points of all the synthesized compounds were taken in open capillary 
system. The purification of all the compounds was carried out by crystallization in 
appropriate solvents. TLC was carried out on silica gel-G as stationary phase. 
 
[A] PREPARATION OF 4 - METHOXYPHENYL [5 - (3,4 – DIMETHYL) – 
PHENYL AMINO CARBONYL] – 6 – PHENYL - 1,4 - DIHYDRO 
PYRIMIDINE -2(1H) –THIONES. 
 Pls. refer Chapter No.-7, Section:- 7.1, Page No.-327 
 
[B] PREPARATION OF 2-(3,4-DIMETHOXYHENYL)–N-(3,4-METHYL 
PHENYL) -3,5-DIHYDRO – 7 - METHYL -3- OXO – 5 - PHENYL -2H-
THIAZOLO-[3,2-a]  PYRIMIDINE - 6 -CARBOXAMIDES. 
 A mixture of 4 - methoxyphenyl [5-(3,4 – dimethyl) – phenyl amino carbonyl] –
6– phenyl-1,4-dihydropyrimidine-2(1H)–thiones (6 gm, 0.01 mole), monochloro 
acetic acid (1.41 gm, 0.015 mole), anhydrous sodium acetate (2 gm), glacial acetic 
acid (20 ml), acetic anhydride (15 ml) and 4-methoxybenzaldehyde (1.36 gm, 0.01 
mole) were heated to reflux for 3-4 hr. The reaction mixture was cooled to room 
temperature and poured on to crushed ice with vigorous stirring. The precipitated 
solid was filtered under suction, washed with cold water and isolate the product. 
Yield- 52%, m. p.- 212 0C; (C36H31N3O4S; required: C, 71.86; H, 5.19; N, 6.98 %; 
found: C, 71.81; H, 5.23; N, 6.96 %).  
 Similarly, other 2-arylidene -N-(3,4-dimethylphenyl)-3,5-dihydro-7-methyl-3-
oxo-5- phenyl -2H-thiazolo [3,2-a]  pyrimidine - 6 –carboxamide were prepared. The 
physical constants are recorded in Table-15. 
 
TLC System: For [A] and [B]: Ethyl Acetate: Ethylene dichloride (2:8). 
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[C] BIOLOGICAL EVALUATION OF 2-ARYLIDENE –N- (3,4-
METHYLPHENYL)-3,5-DIHYDRO-7- ETHYL-3-OXO-5- PHENYL -2H-
THIAZOLO [3,2- a]  PYRIMIDINE - 6 -CARBOXAMIDES. 
 Antimicrobial testing were carried out as described in Chapter-8.The zones of 
inhibition of test solutions are recorded in Graphical Chart-15a, Table-15a. Page-
No.-399, 400. Result and discussion is given on page no.:- 401. 
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CHAPTER - 8 
STUDIES ON BIOLOGICAL 
ACTIVITY STUDIES 
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 [A]      ANTIMICROBIAL ACTIVITY STUDIES 
 The antimicrobial activities of new synthesized compounds were determined 
using Broth dilution method. The standard strains used for the activity were procured 
from Institute of Microbial Technology, Chandigarh. 
 In this method each synthesized drug was diluted obtaining 2000 
microgram/ml concentration, as a stock solution. The 10 µL suspensions from each 
well was further inoculated on appropriate media and growth was noted after 24 and 
48 hrs at 37˚C. The lowest concentration, which showed no growth after spot 
subculture was considered as MBC / MFC for each drug. The result of this test is 
affected by the size of inoculums. The test mixture should contain 108 organism/ml. 
In this method the results are recorded in the form of primary and secondary 
screening.  
Primary screening: In primary screening 1000ug/ml, 500ug/ ml, 250 ug/ml, and 125 
ug/ml concentrations of the synthesized drugs were taken. The synthesized drugs 
found to be active in this primary screening were further tested in second set of 
dilution against all microorganisms. 
Secondary screening: The drugs found active in primary screening were similarly 
diluted to obtain 100 ug/ml, 50 ug/ml, 25 ug/ml, 12.5 ug/ml, 6.250 ug/ml, 3.125 ug/ml 
and 1.5625 ug/ml concentrations. 
Antibacterial activity: In vitro antibacterial activity of the compounds was carried 
out against culture of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus 
aureus and S.pyogenus at concentrations of 1000, 500, 200, 100, 50, 25, 12.5 µg/ml 
respectively. The drugs Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin, 
Norfloxacin were used as a standard for antibacterial activity at different 
concentration, which is described in Graphical chart no: 1-15 and 1a-15a. 
 
Antifungal activity: In vitro antifungal activity of same synthesized compounds was 
tested against C.albicans, Aspergillus’ s niger and A.clavatus. The compounds were 
tested at different concentrations of 1000,500,200,100 µg/ml respectively, in which 
Nystatin, Greseofulvin used for antifungal activity , at different concentration which is 
described in Graphical chart: 1a-15a and 1a-15a. 
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ANTIMICROBIAL ACTIVITY 
 
 
 
Method     :  Broth Dilution Method 
Gram positive bacteria   :   Staphylococcus pyogenes 
        Streptococcus aureus  
Gram negative bacteria   :  Escherichia coli 
      :  Pseudomonas aeruginosa 
 Fungi      :  Candida albicans 
      :  Aspergillus Niger 
      :  Aspergillus clavatus 
Concentrations for M.I.C.   :  1000 µg/ml, 500 µg/ml,
       250 µg/ml, 125 µg/ml, 
       62.5 µg/ml, 50 µg/ml. 
Solvent     :  DMF  
Standard drugs    :  Gentamycin, Ampicillin, 
        Chloramphenicol, 
        Ciprofloxacin, 
Norfloxacin, 
        Nystatin, Greseofulvin. 
  
 
 
 The antibacterial activity of synthesized compounds was compared with 
standard drugs viz., Gentamycin, Ampicillin, Chloramphenicol, Ciprofloxacin and 
Norfloxacin. Antifungal activity was compared with Nystatin and Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type (I) 
were found to be mild to moderately active against Gram positive and Gram negative 
bacterial strains. 
The maximum activity was observed in compounds bearing R=m-phenoxy 
phenyl, N,N,-dimethylphenyl substituents against E.coli. and P. aeruginosa, in 
comparision to standard drug Ampicillin. However the compounds beaing 2-
thiophene, 5-nitro vanilline substitutes is also giving maximum activity against S. 
pyogenus. 
The significant activity was displayed by the compounds bearing R=N,N-
dimethyl phenyl against S.aureus in comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= m-nitro phenyl, m-phenoxy phenyl, N, N-
dimethyl phenyl, dimethoxy phenyl indicate significant activity in comparision to 
Greseofulvin against C.albicans. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of        
type (II) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= 2-thiophene 
substituent against E.coli. and P. aeruginosa in comparision to standard drug 
Ampicillin. However the compounds bearing R = p-hydroxy and N-N dimethyl 
phenyl substituent are also giving maximum activity against P. aeruginosa. 
The significant activity was displayed by the compounds bearing R= p-
methoxy phenyl and 3,4-dimethoxy phenyl against S. aureus and S. pyogenus in 
comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, 3-methoxy-4-
hydroxyphenyl indicate significant activity to Greseofulvin against C.albicans. 
While compounds bearing R= m-nitro phenyl substitute is giving significant activity 
against A.niger in comparision to Greseofulvin and Nystatin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of        
type (III) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R=m-Methoxy 
phenyl, m-nitro phenyl substituent and R = 3,4-dimethyl phenyl, m-chloro phenyl 
against E.coli. and P. aeruginosa respectively, in comparision to standard drug 
Ampicillin. However The compounds beaing p-methoxy phenyl, methyl phenyl and 
m-chloro phenyl substitutes are also giving maximum activity against. S. pyogenus. 
In comparision to standard drug Ampicillin. 
The significant activity was displayed by the compounds bearing R=m-chloro 
phenyl and p-methyl phenyl against S.aureus in comparision to standard drug 
Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, m-nitro phenyl 
indicate maximum activity in comparision to Nystatin and significant activity in 
comparision to Greseofulvin against C.albicans. while compounds bearing R= p-
methylphenyl substitue is giving significant activity against A. niger in comparision 
to Nystatin and Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
It has been observed from the experimental data that all compounds of        
type (IV) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= phenyl, 2-
thiophene, m-phenoxy phenyl, 4-hydroxy-3-methoxy phenyl substituents against 
E.coli. and P. aeruginosa in comparision to standard drug Ampicillin. However the 
compounds beaing p-methoxy substitute is also giving maximum activity against S. 
aureus. 
The significant activity was displayed by the compounds bearing R=p-
methoxy phenyl against E.coli. and R= 3,4dimethoxy phenyl against S.pyogenus in 
comparision to standard drug Ampicillin. 
Where, compound bearing 3,4-dmethoxy phenyl substitute is indicating 
comparable activity against E.coli and significant activity against P. aeruginosa in 
comparision to standard drug Chloramphenicol. 
 
ANTIFUNGAL ACTIVITY: 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= 3,4-dimethoxy phenyl, m-phenoxy phenyl 
and m-nitro phenyl substitutes indicate maximum activity in comparision to 
Nystatin and significant activity in comparision to Greseofulvin against C.albicans. 
While compounds bearing R= nitro phenyl, 4-hydroxy 3-methoxy phenyl substitutes 
are also giving maximum activity against A.niger and m-phenoxy phenyl, halo 
substituted are showing maximum activity against A. Clavatus in comparision to 
Greseofulvin and Nystatin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
It has been observed from the experimental data that all compounds of        
type (V) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= phenyl, 2-
thiophene, m-nitro phenyl and 3-methoxy 4-hydroxy phenyl substitutes against E.coli. 
and R= m-nitro phenyl, 4-chloro phenyl substitutes against P. aeruginosa in 
comparision to standard drug Ampicillin. However the compounds beaing N,N- 
dimethyl phenyl substitutes  is also giving significant activity against S. aureus .in 
comparision to standard dug Ampicillin. 
The significant activity was displayed by the compounds bearing R=p-
methoxy phenyl, 3,4-dimethoxy phenyl and 3-phenoxy phenyl substitutes against 
E.coli. and S. aureus respectively n comparision to standard drug Ampicillin.  
 
ANTIFUNGAL ACTIVITY: 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= phenyl, p-chloro phenyl, m-bromo 
phenyl, and 3,4 dimethoxy phenyl substitutes indicate significant activity in 
comparision to Greseofulvin against C.albicans. While compound bearing R= m-
phenoxy phenyl substitute indicates maximum activity in comparision to Nystatin 
and significant activity against Greseofulvin.  
The maximum activity was observed also in compounds bearing 3,4-
dimethoxy phenyl, m-nitro phenyl substitutes and m-phenoxy phenyl substitutes 
against A.niger and A.clavatus in comparision to standard drug Nystatin and 
Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(VI) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= m-Methoxy 
phenyl, 3,4-dimethoxy phenyl, 2-thiophene substitutes against E.coli. and S. aureus, 
R= m-nitro phenyl substitutes  against S. pyogenus in comparision to standard drug 
Ampicillin.  
However in the case of P. aeruginosa all the compounds are giving 
maximum activity except R=phenyl, m-phenoxy phenyl and N,N-dimethyl 
substitutes.  
The significant activity was displayed by the compounds bearing R= p-
methoxy phenyl against E.coli and 3,4-dimethoxy phenyl and m-phneoxy phenyl 
against S. aureus in comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= m-phenoxy phenyl, p-chloro phenyl and 
indicate significant activity in comparision to Greseofulvin against C.albicans. 
While compounds bearing R= p-methoxy phenyl substitute is indicating significant 
activity against A.niger in comparision to standard drugs Nystatin and Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(VII) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= p-Methoxy 
phenyl, 3,4-dimethoxy phenyl, m-phenoxy phenyl, 4-hydroxy-3-methoxy phenyl 
substituents against E.coli., R= m-bromo phenyl, 3-methoxy 4-hydroxy phenyl 
substitutes against P. aeruginosa  and p-methoxy phenyl, N,N-dimethyl phenyl, m-
bromo phenyl substitutes against S. pyogenus in comparision to standard drug 
Ampicillin.  
However The compounds beaing 4-N,N-dimethyl phenyl and m-bromo phenyl 
substitutes are giving significant activity against S. aureus in comparision to 
standard drug Ampicillin.  
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= 3,4-dimethoxy phenyl and m-bromo 
phenyl indicate maximum activity in comparision to Nystatin and Greseofulvin 
against A. niger. And compounds bearing R= 3,4 –dimethoxy phenyl and 4- 
hydroxyl-3-methoy phenyl substitutes are also giving maximum activity in 
comparision to Greseofulvin and Nystatin against A. clavatus. 
 While in case of C. albicans all the compounds except R = 3,4-dimethoxy 
phenyl, 2-thiphene and p-chloro phenyl are giving significant activity against 
C.albicans in comparision to Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(VIII) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= 3,4-
dimethoxy phenyl, 4-hydroxy 3-methoxy phenyl substitutes against E.coli., R = m-
phenoxy against P. aeruginosa, R= 3,4- dimethoxy phenyl, m-phenoxy phenyl and 
m-nitro phenyl substitutes against S. pyogenus in comparision to standard drug 
Ampicillin.  
However the compounds beaing N,N-dimethyl phenyl, 4-hydroxy-3methoxy 
phenyl  substitutes are giving significant activity against S. aureus.in comparision to 
standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= m-bromo phenyl indicate maximum 
activity in comparision to Nystatin and Greseofulvin against A.clavatus. While in 
case of C. albicans  all the compounds except R= phenyl, N,N-dimethyl phenyl 
substitutes  are giving significant activity against C.albicans in comparision to 
Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(IX) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= phenyl, 2-
thiophene and p-chloro phenyl substitutes against E.coli, R= p-methoxy phenyl, 2-
thiophene, m-bromo phnyl against P. aeruginosa and R = 3,4-dimethoxy phenyl 
substitutes against S. pyogenus in comparision to standard drug Ampicillin.  
However the compounds beaing R = p-methoxy phenyl, phenyl, 2-thiophene 
and m-bromo phenyl substitutes against S.aureus, are also giving significant activity 
in comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, 3,4-dimethoxy phenyl, 
phenyl, N,N-dimethyl phenyl, m-bromo phenyl and 4-hydroxy-3-methoxy phenyl 
substitutes indicate significant activity in comparision to Greseofulvin against 
C.albicans. While compound bearing R= N,N-dimethyl phenyl substitute is also 
giving maximum activity against A. niger in comparision to Greseofulvin and 
Nystatin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(X) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= 3,4-
dimethoxy phenyl, p-chloro phenyl substituent against E.coli., R= m-phenoxy phenyl, 
N,N-dimethyl phenyl, p-chloro phenyl and 4-hydroxy-3-methoxy phenyl substitutes 
against  P. aeruginosa in comparision to standard drug Ampicillin.  
The significant activity was displayed by the compounds bearing R= p-
methoxy phenyl substitutes against S. aureus and S. pyogenus, R = N,N- dimethyl 
phenyl, 4- chloro phenyl and 4-hydroxy-3-methoxy phenyl substitutes against S. 
aureus in comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However all the compounds except R = phenyl and p-chloro substitutes are 
giving significant activity against C.albicans in comparision to Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(XI) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= phenyl, m-
nitro phenyl substitutes against E.coli. R = m-phenoxy phenyl, m-nitro phenyl, N,N-
dimethyl phenyl and p-hydroxy phenyl against P. aeruginosa and p-methoxy phenyl 
against S.pyogenus in comparision to standard drug Ampicillin.  
The significant activity was displayed by the compounds bearing R= p-
methoxy phenyl substitutes against E.coli and P. aeruginosa ,R= p-hydroxy phenyl 
substitutes against E.coli and in comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-hydroxy phenyl indicate significant 
activity in comparision to Greseofulvin and maximum activity in comparision to 
Nystatin against C.albicans.  
While compounds bearing R= m-phenoxy phenyl, m-nitro phenyl, N,N- 
dimethyl phenyl and p- chloro phenyl substitutes are also giving significant activity 
against C.albicans in comparision to Greseofulvin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(XII) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= p-Methoxy 
phenyl, m-phenoxy phenyl, p- chloro phenyl substitutes against E.coli. R= 3,4-
dimethoxyphenyl substitute against P. aeruginosa in comparision to standard drug 
Ampicillin. However The compounds beaing p-chloro phenyl substitute is also giving 
maximum activity against S. pyogenus. 
 The significant activity was displayed by the compounds bearing R= 3,4-
dimethoxy phenyl substitute against E.coli. and p-methoxy phenyl, 3,4-dimethoxy 
phenyl and N,N-dimethyl phenyl substitutes against S.aureus in comparision to 
standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, m-nitro phenyl and 
N,N-dimethyl phenyl and 2-thiophene indicate maximum activity in comparision to 
Nystatin, and significant activity in comparision to Greseofulvin against C.albicans. 
While compounds bearing R= m-nitro phenyl is also giving maximum activity 
against A. niger in comparision to Greseofulvin and Nystatin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(XIII) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= m-phenoxy 
phenyl, p- hydroxy phenyl and p- chloro phenyl  substitutes against E.coli., P. 
aeruginosa, S.aureus, and S.pyogenus in comparision to standard drug Ampicillin.  
However the compounds bearing p-methoxy phenyl and m-phenoxy phenyl 
substitutes are giving significant activity against E.coli., P. aeruginosa, S.aureus, 
and S.pyogenus in comparision to standard drug Ampicillin. 
. 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compound bearing R= p-chloro phenyl substitute indicate 
maximum activity in comparision to Nystatin and Greseofulvin against A. niger. 
While in case of C. albicans all compounds except 2-thiophene are giving significant 
activity in comparision to Greseofulvin and maximum activity in comparision to 
Nystatin. 
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(XIV) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R= phenyl, p-
hydroxy phenyl and p-chloro phenyl substituents against E.coli. and P. aeruginosa, 
However the compounds beaing 4-hydroxy- 3-methoxy phenyl and m-phenoxy 
phenyl substitute is also giving maximum activity against P. aeruginosa, S. aureus 
and S. pyogenus in comparision to standard drug Ampicillin. 
The significant activity was displayed by the compounds bearing R= phenyl, 
p-methoxy phenyl, and 3-methoxy 4-hydroxy phenyl substitutes against S. aureus in 
comparision to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, m-phenoxy phenyl 
substitutes indicate maximum activity in comparision to Nystatin and Greseofulvin 
against A. niger, where p-methoxy phenyl substitute also giving maximum activity 
agains A. clavatus. In the case of C.albicans all compounds except R= 4-methoxy 
phenyl, 3,4-dimethoxy phenyl and p-chloro phenyl substitutes are giving significant 
activity in comparision to standard drug Greseofulvin.  
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RESULTS AND DISCUSSION: 
 
 
 
 
 
 
 
 
 
 
 
 
ANTIBACTERIAL ACTIVITY: 
 
It has been observed from the experimental data that all compounds of type 
(XV) were found to be mild to moderately active against Gram positive and Gram 
negative bacterial strains. 
The maximum activity was observed in compounds bearing R=p-methoxy 
phenyl, m-phenoxy phenyl, p-hydroxy phenyl, and p-chloro phenyl substitutes against 
E.coli. and P. aeruginosa in comparision to standard drug Ampicillin.  
However the compounds beaing phenyl, 3,4-dimethoxy phenyl, p-hydroxy 
phenyl and p-chloro phenyl substitutes are giving significant  activity against E .coli. 
and S. aureus. 
The significant activity was displayed by the compounds bearing R= p-
methoxy phenyl and p-hydroxy phenyl substitutes against S. pyogenus in comparision 
to standard drug Ampicillin. 
 
ANTIFUNGAL ACTIVITY: 
 
The antifungal data revealed that compounds were least toxic to the fungal 
strain. However the compounds bearing R= p-methoxy phenyl, m-phenoxy phenyl, 2-
thiophene and p-chloro phenyl indicate maximum activity in comparision to 
Nystatin and significant activity in comparision to Greseofulvin against C.albicans. 
While compounds bearing R= m- phenoxy substitute was displayed maximum 
activity against A.niger and m-nitro substitute against A. clavatus in comparision to 
Greseofulvin and Nystatin. 
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[B]       ANTITUBERCULAR ACTIVITY 
 
 The antitubercular evaluation of the selected compounds was carried out at 
Microcare Laboratories and Tuberculosis Research Center- SURAT. 
 
INTRODUCTION: 
 
 
MYCOBACTERIUM:- 
  
   Hansen [1868] discovered the first member [lepra bacilli], Robert Koch 
[1882] isolated mammalian tubercle bacilli and Johne [1895] described 
Mycoparatuberculosis [Johne’s bacillus]. Mycobacteria are slender bacilli and 
sometimes exhibit filamentous forms resembling fungal mycelium [from Greek, 
Myces meaning fungus] and hence they are so named. They are difficult to stain by 
ordinary stains because of the presence of waxy materials in their cell walls. Although 
they are gram positive, they stain poorly, if at all, by gram’s technique. They are 
better stained by hot carbol fuchsin, and once stained; they resist decolourisation by 
dilute minerals acids and are, therefore, referred to as Acid Fast Bacilli or AFB. These 
organisms are non motile, non capsulated, non sporing and mostly very slow growing. 
The genus includes obligate parasites pathogenic to man, mammals; birds and 
reptiles, opportunistic pathogens and saprophytic varieties. 
  
MYCOBACTERIUM TUBERCULOSIS:- 
  
Morphology: -  
 
 These are nonmotile, nonsporing and no capsulated bacilli, arranged singly or 
in groups. They are acid-fast due to the presence of mycolic acid in cell-wall and 
weakly Gram positive. With Ziehl-Neelsen stain, M.tuberculosis look slender, straight 
or slightly curved rod with beaded or barred appearance and M.bovis appear 
straighter, stouter and shorter with uniform staining. 
 Culture: - 
  Tubercle bacilli are aerobes, grow slowly (generation time 14-15 hours), 
optimum temperature 370C, pH 6.4-7.0. They grow only in specially enriched media 
containing egg, asparagines, potatoes, serum and meat extracts. Colonies appear in 2-
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6 weeks. M.tuberculosis grows more luxuriantly in culture (eugenic) than M.bovis 
which grows sparsely (dysgenic). 
           The drug susceptibility test may be performed by either the direct or the 
indirect method. The direct drug susceptibility test is performed by using a subculture 
from a primary culture as the inoculums.  
  
EVALUTION TECHNIQUES:- 
Three well-known measures of sensitivity test are available: 
(1) The minimal inhibitor concentration or the MIC,  
(2) The resistance ratio or the RR, and 
(3) The proportion method.  
These tests are set up on solid media.  
  
(1) The minimal inhibitor concentration: 
 Mic is defined as the minimal concentration of the drug required to inhibit the 
growth of the organisms, where growth is defined as 20 colonies or more .This 
definition of growth is chosen so that only a small proportion (e.g. 1%) of wild strains 
would be classified as resistant by its use. This method is simple and be carried out 
with a single drug containing slope although it is preferable to use more than one 
slope. 
  
(2) Resistance ratio:               
 This consists of expression the resistance as a ratio of the MIC of a test strain 
to that of control strain. This procedure calls for a rigid standardization since the 
inherent technical errors usually make it less efficient than the MIC method in 
distinguishing sensitive and resistant strains. A further disadvantage of the use of RR 
is that there may be more variation in sensitivity of the control strain than in wild 
strain resulting in increase in the error. However, the RRs’ are more than one slope. 
 (3) Proportion method:  
  This method of testing sensitivity has a high degree of precision. The 
inoculum suspension is standardized by weight of the bacilli and serial ten-fold 
dilution of the suspension are made for seeding onto drug free and drug containing 
slopes. The proportion of resistant depending on the proportion. Two variants, a 
simplified variant and standard variant, are over a period of years.  
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 We have used the minimal inhibition concentration to evaluate the anti-
tuberculosis activity. It is one of the non automated in vitro bacterial susceptibility 
tests. This classic method yields a quantitative result for the amount of antimicrobial 
agents that is needed to inhibit growth of specific microorganisms. It is carried out in 
bottle. 
  
DETERMINATION OF MINIMAL INHIBITION CONCENTRATIONS BY 
L.J SLOPE METHOD: 
 
MATERIALS AND METHOD:- 
 
1. All the Synthesized Drugs Were Used For Anti-tubercle Test Procedures 
2. All Necessary Controls Like: 
Ø       Drug Control 
Ø       Vehicle Control 
Ø       Agar Control 
Ø       Organism Control 
Ø       Known Antibacterial Drugs Control 
Ø       M.Tuberculosis H37 rv Cultures Were Tested Against Above 
Mentioned Known and Unknown Drugs. 
Ø       L.J Was Used As Nutrient Medium To Grow And Dilute The Drug 
Suspension For The Test. 
Ø       Inoculum Size for Test Strain Was Adjusted to 1mg/ml. 
Ø       Following common standard strain is used for screening of antitubercle 
activities: The strains were procured from Institute of Microbial Technology, 
Chandigarh. 
·     Mycobacterium tuberculosis H37Rv [Acid Fast Bacilli] 
 
·     DMSO was used as diluents / vehicle to get desired concentration of 
drugs to test upon Standard bacterial strains. 
 
METHODS USED FOR PRIMARY AND SECONDARY SCREENING: 
  Each synthesized drug was diluted obtaining 2000 micro gram /ml 
concentration, as a stock solution. 
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Primary screen:    In primary screening 500 micro/ml, 250 micro/ml, and 125 
micro/ml concentrations of the synthesized drugs were taken. The active 
synthesized drugs found in this primary screening were further tested in a 
second set of dilution against all microorganisms. 
Secondary screen:  The drugs found active in primary screening were 
similarly diluted to obtain 100 micro/ml, 50 micro/ml, 25 micro/ml, 12.5 
micro/ml, 6.250 micro/ml, 3.125 micro/ml and 1.5625 micro/ml 
concentrations.  
Reading Result:-                            
 The highest dilution showing at least 90 % inhibition is taken as MIC.The 
result of this is much affected by the size of the inoculum. The test mixture 
should contain 108 organism/ml.              
The Standard Drugs:- 
The Standard strain M.tuberculosis, H37RV is tested with each new batch 
of medium. The recommended drug concentrations are 4 mg/l for 
streptomycin, 0.2 mg/l for isoniazide, 40 mg/l for Rifampicin and 2 mg/ l for 
ethambutol. 
 
METHOD   :        L.J.MEDIUM [CONVENTIONAL METHOD] 
 
BACTERIA   :       MYCOBACTERIA TUBERCULOSIS H37RV 
 
CONCENTRATION :       1000, 500, 250, 125, 100, 62.50, 50, 25, 12.5, 6.25 
            µg/ml. 
 
STANDARD DRUGS :       ISONIAZID. 
  
 The antitubercular activity data have been compared with standard drug 
Isoniazid at different concentration and which showed 98 % Inhibition, the data of % 
inhibition are recorded in Table No.1b and onwards. 
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TABLE:-1b:-ANTITUBERCULAR ACTIVITY OF 2,3-DICHLORO-N-(3-
SUBSTITUTED STYRYL CARBONYL) BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
CODE 
 NO. 
Where, 
R = 
MTb 
Strain 
MIC 
µg/ml 
% 
Inhibition 
REMARKS 
1 MM # 01 3,4-(OCH3)2-C6H4 H37RV 12.5 99% ISONIAZID = 
0.20 µg/ml 
2 MM # 02 4-OCH3-C6H4- H37RV 250 98% 98% inhibition 
3 MM # 03 4-Cl- C6H4 H37RV 500 98%  
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Cl
O
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R
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TABLE:-2b:- ANTITUBERCULAR ACTIVITY OF 2,3-DICHLORO-  N- [3- {3-
ARYL-1[H] PYRAZOLINE-5-YL} PHENYL] BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
CODE 
 NO. 
Where, 
R = 
MTb 
Strain 
MIC 
µg/ml 
% 
 Inhibition 
REMARKS 
1 MM # 01 4-OCH3-C6H4- H37RV 100 99% ISONIAZID = 
0.20 µg/ml 
2 MM # 02 3,4-(OCH3)2-C6H4 H37RV 500 98% 98% inhibition 
3 MM # 03 4-Cl- C6H4 H37RV 500 98%  
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TABLE:-3b:-ANTITUBERCULAR ACTIVITY OF 2, 3-DICHLORO-   N – [3-
{3-(ARYL)-1-PHENYL - 1[H] PYRAZOLINE – 5 - YL} PHENYL] 
BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No. 
CODE 
 NO. 
Where, 
R = 
MTb 
Strain 
MIC 
µg/ml 
% 
 Inhibition 
REMARKS 
1 MM # 01 4-OCH3-C6H4- H37RV 500 98% ISONIAZID = 
0.20 µg/ml 
2 MM # 02 4-Cl- C6H4 H37RV 500 98% 98% inhibition 
3 MM # 03 3-Br- C6H4 H37RV 250 98%  
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TABLE:-4b:-ANTITUBERCULAR ACTIVITY OF SYNTHESIS AND 
STRUCTURE ELUCIDATION OF 2,3-DICHLORO-N-[3-(2-
AMINO-4-ARYL-3-CYANO PYRIDINE-6-YL)] BENZAMIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sr. 
No 
CODE 
 NO. 
Where, 
R = 
MTb 
Strain 
MIC 
µg/ml 
% 
 Inhibition 
REMARKS 
1 MM # 01 4-OCH3-C6H4- H37RV 250 98% ISONIAZID = 
0.20 µg/ml 
2 MM # 02 3,4-(OCH3)2-C6H4 H37RV 500 98% 98% inhibition 
3 MM # 03 3-C6H5-O-C6H4 H37RV 500 98%  
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LIST OF NEW COMPOUND 
  
 
                            R             R 
 4-OCH3-C6H4-       4-OCH3-C6H4-               
 C6H5-        C6H5-  
             3,4-(OCH 3)2-C6H4-      3,4-(OCH3)2-C6H4- 
    C4H7S  C4H7S 
              3-C 6H5-O-C6H4 -                   3-C6H5-O-C6H4- 
             4-N(CH 3)2-C6H4-      4-N(CH3)2-C6H4- 
             4-Cl- C 6H4-                4-Cl- C6H4 
             3-Br- C 6H4-       3-Br- C6H4- 
             3-NO 2-C6H4-       3-NO2-C6H4- 
             4-OH,3-OCH 3-C6H3-      4-OH,3-OCH3-C6H3- 
 
\\\ 
 
 
 
              R R        
   4-OCH3-C6H4-                        4-OCH3-C6H4-  
              C 6H5-                    C6H5- 
              3,4-(OCH 3)2-C6H4-                               3,4-(OCH 3)2-C6H4- 
  C4H7S  C4H7S 
              3-C 6H5-O-C6H4 -      3-C6H5-O-C6H4- 
             4-N(CH 3)2-C6H4-      4-N(CH3)2-C6H4- 
             4-Cl- C 6H4-                4-Cl- C6H4 
             3-Br- C 6H4-       3-Br- C6H4- 
             3-NO 2-C6H4-       3-NO2-C6H4- 
             4-OH,3-OCH 3-C6H3-                                                       4-OH,3-OCH3-C6H3- 
Cl
Cl
O
NH
N
N
R
Cl
Cl
O
NH
N
N
R
O
CH3
Cl
Cl
O
NH
N
N
R
S
NH2
Cl
Cl
O
NH
N
NH
R
  
 
R        R 
4-OCH3-C6H4- 4-OCH3-C6H4- 
C6H5- C6H5- 
3-NO2-C6H4- 3-NO2-C6H4- 
4-OH-C6H5- 4-OH-C6H5- 
4-OH,3-OCH3, 5-NO2 C6H2- 4-OH,3-OCH3, 5-NO2 C6H2- 
3-C6H5-O-C6H4 3-C6H5-O-C6H4 
4-N(CH3)2-C6H4 4-N(CH3)2-C6H4 
3,4-(OCH3)2-C6H4 3,4-(OCH3)2-C6H4 
4-OH,3-OCH3-C6H3 4-OH,3-OCH3-C6H3 
C4H7S C4H7S 
 
 
 
 
                    
R         R 
 
 
 
 
4-OCH3-C6H4- 
C6H5- 
3,4-(OCH3)2-C6H4 
C4H7S 
3-C6H5-O-C6H4 
4-N(CH3)2-C6H4 
4-Cl- C6H4 
3-Br- C6H4 
3-NO2-C6H4- 
4-OH,3-OCH3-C6H3 
4-OCH3-C6H4- 
4-NO2-C6H4- 
4-Cl-C6H4- 
3,4-(CH3)2-C6H4- 
4-CH3-C6H4- 
2,4(CH3)2-C6H4 
3-NO2-C6H4 
C6H5 
2-CH3-C6H4 
3-Cl-C6H4 
O
CH3
CH3 N N
O S
NH
R
O
CH3
CH3
O
NH N
R
O
CH3
CH3 N N
O R
Cl Cl
O
NH
O R
  
 
 
R        R 
 
 
 
 
 
 
 
 
 
 
 
 
 
R        R 
4-OCH3-C6H4- 
C6H5- 
3-C6H5-O-C6H4 
3,4-(OCH3)2-C6H4 
4-OH,3-OCH3-C6H3 
3-NO2-C6H4- 
C4H7S 
4-OH-C6H5- 
4-N(CH3)2-C6H4 
4-Cl- C6H4 
 
4-OCH3-C6H4- 
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